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Erratum
On page 25 of this dissertation (Chapter 2. Materials, Methods & Preparative
Experiments) the entry for the composition of the PPDK activity assay buffer was
erroneous. The correct specification for this buffer is as follows:
PPDK activity assay buffer
1X PPDK-PBS Buffer: 1X PBS, 20 mM NH4Cl, 1 mM MgCl2, pH 7.1
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Chapter 1
Introduction
1.1 Infections with filarial nematodes: Past and
present
"SiR,-Permit me to call the attention of your readers, and especially that of fo-
reigners, to some recent additions to our knowledge of the prevalence and probable
source of various haematozoa infecting mankind and animals." [50]: "Those who take
an interest in helminthological studies may remember that in the month of July last
I was permitted to announce in THE LANCET the discovery of a new entozoon. In
honour of the discoverer I named the worm "Filaria Bancrofti"" [51]. In these words
T. Spencer Cobbold addressed the editors and the public readership of The Lancet
in the 1870’s and praised the work by Lewis, Wucherer, Bancroft and others who
worked on the recent discoveries of human pathogenic filarial nematodes that were
assumed as the causative agents of elephantiasis by Manson a few years later [215].
While the presence of this scourge was documented already by ancient craftworks
that date back to Pharaonic Egypt, roughly 3000 years before the causative agents
were discovered, today, more than 130 years after this discovery this vector-borne
disease is known as lymphatic filariasis (LF) and is still considered a major public
health problem in endemic tropical and subtropical regions of the old and new world
by the WHO [3]. More than 120 million people worldwide suffer from infection,
while more than 1.2 billion people are at risk of infection. Filaria bancrofti is
now called Wuchereria bancrofti that, along with Brugia malayi and Brugia timori,
constitutes the causative agents of LF. Another filarial disease that appears on
the WHO’s list of neglected tropical diseases is Onchocerciasis (Oncho) caused by
the filarial nematode Onchocerca volvulus. This disease is mainly endemic in Sub-
Saharan Afica with foci in Latin America and Yemen with a total of ∼37 million
people infected worldwide [1, 2, 4].
1.2 Life cycle of filarial nematodes and pathogenesis
Chronic manifestations of both diseases are dreaded as they are among the leading
causes of disability in the developing world. They burden patients with social stig-
mata and confront their families and societies with considerable economic losses.
Pathologies are closely related to the complex life cycle of the parasitic worms (see
Fig. 1.1): Filarial larval stages infect the human host during the blood meal
of an infected arthropod intermediate host, i.e. a variety of mosquito vectors for
lymphatic filariae or the black fly, genus Simulium, for O. volvulus. These L3 lar-
vae migrate within the human body to their destined tissue-sites and develop into
7
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adults after several molts. The causative agents of LF reside in worm nests in the
lymphatics while O. volvulus is found in subcutaneous nodules. Adult worms are
able to persist in the human host for more than a decade and their reproductive
activity leads to the production and release of millions of L1 stage larvae (micro-
filaria, MF) for many years. While in LF microfilariae appear in the blood of the
patients (microfilaremia), in Oncho, MF migrate within the dermis (microfilari-
dermia). Both localizations allow the uptake of MF during another blood meal of
their required arthropod vector, in which MF develop into infective L3 larvae. Con-
tinuous reinfection and immunomodulation by the worms lead to chronic disease
in which a complex interplay of excretory/secretory worm products and the host
inflammatory reaction may lead to the tissue-destructive and -remodelling effects
characteristic for severe patholgies: Hydrocele and lymphedema that may develop
into elephantiasis are characteristic for LF. In Oncho manifestations of skin disease
including dermatitis and depigmentation are common. Ocular onchocerciasis may
develop as a result of the inflammatory reaction elicited by MF in the eye and may
provoke keratitis and blindness (hence the alternative name River Blindness for
Onchocerciasis) [249, 119, 206].
1.3 An introduction to Wolbachia endobacteria
Filarial nematodes are known to carry endosymbiotic bacteria of the genus Wol-
bachia, obligate intracellular bacteria that belong to the order of Rickettsiales and
class of α-proteobacteria [76]. Wolbachia pipientis was discovered by Hertig and
Wolbach in 1924 in gonad cells and eggs of the mosquito Culex pipiens [110]. To-
day it is expected that Wolbachia are able to infect ∼66% of arthropod species with
either very high (> 90%) or very low (< 10%) infection frequencies [113]. Wolbachia
strains infecting arthropods are endosymbionts [63] or reproductive parasites that
induce a sex-ratio distortion by different mechanisms like cytoplasmic incompati-
bility [29, 218], feminization [218], male killing [128] or parthenogenesis [127, 239]
(all reviewed in [21]).
Within filarial nematodes, Wolbachia were first described as Rickettsia-like mi-
croorganisms in the hypodermal chords of larvae of the dog heart worm Dirofilaria
immitis and of Brugia pahangi [174] almost thirty years ago. Two years later,
these microorganisms were also identified in the lateral chords of adult worms and
the uteri, oocytes and MF of female O. volvulus [152] and B. malayi worms [151]
and were found to be vertically transmitted [151]. In contrast to their parasitic
arthropod-infecting counterparts, Wolbachia always have a mutualistic relationship
to their nematode hosts. Although Wolbachia are named as one species (Wolbachia
pipientis), phylogenetic analyses have clustered Wolbachia strains into currently
nine different "supergroups", but this classification is continuously revisited. Super-
groups A and B traditionally contain the classic Wolbachia that infect arthropods
and the members were classified according to their ftsZ gene sequence [264]. More
recently performed phylogenetic studies also accounted for other phylogenetics, such
as of 16S rRNA and Wolbachia Surface Protein [76] or other protein protein coding
genes [32]. FurtherWolbachia from collembolan and isopteran species are contained
in supergroups E and H [256, 30]. Supergroup G was first described to comprise
Wolbachia from spiders [219], but was later suggested to be removed as the strain
apparently resulted from a recombination event between A and B lineages [19].
Wolbachia supergroups C and D contain the endosymbionts of filarial nema-
todes: C comprises Wolbachia from Onchocerca spp. and Dirofilaria spp., while the
endosymbionts of Brugia spp., W. bancrofti, as well as those of the rodent filarial
nematode Litomosoides sigmodontis are assigned to the D group [20]. Wolbachia
of the filaria Dipetalonema gracile were assigned to group J, the first endosymbiont
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Figure 1.1: Life cycle of filarial nematodes
The figure depicts key stages of the infection cycle of different filarial nematodes in
their mammalian definite host (upper part) and the arthropod intermediate host (lower
part). For the different filarial species the corresponding details on the infection cycle
are highlighted in color: B. malayi (green), O. volvulus (blue) and the rodent parasite
L.sigmodontis (yellow).
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of a plant-parasitic nematode (Radopholus similis) to supergroup I [101]. Of note,
F-group Wolbachia are a relatively heterogenous group with a broad host range
including both filarial nematode (Mansonella spp. and others) [41, 162] and arthro-
pod species like lice [55] or scorpions [18].
Interestingly, several filarial nematodes including Loa loa, the causative agent
of loiasis, Acanthocheilenoma spp. or O. flexuosa were shown not to harbor Wol-
bachia endobacteria [172, 253, 175]. Furthermore, with the exception of the recently
identified group I nematode R. similis [101], no Wolbachia have been identified in
non-filarial nematodes [31]. Within the possible scenarios of endosymbiont acquisi-
tion by filarial nematodes, in general, a single infection event of a common filarial
ancestor with secondary loss of the endosymbiont from species that are found to be
Wolbachia-free is favoured over a multiple-infection scenario [31, 43, 248]. This hy-
pothesis has recently been strengthened by the identification of Wolbachia-like gene
sequences in the genomes of Wolbachia-free filarial worms [175]. However the diver-
gent F lineage has possibly been acquired by filariae rather recently in a secondary
infection event while certain ancient filarial lineages (e.g. Oswaldofilariinae) seem
to have branched off before the acquisition of the endosymbiont by an onchocercid
ancestor [77].
Wolbachia generally reside in vacuoles in the cytoplasm of their host cells [152]
and endosymbiont numbers are conrolled by autophagy of the filarial host [259].
While Wolbachia numbers in the lateral chords of MF and L3 larvae are very low,
higher levels are found in L4 larvae with peak multiplication rates for young adults.
Wolbachia are mainly found in the female reproductive tract, including ovaries and
embryos [80]. This asymmetric distribution pattern within the body of the worm is
due to asymmetric segregation of Wolbachia towards posterior blastomeres during
the first division rounds of embryonic cells. Out of these posterior blastomeres
germline cells will emerge and the population of lateral chords is enabled by syncytial
formation involving cells of the Wolbachia-containing lineage [158]. In the same
study, single Wolbachia were also found in the secretory canal, indicating a possible
secretion of the endosymbiont by its hosts.
Wolbachia are also of major importance for the pathogenesis of filarial diseases.
Due to their prokaryotic structural components likeWolbachia Surface Protein they
are able to activate pattern-recognition receptors such as Toll-like receptor 2 and
thus drive innate immune responses [221, 114]. Wolbachia components are able to
recruit neutrophils to the site of infection and thus trigger the detrimental immuno-
logical cascade in the cornea that may cause stromal haze and develop into blindness
[221, 94]. Wolbachia components are also considered to contribute to the chronic in-
flammation and tissue-remodeling effects leading to lymphedema [62, 206]. Finally,
the endosymbiont has been correlated with side effects of antifilarial chemotherapy
which leads to a massive release of Wolbachia antigen upon death of filarial worms
that subsequently induce severe inflammatory reactions [56].
1.4 Mutualism between Wolbachia and filarial ne-
matodes
In the past, evidence for the mutualistic role of Wolbachia within filarial nematodes
was mostly restricted to functional defects of the worms elicited by depletion of
Wolbachia by antibiotic treatment. A remarkable coincidence between Wolbachia
from nematodes and arthropods is the preferential localization in the female repro-
ductive tract, that allows the cytoplasmic transmission from mother to progeny.
It is therfore not surprising that endosymbiotic Wolbachia are required to sustain
filarial fertility and embryogenesis [116, 118]. Development of female worms of the
10
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model filarial nematode L. sigmodontis requires higher Wolbachia levels than the
development of males does, such that a reduction of Wolbachia levels in adult fe-
males by antibiotic treatment led to a sex-ratio distortion of worms in the daughter
generation [9]. In addition, Wolbachia have been described to be required to sustain
the L4-L5 larval molt of B. pahangi [42].
Analysis of the Wolbachia-filaria symbiosis was brought to the next level by
elucidation of the genome of Wolbachia endosymbiont of B. malayi [81] and the
draft nuclear genome of its host B. malayi [93]. The endosymbiont possesses a very
reduced genome ∼1.1 Mb with a G+C content of 34%, while the nematode genome
is predicted to be 90 - 95 Mb with a G+C content of 30.5% containing 14,500 -
17,800 protein-coding genes, which is several thousand genes less than reported for
the free-living nematode Caenorhabditis elegans (19,507 genes) [265]. Several bio-
chemical pathways for the synthesis of essential molecules of life are only conserved
in either the filarial host or the endosymbiont genome indicating these organisms
have evolved an elaborate division of labor. In addition to providing a defined and
protective habitat for their endosymbionts, the worms seem to provide amino acids
to the Wolbachia which only have the genes required for de novo synthesis of meso-
diaminopimelinic acid, a prokaryote-specific amino acid incorporated in bacterial
peptidoglycan. Furthermore, Wolbachia are unable to synthesize several essential
vitamins and cofactors de novo including biotin, folate, Coenzyme A, lipoic acid,
ubiquinone and pyridoxal phosphate and thus likely depend on their supply by the
host [81]. In contrast, Wolbachia have conserved genes required for de novo syn-
thesis of purine, flavins and heme that are mostly absent from the filarial genome.
The dependence on heme biosynthesis of Wolbachia may explain the previously
mentioned defects in reproduction and molting [42] as there is evidence for a func-
tional ecdysone signalling system (activated by ecdysteroid-like hormones) [252, 99]
that commonly coordinates these events and mostly involves heme-dependent cy-
tochrome P450 [129].
1.5 Model systems of filarial nematodes
In order to study the biology of parasitic filarial worms under defined experimental
conditions, biomedical research relies strongly on the use of common laboratory ani-
mals such as mice and rats unless clinical material is used. This fact often precludes
the detailed study of human pathogenic filarial species, whose life cycle is mostly
not compatible with rodent hosts and requires related model organisms, instead.
The only exception is B. malayi which can be cultivated in Mongolian gerbils and
mosquitoes [10]. For the current study the two following model filarial nematodes
of rodents, Litomosoides sigmodontis and Acanthocheilonema viteae, were used.
1.5.1 Litomosoides sigmodontis
Litomosoides sigmodontis (Chandler, 1931) naturally infects the cotton rat (Sig-
modon hispidus as the definite host and infective larvae are transmitted by the dust
mite Ornithonyssus bacoti [17]. Adult filarial worms of these species reside in the
thoracic cavity (single worms may also be found sporadically in the peritoneal ca-
vity), but do not evoke evident pathology, a feature in common with Mansonella
perstans, which may cause clinically mild infections in humans [121]. As in the cot-
ton rat, L. sigmodontis may reach patent infection in Mongolian gerbils (Meriones
unguiculatus) with similar worm burden [122, 12]. An overview of the L. sigmo-
dontis life cycle is also given in Fig. 1.1. L. sigmodontis is able to reach patency in
the BALB/c mouse strain although lower worm burdens are achieved in the pleural
cavity and worms are smaller compared to those developing in the natural host,
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the cotton rat [203]. In BALB/c mice, L3 larvae reach the pleural cavity at ∼7
dpi, where they molt to the L4 stage. L4 larvae again molt into adult worms at
∼4 weeks post infection and the mice may become microfilaremic at ∼55 - 60 dpi
[122, 7, 16]. Other mouse strains (e.g. C57BL/6 mice) are not permissive for the
development of patent infection of L. sigmodontis which is likely a consequence of
a different bias of the immune system in these mice [15].
Of note, L. sigmodontis carries a strain of Wolbachia endosymbionts that like
Wolbachia of B. malayi belongs to supergroup D [20]. In consequence, L. sigmo-
dontis is not only an excellent model to study the biology and immunology of filarial
infections [122, 7], but it is also suitable for testing the effect of drugs that target
Wolbachia [116].
1.5.2 Acanthocheilonema viteae
Another model filarial nematode able to infect Mongolian gerbils is Acanthocheilo-
nema viteae (previously named Dipetalonema viteae), that is transmitted by tick
vectors (Ornithodoros moubata). This filaria infects predominantly the subcuta-
neous and intramuscular tissue of their hosts [243]. In contrast to L. sigmodontis,
A. viteae, like other Acanthocheilonema species, do not have Wolbachia symbionts
[116, 175, 254]. Absence of Wolbachia renders this filarial nematode a control or-
ganism for the study of Wolbachia-targeting drugs.
1.6 Antifilarial drugs
Before the different drugs used for the treatment of filarial diseases are introduced,
it should be remarked that the efficacy of antifilarial drugs may be classified as to
which life stages of the worms are efficiently killed: Drugs that kill MF are termed
"microfilaricidal drugs", while those that induce death of adult worms are termed
"macrofilaricidal". It is further differentiated between classical anthelminthics that
target worm processes and antibiotics that deplete Wolbachia endosymbionts and
have secondary effects on their filarial hosts. For classical anthelminthics the mode
of action was mostly delineated from studies using non-filarial nematodes like As-
caris suum or Caenorhabditis elegans and is assumed to apply to filarial nematodes,
often without experimental verification.
1.6.1 Classical anthelmintics
In many countries endemic for filariases Mass Drug Administration Programs (MDA)
are carried out that aim for the elimination of Onchocerciasis as a public health
problem and envisage the final eradication of LF [3, 1, 2, 4]. These programs
employ annual treatment rounds of single-dose combination therapies with classi-
cal anthelmintics (diethylcarbamazine (DEC) + albendazole (ALB) or ivermectin
(IVM) + ALB).
DEC is regarded as the most powerful antifilarial drug with efficient microfilari-
cidal and weak macrofilaricidal effect [193] and is used exclusively against LF. Its
molecular targets and mechanism of action remain unknown [92]. One study re-
vealed DEC-elicited defects ofW. bancrofti microfilariae in vitro and in vivo, evident
in exsheathment, apoptosis and organelle damage [201]. Other studies using murine
models demonstrated that functional host pathways (arachidonic acid pathway and
inducible nitric-oxide synthase (iNOS)) were required to achieve a reduction of mi-
crofilaremia by DEC-treatment [173].
IVM is the most prominent member of the macrocyclic lactone drugs to which
also moxidectin belongs. The main effect of IVM is its agonistic activity on nema-
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tode glutamate-gated chloride channels (GluCl) (with lower potency also on other
ligand-gated ion channels) depolarizing interneurons and inhibitory motoneurons
resulting in a flaccid paralysis of the worms, affecting body wall and pharyngeal
musculature [123, 144, 202]. For MF of B. malayi an IVM-elicited neuromuscu-
lar block of the excretory-secretory apparatus has been demonstrated that pu-
tatively disrupts immunomodulation via excretory/secretory products enabling a
rapid clearance of MF by the human immune system [186]. Consequently, for IVM
only microfilaricidal activity has been reported [125].
In Onchocerciasis patients, DEC provokes serious adverse events (Mazzotti reac-
tion) [82] which prevents the use of this drug for MDA in Oncho-co-endemic areas.
As a consequence, Onchocerciasis control programs rely exclusively on IVM. IVM,
in turn, may cause severe encephalopathies in highly microfilaremic patients infected
with loiasis [88, 46], another comparatively benign filarial disease caused by the eye
worm Loa loa [195]. Sub-optimal responses against IVM in clinical medicine and
clear IVM-resistance in veterinary medicine have been reported in several studies
[192, 49, 90] and are raising serious concern about the future efficacy of this drug
in disease eradication programs. Macroyclic lactone resistance may involve altered
sequences or expression of P-glycoprotein drug-efflux transporters [35] or GluCl-
subunits [170, 95]. For DEC similar observations of drug resistance have been made
[73, 238].
ALB belongs to the class of broad-spectrum benzimidazole anthelminthics. These
drugs specifically target nematode β-tubulin and induce disintegration of micro-
tubules [156]. A recent study revealed that albendazole sulfone, one of the two
major metabolites of albendazole in vivo, also reduced Wolbachia levels [226]. The
authors conclude that it must be considered that the antifilarial activity by ALB
is a combination of destabilization of microtubules in the nematode and an ef-
fect on Wolbachia. However, while prolonged treatment with higher doses was
observed to have some macrofilaricidal effects, the single doses used in combina-
tion to DEC/IVM during MDA are mainly to enhance the microfilaricidal effect of
DEC/IVM and the low macrofilaricidal effect of DEC [194].
1.6.2 Wolbachia-depleting antibiotics
In the late 1990s pioneering studies first aimed to dissect the role ofWolbachia for the
biology of their filarial hosts by eliminating the endosymbionts by antibiotic treat-
ment. Hoerauf and coworkers found that tetracycline treatment of L. sigmodontis-
infected mice efficiently depleted the endobacteria from their host causing infertility
of adult female worms [116], while several other antibiotics such as chlorampheni-
col, macrolides or ciprofloxacin had no effect on Wolbachia levels and did not affect
worm fertility [118]. In parallel, studies on B. pahangi and D. immitis-infected dogs
reported a block of filarial embryogenesis after tetracycline treatment [22]. A mile-
stone in antifilarial drug discovery subsequently was the successful demonstration
that doxycycline treatment leads to depletion of the endobacteria from O. volvulus
in vivo resulting in sterility and death of adult worms [117, 115, 159, 247]. Thus
Wolbachia were established as an excellent antifilarial drug target to treat human
disease. Doxycyline, and tetracyclines in general, are inhibitors of protein transla-
tion preventing the attachment of aminoacyl-tRNAs to the ribosomal acceptor site
and have a bacteriostatic effect [47].
The antifilarial effect achieved by Wolbachia-depleting antibiotics in the clinic
has several major advantages compared to classical anthelmintic therapy. Doxycy-
cline therapy induces a long-term sterililizing effect and has pronounced macrofila-
ricidal activity [248, 61, 120]. Pathology was also reported to be ameliorated after
doxycycline therapy [62, 167]. Due to the slow death of adult worms (> 12 months
after treatment) and the lack of abrupt release of highly-inflammatory Wolbachia
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antigens, doxycycline causes few side effects [62]. Furthermore, the absence of Wol-
bachia endobacteria in L. loa [172, 40] allows the safe use of Wolbachia-targeting
drugs in areas co-endemic for loiasis. However, the long treatment regimen of 3-
5 weeks required for efficient depletion of Wolbachia is a major disadvantage and
contraindications for children and pregnant and breast-feeding women prevent the
use of this drug in MDA [119, 91]. Nevertheless, studies undertaken in Cameroon
successfully demonstrated the general feasibility of large-scale distribution of doxy-
cycline (100 mg/day for 6 weeks) on a community-directed basis even for such pro-
longed treatment times [261, 244]. Another registered drug with activity against
Wolbachia is rifampicin, an antibiotic commonly used for the treatment of tuber-
culosis targeting the bacterial DNA-dependent RNA polymerase [258, 251, 233].
Combination therapy of doxycycline with rifampicin has been shown to shorten the
required treatment regimens [60] and is a first step towards the development of
anti-Wolbachia therapies and treatment regimens more suitable for MDA.
1.6.3 A call for the development of novel antifilarial drugs
Antifilarial treatment in MDA mainly has microfilaricidal effects and aims at a re-
duction of transmission. As the long-lived adult worms are only temporarily para-
lyzed and start production of MF again 6 - 12 months after treatment [14], MDA
programs have to be done repeatedly over the entire life-span of the filariae in order
to be successful. Adult filariae are able to persist in their human hosts for more
than a decade and, in consequence, MDA programs using microfilaricidal drugs
are organisationally and economically very challenging, especially in the context
of political instabilities in many endemic countries. On this background develop-
ment of resistance against DEC, and especially IVM, the mainstay of antifilarial
therapy is a serious threat to the ambitious goals of WHO’s elimination programs
[25, 91]. Therefore the discovery of novel, preferentially macrofilaricidal, antifilarial
drugs has become a priority in biomedical filarial research. The great efficacy and
specificity possible with Wolbachia-targeting antibiotics make this endobacterium
a prime target for novel strategies in antifilarial drug discovery. Sequencing of the
Wolbachia genome and identification of essential biochemical pathways in these en-
dobacteria allowed the designation of Wolbachia enzymes as putative drug targets
[81, 93, 207, 124, 232]. In the current study, two prioritized potential drug targets,
the heme biosynthetic enzyme δ-aminolevulinic acid dehydratase (ALAD) and the
glycolytic/gluconeogenetic enzyme pyruvate phosphate dikinase (PPDK), were sub-
jected to a target-based drug discovery approach to satisfy current needs for novel
antifilarial agents.
1.7 Heme biosynthesis in filarial nematodes
Biosynthesis of tetrapyrroles is a highly conserved biosynthetic pathway that is
elementary for the production of biomolecules with paramount importance for li-
ving organisms. In porphyrins the four pyrrole rings are linked at the α postion
via methine bridges and the most prominent porphyrin, heme, complexes a fer-
rous (Fe2+) or ferric iron (Fe3+) at the center of the ring. Heme is an essential
prosthetic group in enzymes involved in a broad spectrum of vital processes in life.
Heme-dependent proteins are, e.g. hemoglobin/myoglobin (oxygen transport) [260],
cytochrome b and cytochrome c oxidase (oxidative phosphorylation in bacteria and
mitochondria) [150], cytochrome P450 (metabolization and detoxification of xeno-
biotics) [53], catalases and peroxidases (degradation of harmful H2O2 [276, 277]),
cyclooxygenases (prostaglandin biosynthesis) [166] and many more.
Chlorins contain three pyrrole and one pyrroline ring. Their most prominent
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members, the chlorophylls required for photosynthesis in plant cloroplasts, complex
a magnesium ion in the center of the ring [245]. Further tetrapyrrole-derivatives
represent the core of cobalamins (vitaminB12) [217].
Heme biosynthesis is a complex metabolic pathway that includes six common
precursors and, in eukaryotic cells, is compartmentalized between the cytosol and
mitochondria in metazoan and fungal cells and between the mitochondria and the
chlorplast in plants (Fig. 1.2). The only biosynthetic step which uses variable
substrates and enzymes, respectively, in different organisms is the first step: In
the C4 or Shemin pathway of non-photosynthetic eukaryotes and α-proteobacteria
δ-aminolevulinic acid synthase uses glycine and succinyl-CoA for the synthesis of
5-aminolevulinic acid (5-ALA), while the alternative C5 pathway for 5-ALA syn-
thesis in photosynthetic organisms, archaea and most bacteria requires two enzy-
matic steps starting with glutamyl-tRNA [255]. The next steps are common in
all tetrapyrrole synthesizing organisms: δ-aminolevulinic acid dehydratase (ALAD,
also known as porphobilinogen synthase, PBGS, E.C. 4.2.1.24) catalyzes the asym-
metric condensation of two molecules of 5-ALA to the pyrrole porphobilinogen.
Porphobilinogen deaminase then produces the linear tetrapyrrole hydroymethylbi-
lane, which is cyclized by uroporphyrinogen III synthase to uroporphyrinogen III.
The three following enzymatic steps catalyzed by uroporphyrinogen III decarboxy-
lase, coproporphyrinogen III oxidase and protoporphyrinogen IX oxidase alterate
the side chains of the cyclic tetrapyrroles and produce the precursors copropor-
phyrinogen III, protoporphyrinogen IX and protoporphyrin IX. The final step is
the incorporation of Fe2+ into the center of protoporphyrin IX to form heme b,
the most common heme form [107]. Chlorophyll synthesis branches off with the
incorporation of Mg2+ into protoporphyrin IX by Mg2+ chelatase [52].
The Wolbachia genome contains all genes necessary for de novo heme biosynthe-
sis except the hemG or hemY gene encoding protoporphyrinogen IX oxidase (PPO)
in γ-proteobacteria or eukaryotes. As in other bacteria, this function is probably
encoded by a yet unidentified gene [81]. Unlike Wolbachia, their nematode host B.
malayi lacks all heme-biosynthetic genes except the gene for ferrochelatase (FC)
catalyzing the final step of heme biosynthesis [93]. Interestingly, phylogenetic ana-
lysis of the FC gene homolog revealed a putative horizontal gene transfer from an
α-proteobacterium that likely belongs to the Rhizobiales [232] and not from Wol-
bachia.
Suitability of endobacterial heme biosynthesis as an antifilarial drug target was
validated by Wu and coworkers [270] who showed that inhibitors of ALAD (suc-
cinyl acetone) and FC (N-methyl mesoporphyrin) reduced the motility of B. malayi
adult female worms in an ex vivo survival assay. Addition of exogenous heme
did not rescue these worms indicating the filariae were unable to use this external
heme source for their needs. Further evidence for the biological relevance of Wol-
bachia-derived heme biosynthesis in symbiosis was uncovered by microarray studies
analysing differential gene expression of L. sigmodontis after depletion of Wolbachia
by doxycycline treatment [241]. Several mitochondrial heme-dependent genes were
up-regulated in response to Wolbachia-depletion, while expression patterns of these
genes in Wolbachia-free A. viteae were unaffected by tetracycline treatment. This
differential gene expression is regarded as a desperate response of the worm to
overcome malfunctioning of its mitochondrial respiratory chain as a consequence of
heme-deficiency subsequent to endosymbiont loss.
In order to develop drugs that are efficient against Wolbachia, but harmless for
humans, potential drug targets must be species-specific. The heme-biosynthetic en-
zyme with the greatest structural divergence from its human ortholog, and therefore
the best suited for the discovery of such inhibitors, is δ-aminolevulinic acid dehy-
dratase of Wolbachia of Brugia malayi (wALAD). As currently known inhibitors,
such as the already mentioned substrate analog succinyl acetone, target structural
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Figure 1.2: Heme biosynthesis pathway
Overview of the heme biosynthesis pathway in Wolbachia with the involved substrates and
enzymes (with common abbreviations) is depicted in black font. This pathway is shared
by non-photosynthetic eukaryotic organisms such as mammals and other α-proteobacteria.
The alternate C5 pathway for the production of 5-ALA in plants and other bacteria, as
well as the branching point for chlorophyll biosynthesis of photosynthetic organisms are
depicted in gray.
16
CHAPTER 1. INTRODUCTION
features that are highly conserved in ALAD orthologs from different species, dis-
covery of Wolbachia-specific inhibitors of ALAD enzymatic function was a major
ambition of this study.
1.8 δ-Aminolevulinic Acid Dehydratase (ALAD)
δ-aminolevulinic acid dehydratase (ALAD) is a homo-oligomeric enzyme with each
subunit of the protein adopting an (α/β)8-barrel (TIM-barrel) fold with an extruded
N-terminal arm region important for intersubunit contacts [72, 83]. The active site
is located in a cavity in the center of the α/β8-barrel domain and catalyzes the
condensation of 2 molecules of 5-aminolevulinic acid (5-ALA) to porphobilinogen
[134]. Distinct binding sites for the 5-ALA molecules exist that are termed A-
site and P-site. The corresponding substrate molecules that give rise to the acetyl
and propionyl moieties, respectively, in the final porphobilinogen product are called
A-side 5-ALA and P-side 5-ALA (Fig. 1.3, [134]).
ALAD enzymes are the prototype of so-called morpheeins, i.e. allosteric proteins
that form an equilibrium of different quaternary assemblies that show characteristic
differences in their functional properties, i.e. catalytic activities in the case of ALAD
[135, 137]. The basic building blocks are asymmetric dimers which may adopt diffe-
rent allosterically driven conformations that lead to an orientational rearrangement
of the N-terminal arm towards the (α/β)8-barrel ("hugging dimer" vs. "detached
dimer" and "pro-octamer dimer" vs. "pro-hexamer dimer") [37, 137]. These dimers
have an intrinsic propensity to form different higher molecular weight oligomers,
most commonly hexameric or octameric assemblies. Hexameric assemblies are usu-
ally characterized by low enzymatic activity [37], while the octamer represents the
conformation of high enzymatic activity.
Although the catalytic mechanism including the involved catalytic amino acids
of the active center are well conserved throughout orthologous enzymes of dif-
ferent organisms, decisive differences are observed in the metal-cofactor require-
ments of different ALAD orthologs with structural and functional differences both
at active and allosteric sites [229, 133]. Mammalian enzymes, including the hu-
man ortholog (hALAD), as well as orthologs of yeast and several bacteria, share
a Zn2+-binding cysteine-rich consensus sequence (DXCXCX(Y/F)X3G(H/Q)CG)
[133]. While binding and Schiff-base formation of the first P-side 5-ALA molecule
with an active site lysine-residue (Lys252 of hALAD) occurs independent of any
metal ions, formation of a ternary complex between the active site Cys-residues,
Zn2+ and C4-carbonyl oxygen and C5-NH2 nitrogen atoms of A-side 5-ALA are
required for binding of this second molecule, followed by closure of the active-site
lid and conductance of the catalytic reaction in a Knorr-type mechanism [133]. In
contrast, enzymatic activity of Wolbachia ALAD (wALAD) was shown to be Zn2+-
independent, but required Mg2+ [270]. Dependence on binding of catalytic Mg2+
to the active site and/or stimulation of catalytic activity by Mg2+ binding to an
allosteric site (Mgc-site) has been demonstrated for a variety of other ALAD or-
thologs from plants, bacteria and protozoa [26, 205, 83, 148, 227]. The allosteric
Mg2+-binding site is located at the subunit interface of two pro-octamer dimers and
the induced allosteric effect is a major stabilizer of the active octameric assembly
[137]. In the crystal structure of Pseudomonas aeruginosa ALAD Mg2+ of the al-
losteric site was coordinated to Glu245 and five H2O molecules and was revealed
to induce a conformation that allows closure of the active site lid prior to catalysis
[83]. The conserved glutamic acid ligand of allosteric Mg2+ is also conserved in
wALAD, but is absent in the hALAD sequence. Whether catalytic Mg2+ or al-
losteric Mg2+ leads to the observed Mg2+-responsiveness of wALAD has not been
dissected. Instead of the Cys-rich Zn2+-binding motif of hALAD, wALAD features
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Figure 1.3: The chemical reaction catalyzed by δ-aminolevulinic acid
dehydratase
a) Quaternary structure of the assymetric "hugging" dimer of P. aeruginosa ALAD (PDB
structure 1B4K [83]) as the building block of the active octameric assembly. Secondary
structure elements of the active protomer (with open active site) are shown in a ribbon
diagram and are highlighted in color: β-sheets (dark green), α-helices (light green) and
loops (white). Structural elements of the second inactive protomer are uniformly displayed
in orange. The allosteric Mgc-ion is displayed as a purple ball, the active site - directed
inhibitor levulinic acid is displayed in ball and stick representation. The image was created
using Marvin Space 5.8.1 (ChemAxon, Budapest, Hungary). b) The chemical reaction
catalyzed by ALAD.
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an aspartic acid rich sequence characteristic of Zn2+-independent orthologs. Al-
though no species-selective inhibitor of wALAD was known prior to this work, the
outlined phylogenetic variations in the metal binding sites with their corresponding
structural and functional differences provide the molecular basis for the develop-
ment of selective inhibitors that specifically target ALAD orthologs from certain
organisms. It should thus be possible to identify inhibitors of potential therapeu-
tic significance that specifically target wALAD and interrupt heme biosynthesis in
the filarial endosymbiont without affecting this essential biochemical pathway in
humans.
1.9 Pyruvate Phosphate Dikinase (PPDK)
Another promising anti-Wolbachia drug target is the enzyme pyruvate phosphate
dikinase (PPDK; E.C.2.7.9.1) [212], which is found exclusively in prokaryotes, pro-
tozoa and plants, but not in mammals. PPDK catalyzes the following reversible
conversion of phosphoenol pyruvate (PEP) to pyruvate [74, 268]:
phosphenolpyruvate+AMP + PPi
PPDK,Mg2+
⇐⇒ pyruvate+ATP + Pi (1.1)
PPDK may, in principle, function both in the glyocolytic and gluconeogenetic di-
rection, whereas mammalian cells use pyruvate kinase (PK) for glycolysis and a two-
step mechanism involving the conversion of pyruvate to oxaloacetate by pyruvate
carboxylase followed by conversion of oxaloacetate into PEP by PEP carboxykinase
for gluconeogenesis. In glycolysis, PK catalyzes one substrate-level phosphorylation,
i.e. phosphoryl transfer from PEP onto ADP creating ATP. In contrast, PPDK uses
AMP and pyrophosphate as cosubstrates with PEP to catalyze a double phosphoryl
transfer to AMP to form ATP with the release of orthophosphate. Consequently the
latter mechanism is energetically more favourable with higher ATP-yields per glu-
cose catabolism [177] and the small ∆G generally allows reversibility of the reaction
[268]. Wolbachia lack 6-phosphfructokinase, an enzyme catalyzing an irreversible
glycolytic reaction, but they do possess a gene encoding fructose-1,6-bisphosphatase,
the corrsponding gluconeogenetic enzyme [81]. As glucose-6-phosphate utilizing en-
zymes are not encoded in the endobacterial genome, gluconeogenesis in Wolbachia
likely ends with the production of fructose-6-phosphate a precursor of bacterial
peptidoglycan components [81]. Despite the absence of the initial glycolytic en-
zymes hexokinase, phosphoglucose isomerase and 6-phosphofructokinase Wolbachia
may simply import downstream glycolytic metabolites from the filariae in order to
produce pyruvate. 32P-NMR studies revealed that B. malayi stores high concentra-
tions of PEP as an energy reservoir [230] that, if accessible to the endobacteria, may
also be exploited by PPDK functioning in the glycolytic direction. The absence of
PPDK from mammalian cells and the lack of sequence homology to PK due to its
unique reaction mechanism make PPDK an excellent drug target [212].
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1.10 Aim of this work
The discovery of novel chemotherapeutic options to treat lymphatic filariasis and
onchocerciasis is a fundamental requirement in order to overcome resistance de-
velopment against conventional antifilarial drugs and to finally eradicate these fi-
larial diseases. Given the excellence of the Wolbachia endosymbiont as a target
for antifilarial chemotherapy, the aim of the current study was to subject two es-
sential enzymes of these endobacteria to a target-based drug discovery approach
and to validate the potential of identified inhibitors as novel antifilarial drug can-
didates. The target proteins were pyruvate phosphate dikinase (PPDK), a gly-
colytic/gluconeogenetic enzyme without mammalian ortholog, and δ-aminolevulinic
acid dehydratase (ALAD), an enzyme with substantial sequence variation from the
human ortholog that catalyzes the second step of heme biosynthesis in Wolbachia.
For both target proteins enzymatic assays were established and implemented in
High-Throughput Screening against a diversity-based chemical library comprising
∼18,000 drug-like small molecules in order to identify novel inhibitors. Candidate
inhibitors were characterised with regard to specificity and the underlying inhibitory
mechanism. Eventually, using a filarial ex vivo culture system and a natural murine
infection model employing the rodent filarial nematode Litomosoides sigmodontis,
validated inhibitors were tested for their potency as novel antifilarial agents. Any
successful candidate might open new avenues for the development of potent antifi-
larial drug leads that may also be applicable to other human pathogens.
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Materials, Methods &
Preparative Experiments
The specific origin of reagents or instruments used in the experiments of this work
are stated in the corresponding sections. If the source of the reagents is not men-
tioned, they were purchased from Sigma Aldrich (Munich, Germany) or Merck
(Darmstadt, Germany). Glassware was from Schott (Mainz, Germany) or Sklarny
Kavalier (Sàzava, Czech Republic).
2.1 Materials
2.1.1 Instruments and Equipment
The following standard instruments and equipment were used throughout the ex-
perimental procedures if not stated otherewise.
Centrifuges
Hettich Mikro 200 (Hettich-Zentrifugen, Tuttlingen, Germany)
Used for micro reaction tubes in DNA preparation protocols at RT
Eppendorf Centrifuge 5417R (Eppendorf AG, Hamburg, Germany)
Used for micro reaction tubes at different temperatures
Heraeus Multifuge 4KR (Heraeus Instruments, Osterode, Germany)
Used with LH-4000 rotor (75006475) for 96-well plates and 15 and 50
mL reaction tubes
Sorvall Evolution RC Superspeed Centrifuge (Thermo Scientific, Drei-
eich, Germany)
Used with SLC 4000 rotor for large volumes of bacterial cell cultures in
1 L centrifugation beakers.
Hettich EBA 20 (Hettich-Zentrifugen, Tuttlingen, Germany)
Used with E1624 rotor for P. falciparum culture
Syringes and needles
Syringes and needles used were from B.Braun Melsungen AG (Melsungen,
Germany) or Beckton Dickinson S.A. (Fraga, Spain).
Syringes: Omnifix R©- F 1 ml (Braun), BD Discardit II (5 mL, 10 mL,
20 mL) (BD)
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Needles: Sterican 0,40 mm x 20 mm (Braun); BD MicrolanceTM 3 0,9
mm x 40 mm
Microscopes
Leitz Diaplan Photomikroskop (Leitz, Wetzlar, Germany)
Zeiss Axioskop 50 (Carl Zeiss AG, Jena, Germany)
Leica DM IL Durchlichtmikroskop (Leica Microsystems, Wetzlar, Ger-
many)
Pipettes and Pipettors
Pipettes were from Eppendorf (Eppendorf AG, Hamburg, Deutschland) or
Gilson Inc. (Middleton, USA).
Spectrophotometer
Nanovue Plus spectrophotometer (GE Healthcare Europe, Germany)
SpectraMAX 340 Pc with analysis software SoftMax Pro (Molecular De-
vices, Sunnyvale, USA)
InfiniteTM200 NanoQuant (Tecan, Männedorf, Switzerland)
Shaker
Shaker MS2 (IKA-Werke GmbH, Staufen, Germany)
IKA KS 250B (IKA-Werke GmbH, Staufen, Germany)
Stuart mini orbital shaker SSM1 (Bibby Scientific Limited, Stone, Stafford-
shire, UK)
Thermo Shaker
Eppendorf Thermomixer compact (Eppendorf AG, Hamburg, Germany)
Vortex-Mixer (VWR International GmbH, Darmstadt, Germany)
2.1.2 Reagents and Solutions
All solutions were prepared with ultrapure H2O produced with a Direct-Q
R© 3 UV
Ultrapure (Type 1) Water System in combination with a BioPak ultrafilter for ultra-
pure pyrogen-free, DNAse-free and RNAse-free water (Merck Millipore, Darmstadt,
Germany).
ALAD activity assay buffers
wALAD Buffer 1: 100 mM Tris (pH 8.0), 5 mM DTT, 10 mM MgCl2
wALAD Buffer 2: 100 mM Tris (pH 8.0), 5 mM DTT, 1 mM MgCl2
hALAD Buffer: 100 mM Tris (pH 7.5), 5 mM DTT, 10 µM ZnCl2
Bacterial strains
Top 10 E. coli: Strain used for primary transformation of cloned genes
and plasmid purification. The strain was purchased from Life Technolo-
gies (Darmstadt, Germany).
T7 Express competent E. coli (NEB 2566 E. coli): Strain used for
recombinant protein expression. The strain was purchased from New
England Biolabs (Ipswich, MA, USA)
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BL 21 E. coli: Strain used for recombinant protein expression. The
strain was purchased from Life Technologies (Darmstadt, Germany).
Pseudomonas aeruginosa (PA01) were kindly provided by Dr. B.
Henrichfreise (Institute for Medical Microbiology, Immunology and Para-
sitology, Pharmaceutical Microbiology Unit, University of Bonn)
E. coli were grown on/in LB agar/bouillon (see below), P. aeruginosa on/in
Müller-Hinton agar/bouillon (CM0405, Oxoid Limited, Basingstoke, UK). All
media were prepared according to standard protocols of the Nährbodenküche
in the IMMIP. Permanent cultures of bacterial strains were supplemented with
15% DMSO and kept at -80 ◦C.
Cell lines, cell culture media and reagents
Cell culture reagents were from PAA Lab. (Pasching, Austria) or Life Tech-
nologies (Darmstadt, Germany). Sterile plastic ware like cell culture plates (F-
bottom), cell culture flasks and pipettes were from Greiner Bio-One (Fricken-
hausen, Germany).
LLC-MK2 cells and culture medium:
LLC-MK2 monkey kidney cells from the rhesus monkey Macaca mu-
latta) were kindly provided by S. Townson (London School of Hygiene
& Tropical Medicine, UK). LLC-MK2 culture medium was Minimal Es-
sential Medium with 10% fetal bovine serum, 2 mM L-glutamine and 1X
Penicillin/Streptomycin.
HEK cells and culture medium:
Human Embryonic Kidney (HEK) cells co-transfected with Toll-Like Re-
ceptor 1/6 (HEK cells) were from Life Technologies (Darmstadt, Ger-
many). The culture medium was Dulbecco’s modified eagle medium
(DMEM High Glucose, L-Glutamine) with 10% fetal bovine serum and
10 µg/mL blasticidin.
P. falciparum culture medium:
P. falciparum medium 500 mL RPMI (with 25 mM HEPES, without
glutamine, with phenol red)
500 µL Gentamycin
5 mL L-Glutamine
25 mg Hypoxanthin
2,5 g Albumax II (was dissolved in 50 mL of RPMI medium at 37 ◦C
and filter sterilized before it was added to medium)
Medium was stored at 4 ◦C for up to 4 weeks
LB medium and agar
10 g Bacto-tryptone
5 g Bacto-yeast extract
10 g NaCl
ad 1 L
1 pellet NaOH, to adjust to pH 7, autoclave
For agar plates, 15 g agar was added to the medium and agar was poured into
petri dishes
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Modified Ehrlich’s Reagent (MER)
1 g para-dimethlyaminobenzaldehyde
42 mL acetic acid
12 mL perchloric acid
7,3 mL 12% trichloroacetic acid
1XPBS:
137 mM NaCl
2.7 mM KCl
1 mM Na2HPO4 x 2H2O
1.76 mM KH2PO4
PCR Primers
T7-FW:
5’-TAA TAC GAC TCA CTA TAG GG -3’
T7-RV:
5’-GCT AGT TAT TGC TCA GCG G-3’
pALAD FW1-NheI:
5’-GCT AGC AGC TTC ACT CCC GCC-3’
pALAD RV1-XhoI:
5’-CTC GAG ACG CCC CCG TCT TAA TTG TTC T-3’
pALAD FW2-NdeI:
5’-GTC ATA TGA GCT TCA CTC CCG CC-3’
pALAD FW3-SacI:
5’-GTG AGC TCC AGC TTC ACT CCC GCC-3’
pALAD RV2-NotI:
5’-CGG CGG CCG CGA TAC GTT CGA TCT CAT-3’
pALAD RV3-XhoI:
5’-GTC TCG AGA CGC CCC CGT CTT AAT TGT TCT-3’
Tg529-Fw:
5’-GAT ATC AGG ACT GTA GAT GAA GG-3’
Tg529-Rv:
5’-GCG TCG TCT CGT CTA GAT C-3’
Tg529-probe:
5’-6-FAM-AAG CGA CGA GAG TCG GAG AGG GAG-3’-BHQ-1
MM-bactin-FW:
5’-GAT GAG ATT GGC TTT A-3’
MM-bactin-RV:
5’-AAC CGA CTG CTG TCA CCT TC-3’
LsFtsZ-FW:
5’-CGA TGA GAT TAT GGA ACA TAT AA-3’
LsFTsZ-RV:
5’-TTG CAA TTA CTG GTG CTG C-3’
LsFTSZ-probe:
5’-6-FAM-CAG GGA TGG GTG GTG GTA CTG GAA-3’-TAMRA
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LsActin-FW:
5’-ATC CAA GCT GTC CTG TCT CT-3’
LsActin-Rv:
5’-TGA GAA TTG ATT TGA GCT AAT G-3’
LsActin-probe:
5’-HEX-ACT ACC GGT ATT GTG CTC GAT T-3’-TAMRA
PPDK activity assay buffer
PPDK Buffer: 250 mM imidazole, 100 mM NH4Cl, 50 mM MgCl2, pH
6.3
PPDK-PBS Buffer: 1x PBS, 100 mM NH4Cl, 1 mM MgCl2, pH 7.1
Protein purification buffers
Lysis Buffer: 100 mM Tris-HCl (pH 8.0), 300 mM NaCl, 10 mM imi-
dazole
Wash Buffer: 100 mM Tris-HCl (pH 8.0), 300 mM NaCl, 50 mM imi-
dazole
Elution Buffer: 100 mM Tris-HCl (pH 8.0), 300 mM NaCl, 25 mM
imidazole
Pyruvate Detection Reagent (PDR)
2 N HCl (5 parts)
0.167% 2,4-dinitrophenylhydrazine in 1 N HCl (1 part)
S.O.C. medium
10 g Bacto-tryptone
5 g Bacto-yeast extract
5 g NaCl
10 mM MgSO4 glycerol
10 mM MgCl2
ad 1 L with H2O
adjust pH to 7.0 with NaOH, autoclave
filter sterilize and add glucose to 20 mM final concentration
10X TBE-Buffer:
108 g Tris base
55 g boric acid
9.3 g Na2EDTA x 2H2O
ad 1 L with H2O
TE-Buffer:
10 mM Tris (pH 7.5)
1 mM EDTA
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2.2 Methods
2.2.1 Agarose gel electrophoresis
PCR products and plasmids were analyzed by agarose gel electrophoresis. 1% A-
garose gels (Biozym LE Agarose (Biozym Scientific GmbH, Hessisch Oldendorf,
Germany) were cast in 0.5% TBE buffer and the DNA-stain Safe Red TM (Applied
Biological Materials Inc., Richmond, BC, Canada) was added at a 1:2000 dilution.
Samples were mixed with 6x Gel Loading Dye Blue before application on the gel
(New England Biolabs, Ipswich, MA, USA) and 5 µL of a 1 kb DNA ladder (New
England Biolabs, Ipswich, MA, USA) was added for reference of band sizes. For
standard analytical gels 10 - 30 ng of DNA or 5 - 20 µL PCR product was loaded
per sample. For preparative gels the entire PCR product was loaded. Standard gels
were run at 120 V for 45 min before DNA-bands were visualised using a Biome-
tra UV solo gel documentation chamber (Biometra, Göttingen, Germany). Bands
from preparative gels were viewed and excised on a Biometra UV-transilluminator
FLX-20M (Biometra) and DNA was purified using the Invisorb R© Spin DNA ex-
traction/Fragment CleanUp kit (STRATEC Molecular GmbH, Berlin, Germany).
2.2.2 Polymerase Chain Reactions (PCR)
All reagents used for PCR were from Qiagen (Hilden, Germany), Fermentas (St.
Leon-Rot, Germany), Finnzymes (Vantaa, Finland) or New England Biolabs (Ips-
wich, MA, USA). Primers were ordered from Biolegio (Nijmegen, The Netherlands).
Phusion Taq PCR
Standard PCR reactions for amplification of gene fragments were carried out using
the following standard protocol. Primers were kept in TE-Buffer and used from 10
µM stocks.
Final con-
centration
Volume [µL]
5x Buffer HF 1x 4
Fw Primer [10 µM] 500 nM 1
Rv Primer [10 µM] 500 nM 1
dNTP mix [10 mM] 200 µM 0.4
Phusion Taq [2U/µL] 0.02 U 0.2
DNA 1 - 2
H2O ad 20
In order to determine optimal annealing temperatures a temperature gradient
PCR was run on the iCycler (Bio-Rad Laboratories GmbH, München, Germany).
Regular PCR reactions were carried out on a MWG Biotech Primus 96 plus ther-
mocycler (MWG Biotech AG, Ebersberg, Germany).
Cycling protocol:
1. Denaturation 98 ◦C 5 min
2. Amplification cycles: 35
a Denaturation 98◦C 10 s
b Annealing 50 ◦C - 72 ◦C 20 s
c Amplification 72 ◦C 1 min
3. Last amplification step 72 ◦C 10 min
4. Cool down to 8◦C
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Colony PCR
The success of cloning procedures was verified directly after colony growth by colony
PCR. Single colonies were picked with a loop, streaked out on a fresh agar plate
and the loop was inserted into 20 µL H2O. Bacteria in the resulting suspension were
lysed by heating for 10 min to 95 ◦C and the lysate was directly used as a template
for PCR. Clones were analysed by both amplification with the specific and the T7
primer set.
Final con-
centration
Volume [µL]
5x Buffer HF 1x 4
Fw Primer [10 µM] 500 nM 1
Rv Primer [10 µM] 500 nM 1
dNTP mix [10 mM] 200 µM 0.4
Phusion Taq [2U/µL] 0.02 U 0.2
Colony lysate 5
H2O ad 20
Realtime Polymerase Chain Reactions (Realtime-PCR)
Realtime-PCR reactions were run on a Rotorgene RG-3000 or 6000 (Corbett Life
Sciences, Germany). Fluorescence was measured on the FAM channel (excitation at
470 nm; detection at 510 nm) for SYBR Green and FAM-labeled Taqman R©-probes.
Data analysis was done using Rotorgene 6 software (Qiagen, Hilden, Germany).
Quantification of T. gondii by Realtime-PCR T. gondii were quantified
by Realtime-PCR amplification using a primer set and Taqman probe specific for
a 529 bp T. gondiirepeat DNA sequence (GenBank: AF146527.1). SYBR Green
based Realtime-PCR of the Macaca mulatta β-actin gene was run separately for
normalization on sample DNA-content and the number of LLC-MK2 feeder cells:
For each sample ∆Ct (Mm-β-actin) values were subtracted from ∆CT (T.gondii) to
give ∆∆Ct values indicative of the T.gondii/LLC-MK2 cell ratio. For calculation
of the amplification efficiency of PCR reactions standard curves (10-fold dilution
rows) of DNA from non-infected LLC-MK2 cells (β-actin PCR) or from the 1%
DMSO-treated infected LLC-MK2 (T.gondii PCR) were measured.
Protocol for (Mm-β-actin) PCR:
Mm-β-actinPCR Final con-
centration
Volume [µL]
10X PCR Buffer (incl. 15 mM
MgCl2 )
1X 2
MgCl2 [25 mM] 1.5 1.2
MM-bactin-FW [5 µM] 300 nM 1.2
MM-bactin-RV [5 µM] 300 nM 1.2
dNTP mix [10 mM] 50 µM 0.1
SYBRGreen I dye 0.2
HotStar Taq [5 u/µL] 0.5 u 0.1
DNA 2
H2O 12
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Mmβ-actin PCR
1. Denaturation 95 ◦C 15 min
2. Amplification cycles: 45
a Denaturation 94 ◦C 15 s
b Annealing 58 ◦C 20 s
c Amplification 72 ◦C 20 s
3. Melting curve 59 ◦C - 95 ◦C
Protocol for (T. gondii) PCR:
T.gondii PCR Final con-
centration
Volume [µL]
10X PCR Buffer (incl. 15 mM
MgCl2 )
1X 2
MgCl2 [25 mM] 2.5 2
Tg529-FW [100 µM] 300 nM 0.06
Tg529-RV [100 µM] 300 nM 0.06
Tg529-probe [5 µM] 50 nM 0.2
dNTP mix [10 mM] 50 µM 0.1
HotStar Taq [5 u/µL] 0.5 u 0.1
DNA 2
H2O 13.48
T.gondii PCR
1. Denaturation 98 ◦C 15 min
2. Amplification cycles: 45
a Denaturation 95 ◦C 10 s
b Amplification 60 ◦C 30 s
Data was acquired on the FAM (excitation at 470 nm, detection at 510 nm) for
both PCR reactions.
Quantification of Wolbachia ftsZ copy-numbers in L. sigmodontis L.
sigmodontis Wolbachia were determined by amplifying the Wolbachia ftsZ and L.
sigmodontis-actin gene by Duplex Realtime-PCR using Taqman R© probes. These
PCR experiments were physically performed by Katharina Gorski-Rzepinski.
PCR protocols were as follows:
Wolbachia ftsZ/LsActin Du-
plex Realtime PCR
Final con-
centration
Volume [µL]
Qiagen’s Quantitect Multiplex
NoROX Mastermix
1X 10
nuclease-free H2O 4.1
LsFtsZ-FW [10 µM] 500 nM 1.0
LsFtsZ-RV [10 µM] 500 nM 1.0
LsFtsZ-probe [5 µM] 25 nM 0.1
LsActin-FW [10 µM] 400 nM 0.8
LsActin-RV [10 µM] 400 nM 0.8
LsActin-probe [5 µM] 50 nM 0.2
DNA 2
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Wolbachia ftsZ/LsActin Duplex Realtime PCR
1. Denaturation 98 ◦C 15 min
2. Amplification cycles: 45
a Denaturation 95 ◦C 15 s
b Amplification 58 ◦C 45 s
Data was acquired on the FAM (excitation at 470 nm, detection at 510 nm,
gain 10) and JOE channels (excitation at 530 nm, detection at 557 nm, gain 10)
to measure 6-FAM fluorescence and HEX fluorescence, respectively. For calcula-
tion of Wolbachia ftsZ and LsActin gene copy numbers, data was normalized on
adjusted standard curves for plasmids containing Wolbachia ftsZ or LsActin genes,
respectively. As the performance of this Duplex PCR is very reliable, single plas-
mid concentration samples were included in the PCR run and a previously recorded
standard curve was imported and adjusted to the measured sample.
2.2.3 Cloning
The P.aeruginosa ALAD (pALAD) gene was cloned into the pET-21b plasmid vec-
tor (Novagen, Merck Chemicals, Darmstadt, Germany) after sequential restriction
digest, 5’-dephosphorylation and ligation. Reagents used were from New England
Biolabs (Ipswich, MA, USA) unless stated otherwise. Both amplified PCR product
and plasmid vectors were restriction digested in the following reaction mixture:
DNA (PCR product or plasmid) ∼500 ng
100X BSA 0.2 µL
10X Buffer 4 2 µL
XhoI 1 µL
NdeI 1 µL
H2O ad 20 µL
After incubation at 37 ◦C for 1 h, restriction enzymes were heat-inactivated for
20 min at 65 ◦C and DNA was purified using the MinElute PCR purification Kit
(Qiagen, Hilden, Germany).
In order to minimize religation of the digested plasmid, only the restricton di-
gested (RD) plasmid DNA was subjected to 5’-dephosphorylation using Antarctic
Phosphatase and maximal amounts of DNA.
RD-pET-21b 13 µL (∼150 ng)
10X Phosphatase Buffer 2 µL
H2O 4 µL
Antarctic Phosphatase 1 µL
Total volume 20 µL
Reactions were incubated for 15 min at 37 ◦C for efficient dephosphorylation before
Antarctic Phosphatase was heat-inactivated at 65 ◦C for 5 min.
Ligation mixtures were prepared using a 3:1 molar ratio of the 1.1 kb RD-PCR-
product (∼30 ng) to the 5.4 kb dephosphorylated RD-pET21b vector (50 ng) in a
10 µL reaction volume. 10 µL 2X Ligase Buffer and 1 µL Quick Ligase were added
and the reaction incubated for 10 min at RT.
The ligated pALAD-pET-21b plasmid was then transformed into Top 10 CaCl2-
competent E. coli. 10 µL of ligation mix was added to a 1.5 mL tube containing
200 µL competent cells thawed on ice and the mixture was mixed by gentle tapping
of the tube. After 30 min incubation on ice, cells were heat-shocked for 30 s at 42
◦C and immediately placed on ice for 5 min. 600 µL S.O.C. medium equilibrated
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to room temperature was added and bacteria were allowed to grow for 60 min at
37 ◦C, shaking at 150 rpm. Different volumes of transformation mix (50 - 200 µL)
were then spread out on a LB-selection agar plates containing 50 µg/mL ampicillin
and incubated overnight at 37 ◦C.
A detailed overview on the pALAD cloning strategy and the corresponding re-
sults is given below in the Preparative experiments (Section 2.3).
2.2.4 Plasmid and genomic DNA preparations
For plasmid purification single bacterial colonies were inoculated into 10 mL selec-
tion medium and grown overnight at 37 ◦C and 150 rpm. The next day bacterial
cells were pelleted, lysed and the plasmids purified with the Qiagen Miniprep Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s protocols.
For P. aeruginosa DNA preparation a single colony was inoculated into 4 mL
Müller-Hinton-Bouillon (CM0405, Oxoid Limited, Basingstoke, UK) in a 14 mL
polypropylene snap cap tube (greiner bio-one, Frickenhausen, Germany) and incu-
bated overnight at 37 ◦C, 150 rpm. The next day bacterial cells were pelleted, lysed
and the plasmids purified according to the "Protocol for cultured cells" of the Qiagen
DNA Mini Kit.
DNA from T. gondii parasites and LLC-MK2 feeder cells was purified from
trypsinized cells using the QIACube for fully automated sample preparation using
the "DNA Purification from Blood or Body Fluids (Spin Protocol)" of the Qiagen
DNA Mini Kit.
DNA from single L. sigmodontis worms was extracted by Katharina Gorski-
Rzepinski using reagents of the Qiagen DNA Mini Kit in a modified protocol. In
brief, worms were digested in 180 µL Buffer ATL plus 20 µL Proteinase K at 56 ◦C
over night. Samples were supplemented with 200 µL buffer AL and incubated at
70 ◦C for 10 min. 200 µL 100% ethanol were added, the tube was quickly vortexed
and the lysate was transferred to the wells of a 96-well filter plate (Binding plate,
Promega, Madison, WI, USA). The plate was placed into a vacuum filter device
(Vac-Man R© 96 Vacuum manifold, Promega) and the samples subjected to vacuum
filtration. Each well was successively washed with 1 mL of buffer AW1 and AW2.
When all remaining liquid had been sucked off by the vacuum after 5 min, the plate
was centrifuged at 4,400 rpm at RT (Heraeus Multifuge 4KR with LH-4000 rotor)
and residual ethanol was allowed to evaporate (5 min at RT). DNA was dissolved
by the addition of 50 µL buffer AE. After 5 min DNA was eluted under vacuum for
5 min into a clean 96-well plate (Brand, Wertheim, Germany).
2.2.5 DNA sequencing reactions
Sequences of the cloned inserts within the expression plasmids were verified by
sequencing. Samples were prepared containing 0.3 -0.7 ng plasmid and 20 pmol
primer in 7 µL volume and sent to Seqlab (SEQLAB Sequence Laboratories Göt-
tingen GmbH, Göttingen, Germany) for Extended Hot Shot sequencing. pET-21a
and pET-21b vectors featured a T7 promotor upstream of the multiple cloning site
and cloned inserts were flanked by the T7 promoter and T7 terminator binding
sites. Each clone was sequenced in two different reactions in both directions in two
different reactions with either T7 promoter or T7 terminator primer.
2.2.6 Recombinant protein expression
pET-21a-based expression plasmids containing the hemB gene (ALAD) sequence
from Wolbachia of Brugia malayi (wALAD) and a cDNA-derived human sequence
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(hALAD) were kindly provided by Dr. Barton Slatko (New England Biolabs, Ips-
wich, MA, USA).
The expression plasmids for wALAD, hALAD or pALAD were transformed into
T7 Express competent E. coli (High Efficiency) (C2566; New England Biolabs)
or CaCl2-competent BL21 E. coli according to the manufacturer’s protocol. Bac-
teria were grown in standard LB-medium and on LB-agar plates and growth of
pET-vector-positive cells were selected with 50 µg/mL Ampicillin. pALAD and
wALAD plasmids were co-transformed with the pRIL plasmid (Stratagene, now
Agilent Technologies, Heilbronn, Germany) encoding additional arginine, leucine
and isoleucine tRNAs that are rare in E. coli. The corresponding selection media
contained additionally 20 µg/mL Chloramphenicol.
For recombinant ALAD protein expression single colonies of successfully trans-
formed bacteria were inoculated into 8 mL of selection medium in 14 mL polypropy-
lene snap cap tubes (Greiner-bio one, Frickenhausen, Germany) and incubated
overnight at 36 ◦C, 150 rpm. The next morning cultures were diluted 1:100 to
1:1000 in 500 mL selection media in 2 mL culture flasks and grown until OD600nm
of 0.1 - 0.2 at 36 ◦C and further until OD600nm 0.5-0.6 at RT. Optical density of 1
mL aliquots from the bacterial cultures were measuerd with a Fisher Scientific Cell
density meter (Thermo Scientific, Dreieich, Germany). wALAD expression protocol
was adapted from Wu et al. [270] and optimized: Starting with an 8h culture at 37
◦C, the culture was diluted 1:250 into 500 mL medium in 2L flasks. Cultures were
grown at RT and 150 rpm until OD600nm 0.5-1.0 was reached.
Protein expression was induced by the addition isopropyl Isopropyl-β-D-thio-
galactoside (IPTG; Fermentas, Thermo Scientific, St. Leon-Rot, Germany) for 24 h
at 23 ◦C. IPTG concentrations were 6.25 µM for wALAD and 100 µM for hALAD
and pALAD. Bacterial cells were harvested by centrifugation at 6000 rpm, at 4 ◦C
for 10 min on a Sorvall Evolution RC Superspeed Centrifuge with SLC 4000 rotor
(Thermo Scientific, Dreieich, Germany). Resulting cell pellets were frozen at -80
◦C before they were thawed and resuspended in 10 mL Lysis Buffer per 500 mL of
initial cell culture. 30 min incubation on ice in the presence of 0.36 mg/mL Chicken
Egg White Lysozyme and 1u/mL Benzonase R© nuclease ensured breaking-up of the
bacterial cell-wall and digestion of genomic DNA before cells were lysed by repetitive
sonification, 6x 10 s followed by 1 min on ice with a Bandelin sonopuls HD 3100
(Bandelin, Berlin, Germany). Lysates were centrifuged for 30 min at 4400 rpm (He-
raeus Multifuge 4KR with LH-4000 rotor) at 4◦C and supernatants were incubated
with 1 mL Ni2+-NTA-Agarose (Qiagen, Hilden, Germany) per 10 mL supernatant
for at least 2 h at 4◦ on a rotating wheel (Dynal R© sample mixer, Life technologies,
Darmstadt, Germany) before the sample was applied onto a polypropylene column
(Qiagen, Hilden, Germany). The Ni2+-NTA-Agarose was washed with excess Wash
buffer containing intermediate imidazole concentration (50 mM) before the protein
was eluted in six 1 mL fractions with Tris-based Elution buffer containing high
imidazole concentration (250 mM). wALAD pellets obtained after centrifugation of
lysates were resuspended in Lysis buffer, centrifuged and the supernatant subjected
to protein purification with Ni2+-NTA-Agarose.
At each purification step aliquots were taken and protein concentrations de-
termined by Bradford assay. All samples were analyzed on a 12% SDS-gel with
subsequent Coomassie blue staining in order to verify the success of recombinant
protein expression and the purification procedure. Glycerol was added to the pu-
rified protein samples to a final concentration of 10% and protein concentrations
were determined as described below. While hALAD protein was stable at 4 ◦C for
several months, pALAD and wALAD were kept at -80 ◦C for long-term storage.
A detailed overview on the protein purification and corresponding results is given
below in the Preparative experiments (Section 2.3).
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Protein concentration measurements
Bradford assay For samples with unknown protein composition the overall pro-
tein concentration was measured using the BIO-RAD Protein Assay with BIO-RAD
Protein Assay Standard II Bovine Serum Albumin (Bio-Rad Laboratories GmbH,
München, Germany). 3 µL per protein sample or BSA standard were transferred
to the wells of a 96-well assay plate and 150 µL of a 1:5 dilution of Assay Reagent.
Protein concentrations were calculated on the basis of photometrically determined
OD595nm measurements with Softmax Pro software (see "Spectrophotometers" in
Section 2.1.1).
OD280nm measurements OD280 nm measurements were done with the NanoVue
spectrophotometer listed above. Protein concentrations were calculated from pri-
mary absorption measurements with the use of specific extinction coefficients of the
proteins. Specific extinction coefficients were calculated on the basis of protein se-
quences fed into the protparam tool of the ExPASy Bioinformatics Resource Portal
(http://web.expasy.org/protparam/).
2.2.7 SDS-PAGE
Protein samples for denaturing polyacrylamide gel electrophoresis (SDS-PAGE)
were mixed with 5X SDS-Loading Buffer. The protein was denatured by 10 min in-
cubation at 95 ◦C. 5 µL Roti R©Mark Protein standard was used for band reference.
Polymerization of the gels were started by addition of 0.1% APS + 0.1% TEMED
or 0.06% APS + 0.4% TEMED for resolving and stacking gels, respectively. Protein
gels were cast using a Mini Protean R© Tetra system (Bio-Rad Laboratories GmbH,
München, Germany).
5X SDS-Loading Buffer:
2.5 mL Upper SDS-gel buffer
1 g sodium dodecyl sulfate (SDS)
100 mg DTT
5 mL glycerol
8 µg bromophenol blue
ad 1 L with H2O, heat to 95
◦C to dissolve
Upper SDS-gel Buffer(4X; pH 6.8):
0.5 M Tris base
0.4% SDS
ad 1 L with H2O, adjust to pH 6.8
Lower SDS-gel Buffer(4X; pH 8.8):
1.5 M Tris base
0.4% SDS
ad 1 L with H2O, adjust to pH 8.8
10X SDS Running Buffer:
121 g Tris base
179 g Tricine
10 g SDS
ad 1 L with H2O
Running conditions: 110 V for 10 min, then at 180 V for 35 min.
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2.2.8 Coomassie blue protein staining
Gels were stained with Coomassie blue (0.05% Coomassie Brilliant Blue R, 50%
methanol, 10% acetic acid) under gentle shaking for 20 min. Gels were destained
in 30% methanol for 2 h to overnight and the gel was scanned with a ScanMaker
i900 Scanner (Microtek, Germany).
2.2.9 Native PAGE
Non-denaturing polyacrylamide gel electrophoresis (Native PAGE) was used to ana-
lyze oligomeric assemblies of ALAD proteins. Gels were cast using a Mini Protean R©
Tetra system (Bio-Rad Laboratories GmbH, München, Germany). Samples were
prepared using 5 - 8 µg protein and different concentrations of ZnCl2, MgCl2, DTT,
5-ALA and wALADin1 in 1X Loading buffer. After preincubation at RT for 30 min
(if not indicated otherwise) samples were loaded onto a 7.5% polyacrylamide gel
(Rotiphorese-Gel 30 T:C 37,5:1). Polymerization of the gels were started by addi-
tion of 0.1% APS + 0.1% TEMED or 0.06% APS + 0.4% TEMED for separating
and collecting gels, respectively.
1X Native Page Running Buffer:
25 mM tris (pH 8.8)
80 mM glycine
4X Gel Buffer:
112 mM tris
112 mM sodium acetate
adjust to pH 6.5
2X Native Page Sample Buffer:
0.2 M Tris-HCl (pH 8.8)
40% glycerol,
0.005% bromophenol blue
Running conditions: 50 V, 25 mA at 4 ◦C for 3-7 h.
2.2.10 In-gel ALAD activity assay
After non-denaturing gel electrophoresis, gels were soaked in Activity Buffer (100
mM Tris (pH 8.0), 10 mMMgCl2, 5 mM DTT and 0.5 mM 5-ALA) and incubated at
37 ◦C for 30 min - 2 h. The gel was then transferred into Modified Ehrlich’s Reagent
(MER), quickly rinsed in H2O and the gel was scanned with a ScanMaker i900
Scanner (Microtek, Germany). Image contrast was adjusted using Adobe Photoshop
Elements 3.0 (Adobe Systems, Munich, Germany).
2.2.11 Dialysis of proteins
Proteins were dialyzed for buffer exchange using Slide-A-Lyzer Dialysis 3,5KMWCO
cassettes of different volumes (Pierce, Thermo Scientific, München, Germany).
Standard dialysis procedures were done overnight at 4 ◦C. The samples were dia-
lyzed against excess buffer (at least 500X). When a very efficient dilution of sample
buffer components was required the dialysis buffer was exchanged after 2 h of dial-
ysis.
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2.2.12 High-Throughput screening
Compounds of the chemical library containing of ∼18,000 drug-like small molecules
(courtesy of Prof. Famulok, Chemical Biology and Medicinal Chemistry Unit,
LIMES-Institute, Bonn, Germany), were used as working solutions at a concen-
tration of 1 mM in DMSO. These screening compound plates had originally been
filled by diluting the compounds from a 10 mM stock solution. A liquid-handling
workstation (Freedom EVO, Tecan, Männedorf, Germany) was employed to pipet
the reaction mixture of both screening assays. Clear flat-bottom 96-well plates
(Brand GmbH, Wertheim, Germany) were used as assay plates in the screening
procedure.
While the first eleven columns per plate were filled with test compounds, the
12th column was used for positive (DMSO, protein, substrate) and negative control
(DMSO, protein, water) of the reaction which were used to calculate Z’-factors [274]
(see Equation 2.1) for each plate with σc+ and σc− being the standard deviation
of the positive control or negative control, respectively, and µc+ and µc− being the
corresponging mean.
Z ′ =
3σc+ + 3σc−
|µc+ − µc−|
(2.1)
2.2.13 Chemical compounds and compound handling
wALADin1 and derivatives were synthesized by V. Halls and Dr. J. Hannam at the
LIMES Institute. wALADin derivative 4 and wALADin2 were custom synthesized
by Hit2Lead.com (ChemBridge Corporation, San Diego, CA, USA). Other com-
pounds were purchased from ChemBridge or Enamine (Kiev, Ukraine). The final
compounds were aliquotted and stored at -20 ◦C. Aliquots were then dissolved in
100% DMSO to give the desired concentrations (standard: 10 mM).
2.2.14 PPDK functional assays
PPDK-DNPH assay/ HT-Screening
This PPDK activity assay is based on the detection of the reaction product pyru-
vate by reaction with 2,4-dinitrophenylhydrazine (DNPH) to a coloured hydrazone
and was employed for HT-Screening of inhibitors. The final reaction volume was 80
µL and the mixture was pipetted in the following steps:
Reaction scheme Volume Final concentration
1. DMSO/ compound 3 µL 37.5 µM
2. Protein in 2X PPDK-PBS buffer 40 µL 100 nM
3. Substrate mix 37 µL
Positive control Negative control
AMP 200 µM 200 µM
PEP 200 µM
PPi 500 µM 500 µM
The reaction mixture was incubated for 50 min at RT, until the assay was
stopped by the addition of 120 µL Pyruvate Detection Reagent (PDR). After an-
other 10 min incubation at RT OD395nm of the plate was measured. The initial
hit-threshold during HT-Screening was chosen to be ± 3SD (60% inhibition). The
20 top hits were obtained from stock solutions and were rescreened in duplicates.
Confirmed hits that were further validated in dose-response curves and control ex-
periments.
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Coupled PPDK-LDK assay
The reaction of PEP to pyruvate as catalysed by PPDK is coupled to lactic acid
dehydrogenase (LDH) from rabbit muscle (L1254, Sigma). The conversion of pyru-
vate to lactate goes along with the oxidation of NADH/H+ to NAD+, and thus a
decrease of NADH/H+ at absorption at 340 nm can be measured spectrometrically
in real time during the course of the reaction.
Reactions were set up in clear flat-bottom 96-well plates (Brand, Wertheim,
Germany) as follows:
Reaction scheme Volume Final concentration
1. DMSO/ compound 3 µL 37.5 µM
2. Protein mix 40 µL
PPDK 100 nM
LDH (1 u/µL) 0.006 u/µL
3. Substrate mix 37 µL
The composition of the substrate solutions were as follows:
Positive control Negative control
AMP 500 µM 500 µM
PEP 500 µM
PPi 2000 µM 2000 µM
NADH/H+ 200 µM 200 µM
Immediately after addition of substrate, the plate was inserted into the spec-
trophotometer and the OD340nm was read for up to 60 min. Slopes of the substrate
turnover were calculated by linear regression over the linear phase of the reaction
(including a lag time of 1-4 min).
2.2.15 Pyruvate Kinase assay
Pyruvate Kinase from rabbit muscle (P1506, Sigma) was used as a control assay for
the specificity of PPDK inhibitory compounds. The general experimental protocol
was as described for the PPDK-DNPH Assay. Instead of PPDK, 0.156 mu/µL
Pyruvate Kinase was used and substrate solution contained 200 µM ADP instead
of AMP/PPi. The reaction was stopped by the addition of 120 µL PDR solution
in the linear phase after 10 min.
2.2.16 wALAD Assay and High-Throughput Screening
The wALAD reaction mixture was pipetted in three steps (2 µL compound, 23 µL
protein-buffer mix, 30 min pre-incubation, 5 µL substrate) with a final reaction
volume of 30 µL. The final concentration of the reagents were 67 µM compound,
6.7% DMSO, wALAD, 200 µM 5-Ala in 100 mM Tris (pH 8.0) with 5 mM DTT
and 10 mM MgCl2. Assay plates were sealed, shortly spun down and incubated at
36 ◦C for 20 min. The reaction was stopped by the addition of 200 µL Modified
Ehrlich’s Reagent (MER) per well. After 10 min incubation at room temperature,
absorption was read at 555 nm.
The primary hit threshold was an inhibition exceeding 3 standard deviations (35%
inhibition) of the DMSO-control. All primary hits were rescreened in duplicate.
In order to focus on high potency hits, the hit threshold for confirmed hits in the
rescreen was set to 50% inhibition. Hit validation was completed by dose-response
curve and specificity tests and were done with fresh compound from stock solutions.
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Purity and identitiy of validated hit compounds were kindly verified by HPLC and
MS-analysis done by K. Rothscheidt at the LIMES-Institute.
2.2.17 ALAD IC50 assays of different orthologs
The general ALAD assay setup was as described for wALAD High-Throughput
Screening assay. IC50 determinations were performed manually using different con-
centrations of the respective proteins under optimal buffer conditions. Besides the
already mentioned orthologs from Wolbachia (wALAD), H. sapiens (hALAD) and
P. aeruginosa (pALAD), other orthologs were from Escherichia coli (EcALAD),
Pisum sativum (PsALAD), Vibrio cholerae (VcALAD) and Yersinia enterocolitica
(YeALAD). MgCl2 concentration was kept constant at 1 mM for all Mg-stimulated
orthologs, ZnCl2 was kept at 10 µM, 5-aminolevulinic acid was 200 µM. Protein
concentration and assay time were chosen such that the enzymatic reaction was
stopped in its linear phase and that subtrate turnover did not exceed 30%.
Ortholog Protein con-
centration
Buffer Incubation
time
wALAD 500 nM 100 mM Tris (pH 8.0), 1 mM
MgCl2, 5 mM DTT
20 min
hALAD 250 nM 100 mM Tris (pH 7.5), 10 µM
ZnCl2, 5 mM DTT
20 min
pALAD 60 nM 100 mM Tris (pH 8.0), 1 mM
MgCl2, 100 mM KCl
10 min
EcALAD 200 nM 100 mM BTP (pH 8.1), 1 mM
MgCl2, 10 µM ZnCl2, 5 mM
DTT
10 min
PsALAD 300 nM 100 mM BTP (pH 8.5), 1 mM
MgCl2, 5 mM DTT
15 min
VcALAD 125 nM 100 mM BTP (pH 8.0), 1 mM
MgCl2, 5 mM DTT, 100 mM
KCl
10 min
YeALAD 150 nM 100 mM BTP (pH 8.0), 1 mM
MgCl2, 5 mM DTT, 100 mM
KCl
10 min
Substrate concentration rows (65 µM - 16.7 mM 5-ALA) in the presence of diffe-
rent concentrations of wALADin1 (0 - 100 µM) were recorded for type-of-enzymatic-
inhibition studies. Graph Pad Prism 5.0 (GraphPad Software, SanDiego, USA) was
used for non-linear regression of the primary data using the "Allosteric sigmoidal"
algorithm and for the generation of linear Eadie-Hofstee representations.
Mg2+-response curves (0 - 5 mM) were recorded in the presence of wALADin1
(0 - 100 µM) applying 500 nM wALAD, 200 µM 5-ALA in order to assess Mg2+-
dependency of wALADin1 inhibition.
2.2.18 Solubility measurements
wALADin1
The UV-VIS absorbance spectrum of wALADin1 from 200 to 700 nm was measured
using the NanoVue spectrophotometer in assay buffer with 1% DMSO. As a refe-
rence the absorption spectrum of a 1%DMSO solution in assay buffer was measured
and subtracted from the wALADin1 absorption curve. For solubility measurements,
different concentrations of wALADin1 were added to assay buffer and incubated at
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RT for > 30 min. Samples were then centrifuged for 5 min at 16,000 rpm (Eppendorf
5417R centrifuge, maximum speed) in order to pellet all crystallized compound,
if any. The supernatant was transferred to another tube and the absorption at
the wALADin1 peak absorption wavelengths was measured. For high wALADin1
concentrations the absorption was measured in the slope region of the absorption
curve in order to prevent saturated OD values > 1.
PPDKin1
Samples were prepared as described for wALADin1 with the difference that com-
pounds were dissolved in H2O or PPDK-PBS buffer with a final DMSO concentra-
tion of 3.75%. Solutions were incubated at RT for 24 h before precipitated com-
pound was pelleted by centrifugation at maximum speed in a table-top centrifuge
for 5 min.
2.2.19 Thermal Shift Assay
Protein thermal melting curves were measured as a function of fluorescence inten-
sity of the environmentally-sensitive dye Sypro R©Orange on a Rotorgene RG-3000
(Corbett Life Sciences, Germany). Protein samples were gradually denatured by
increasing the temperature from 27 ◦C up to 99 ◦C at a heating rate of 0.5 ◦C/ 30
s. Fluorescence of Sypro R©Orange was excited at 470 nm and detected at 510 nm.
Raw data were subjected to 1st derivative analysis of Rotorgene 6 software (Qiagen,
Germany). Visualizations were done with Graph Pad Prism 5.0.
ALAD and wALADin1
Samples were prepared for 5 µM (0.2 mg/mL) wALAD in 1 M Tris pH 8.0, 5
mM DTT, 1mM MgCl2, different concentrations of wALADin1, derivatives or 1%
DMSO as control and 8-16X Sypro R©Orange in a final volume of 20 µL. Control
protein concentrations of hALAD, Chicken Egg White Lysozyme and BSA were
0.2 mg/mL, 3 mg/mL and 0.5 mg/mL, respectively. All samples were prepared in
triplicates.
2.2.20 Cell culture
General cell culture protocols
LLC-MK2 cells or HEK cells were grown in 75 cm2 culture flasks with 12 mL of the
respective culture media. Cells were split 1:4 every 7 days at 90-100% confluency
and the medium was exchanged after 3-4 days of culture. To harvest the cells the
old medium was aspirated, the cell lawn washed in an equivalent volume of pre-
warmed PBS, and cells were incubated in 2 mL 1X Trypsin/EDTA for 3-5 min at
37 ◦C. Cells were completely detached by the addition of 10 mL culture medium
and vigorous pipetting up and down along the bottom of the flask.
All cell culture work was performed under a class II safety cabinet BIOWIZARD
(Kojair Tech Oy, Vilppula, Finland). Non-sterile reagents used in cell culture exper-
iments were filtered through a 0.2 µM Cellulose Acetate Filter (VWR International
GmbH, Darmstadt, Germany) or autoclaved.
Freezing and thawing
LLC-MK2 cells were grown to confluency in a 75 cm2 flask that was distributed
into 4 cryotubes of frozen cells. Cells were detached by standard Trypsin/EDTA
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treatment, centrifuged (5 min, 1200 rpm, 4 ◦C, Heraeus Multifuge 4KR with LH-
4000 rotor) and resuspended in 3 mL standard culture medium. Another 3 mL
of ice-cold culture medium containing 20% DMSO was then added dropwise to
the cells. Cryotubes were placed in a freezing container (Mr. Frosty R©, Thermo
Scientific, Dreieich, Germany) filled with isopropanol and frozen at -80 ◦C.
For new cultures, the cells were quickly thawed from -80 ◦C and pelleted (5
min, 1200 rpm, 4 ◦C, Heraeus Multifuge 4KR with LH-4000 rotor). The DMSO-
containing freezing medium was discarded and cells were resuspended in pre-warmed
culture medium. Cells were cultivated in 25 cm2 culture flasks. HEK cells were
treated in an equivalent manner but were frozen in liquid nitrogen and were thawed
according to the same protocol.
2.2.21 Cytotoxicity assays
50,000 HEK cells or 25,000 LLC-MK2 cells, respectively, were seeded out in 100 µL
medium on a flat-bottom 96-well plate and incubated at 37 ◦C, 5% CO2 overnight.
The next day the medium was replaced by 200 µL filter-sterilized culture medium
containing 15.6 µM - 1 mM compound or 1% DMSO as a 100% viability control.
As a 0% viability control cells from dried out wells were used. After 48 h incubation
(37 ◦C, 5% CO2) 20 µL of sterilized 5 mg/mL Thiazolyl Blue in PBS was added for
1 h at 37 ◦C. MTT-formazan produced by mitochondrial succinate dehydrogenase
was dissolved in 200 µL DMSO at 37 ◦C for 1 h under gentle shaking at 150 rpm.
Absorption was measured at 550 nm and primary data were normalized to the
median OD550nm of 1% DMSO-treated cells (set to 100% viability) to give percent
viability data.
2.2.22 Animal handling
All animals were handled according to European Union and German animal wel-
fare laws. BALB/c mice and Mongolian gerbils for L. sigmodontis infection were
purchased from Elevage Janvier (Le Genest Saint Isle, France) and were were kept
in the home breeding facilities of the IMMIP. Cotton rats were bred in-house at the
IMMIP. A. viteae infected Mongolian gerbils were kindly provided by Prof. Dr. R.
Lucius (Humboldt-Universität Berlin, Germany). Long-term anaesthesia of mice
was obtained by i.m. injection of 0.4% Rompun R© (Bayer Health Care, Leverkusen,
Germany) + 10 mg/mL Ketanest R©(Pfizer Pharma AG, Berlin,Germany) in 50 µL
PBS. For short-term anaesthesia required for i.t. injections mice were exposed to
Isoflurane for 30 - 60 s. Animals were euthanized by exposure to excess Isofluran
until breathing and heart function had stopped.
2.2.23 Infection experiments with filarial nematodes
For natural infection with L. sigmodontis Mongolian gerbils or anaesthetized mice
were exposed overnight to infected tropical dust mites (Ornithonyssus bacoti). L.
sigmodontis infected mites were obtained as part of standard infection cycle in
cotton rats (Sigmodon hispidus) maintained at the IMMIP by B. Dubben and Dr.
S. Specht. For ex vivo experiments with L. sigmdontis Mongolian gerbils and cotton
rats were infected for more than 3 months to ensure patency of infection before the
animals were euthanized and adult L. sigmodontis worms were isolated from the
thoracic cavity. A. viteae were isolated from the subcutaneous tissue of Mongolian
gerbils 6 - 12 months post infection.
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2.2.24 Ex vivo co-culture assay with filarial nematodes
Isolated adult female worms of L. sigmodontis or A. viteae were washed in PBS
and LLC-MK2 medium and were placed on a confluent lawn of LLC-MK2 cells in
6-well plates and incubated at 37 ◦C, 5% CO2. The next day the medium was taken
off for analysis of expelled microfilariae and fresh medium containing drugs at the
indicated concentrations were added. Worms were exposed to the drugs for 14 days,
with medium exchange every 2 days combined with determination of the number
of released microfilariae.
Assessment of worm motility for L. sigmodontis
For a rating of the motility of the worms plates were videotaped daily for 1 min
and attributed a motility score from 0-5 (Supplementary videos 1 - 3). Motility
scores for L. sigmodontis were defined as follows:
Motility
score
L. sigmodontis phenotype
5 Maximum motility, rapid, continuous movements
4 Movements are slower and not continuous
3 Longer times of inactivity or worm is partially stretched, worm
can still perform changes of its position
2 Worm is mostly stretched and is able to make longer movements
not changing its general position
1 Worm is entirely stretched, single movements are visible
0 No movement observed
Healthy A. viteae generally move less vigorously than L. sigmodontis and move-
ments may be interrupted by periods of inactivity (Supplementary videos 1, 4,
5. Motility scores for A. viteae were defined as follows:
Motility
score
A. viteae phenotype
5 Vigorous movements over the entire worm length
4 Movements become less frequent and vigorous
3 Worm is immobile most of the time but is still able to perform
characteristic movements with increasing radius
2 Worm is mostly stretched and movements are rather wave-like
1 Worm is entirely stretched, single shivering movements are
visible
0 No movement observed
Assessment of worm viability (MTT-assay)
After 14 days viability of the worms was examined by an MTT-Assay protocol mod-
ified from Townson et al [251]. Worms were incubated in 2 mL PBS with 0.5 mg/mL
Thiazolyl Blue (MTT) at 37 ◦C for 30 min to allow production of MTT-formazan
by mitochondrial succinate dehydrogenase activity. Worms were transferred into
200 µL DMSO and incubated for 1 h at 37 ◦C at 150 rpm. The concentration of
solubilized MTT-formazan was measured as OD490nm. If the measured OD was
outside the linear range (OD > 1), smaller volumes, i.e. usually 100 µL were re-
measured. Percent viability data were obtained by normalizing MTT assay data to
the median OD490nm of 1% DMSO-treated worms (set to 100% viability).
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2.2.25 wALADin1 in vivo experiments on L. sigmogontis in-
fected mice
8-week-old female BALB/c mice were naturally infected with L. sigmogontis and
treated with different drug formulations.
Intraperitoneal drug delivery: In a first study mice were given 1 mg wALADin1
or 1 mg Doxycycline in 300 µL Minimal Essential Medium (PAA, Pasching, Austria)
containing 3.3% DMSO for 14 - 28 days starting at day 1. In a subsequent study,
500 µL wALADin1 (2 mg or 2 x 2 mg with the 2nd dose given after 6 - 10 h) or wAL-
ADin1 methyl ester (compound 5) (2 mg) or vehicle control were administered i.p.
for 28 days starting at 1 dpi. Vehicle was 25 mM 2-Hydroxypropyl-β-cyclodextrin in
Earl’s balanced salt solution (Life Technologies, Darmstadt, Germany) containing
4% DMSO.
Intrathoracic drug delivery: Mice were treated with 100 µL wALADin1 (0.4 mg)
i.t. for up to 28 days or vehicle control starting at 1 dpi. Vehicle was 30 mM
2-Hydroxypropyl-β-cyclodextrin in Earl’s balanced salt solution (Life Technologies,
Darmstadt, Germany) containing 4% DMSO for 14, 21 or 28 days. A control group
of untreated infected mice was included.
If not stated otherwise, at 35 dpi mice were euthanized and worms were isolated from
the thoracic cavity, counted, staged and their sex and length were determined. For
quantification of endosymbiont Wolbachia levels, DNA was isolated from 10 single
worms per mouse and Wolbachia ftsZ copy numbers were determined and norma-
lized to the number of L. sigmodontis β-actin copy numbers by duplex Realtime-
PCR as described previously [9, 241]. In some experiments isolated worms were
further subjected to MTT assay as described in Section 2.2.24.
2.2.26 Toxoplasma gondii culture
Parasites
Toxoplasma gondii RH strain tachyzoites were received in peritoneal lavage fluid of
infected NRMI mice which are used as part of the diagnostic laboratory routine of
the IMMIP (Dr. I. Reiter-Owona).
Infection of LLC-MK2 cells with T. gondii tachyzoites
Two days before infection with T. gondii ∼20,000 - 25,000 LLC-MK2 cells were
seeded into the wells of a 96-well cell culture plate (see also Section 2.2.20) and
cell concentrations were determined by counting in a Neubauer counting cham-
ber (VWR International GmbH, Darmstadt, Germany). Before infection T. gondii
tachyzoites were centrifuged for 7 min at 371 g at RT. The supernatant (lavage
fluid) was discarded and cells were resuspended in LLC-MK2 medium without an-
tibiotics. The concentration of parasites was determined using a Neubauer counting
chamber. The old antibiotics-supplemented medium of the LLC-MK2 cells was re-
moved, cells were washed once with PBS and T. gondii tachyzoites in LLC-MK2
medium (free of antibiotics) were added at a multiplicity of infection of 5 in a final
volume of 100 µL. After 2 h of culture (37 ◦C, 5% CO2) the medium was removed
and cells were washed twice with PBS in order to remove non-adherent parasites
and synchronize parasite replication. 125 µL of fresh LLC-MK2 culture medium
free of antibiotics but supplemented with the test compounds at the desired con-
centrations were transferred to the wells. After 40 - 48 h of infection, supernatants
containing free parasites from ruptured cells were taken off and cells were detached
by addition of 25 µL 1X Trypsin/EDTA and incubation at 37 ◦C for 5 min. Addi-
tional 100 µL of PBS were added, cells were detached and the sample was combined
with the corresponding supernatant. 200 µL of the resulting LLC-MK2/T. gondii
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tachyzoite suspension was then subjected to DNA extraction (see Section 2.2.4).
Finally tachyzoite and LLC-MK2 numbers were determined by Real-time PCR with
extracted DNA.
2.2.27 Plasmodium falciparum culture
The P. falciparum culture experiments were physically performed by Martina Fendler.
Parasites
P. falciparum 3D7 strain
P. falciparum culture
A+ citrate blood was obtained from the blood bank of the University Hospital of
Bonn. Blood samples were centrifuged at 2000 rpm for 5 min (EBA 20 centrifuge
with E1624 rotor). Serum and buffy coat were removed. Tubes were filled with
RPMI medium (with 25 mM HEPES, without L-Glutamine, PAA Lab., Pasching,
Austria) and centrifuged again for 5 min, 2000 rpm and the upper phase was dis-
carded. This washing procedure was repeated once. Erythrocytes (RBC) were
mixed with an equal volume of RPMI and stored at 4 ◦C for up to 3 weeks. P.
falciparum 3D7 parasites were cultured in A+ RBC in P. falciparum medium at 37
◦C under a defined gaseaous atmosphere (3% O2, 5% CO2, 92% N2). Erythrocytes
(1200 µL RBC in 13 mL medium) were kept in petri dishes (φ=10 cm) and when
parasitemia exceeded 5% a dish of fresh RBC was infected by addition of ∼50 µL
of infected RBC. Medium was exchanged every 24 h. Old medium was removed
without disturbing the sedimented erythrocytes on the bottom of the dish and re-
placed with an equal volume of fresh medium. Parasitemia of culture samples was
determined by Giemsa-staining of blood smears. Blood smears were prepared by
rapid smearing of a drop of the sedimented erythrocyte culture over the surface of
a microscope slide using the edge of another slide.
Giemsa staining
Blood smears were fixed for at least 1 min in methanol and air dried. Smears were
stained in fresh Giemsa Working solution for 15 to 20 min before they were rinsed
with buffer solution, quickly immersed in H2O and dried at air. 1000 erythrocytes
per sample were counted under microscope at 100X magnification and the number
of infected cells (trophozoites plus schizonts) was determined.
Giemsa working solution: 1 mL Giemsas Azur Eosin-Methylenblau Lösung
+ 19 mL buffer solution
Buffer solution: Na2HPO4x 2 H2O / KH2PO4 Puffertabletten pH 7.2 : One
tablet was dissolved in 1 L destilled water.
Compound testing in P. falciparum culture assay
Compounds were tested for anitplasmodial activity in the P. falciparum 3D7 cul-
ture and the effect on the development of parasitemia was followed for 4 days. 1.8
mL P. falciparum culture medium supplemented with compounds at varying con-
centrations or 0.5% DMSO as a negative control were transferred into the wells of a
24-well plate with four replicates per condition. 200 µL of infected RBC at a para-
sitemia adjusted to 0.2% - 0.5% were added. Medium exchange and the collection
of blood smears were done on a daily basis.
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2.2.28 Sequence alignments
Multiple sequence alignments of orthologous ALAD sequences were performed with
GENtle V.1.9.4 (Magnus Manske, Cologne, 2003) using the implemented Clustal W
(Scores: Match: 2; Gap external penalty: -1, Gap penalty: -2; BLOSUM matrix).
For Wolbachia, H. sapiens and P. aeruginosa ALAD sequences of the recombi-
nant proteins were used according to the sequenced expression plasmids. Sequences
of other orthologous proteins were retrieved from the UniProtKB database: E.
coli (P0ACB2), V. cholerae (C3LPU7), Y. enterocolitica (F4MUJ9), P. sativum
(P30124).
2.2.29 Basic Local Alignment Search Tool (BLAST) searches
All BLAST searches were performed on the "BLAST search and download server for
Filaria-EU" (http://xyala.cap.ed.ac.uk/downloads/959nematodegenomes/blast/fi-
lareu.php) hosted by "959 Nematode Genomes" (www.nematodes.org by Mark L.
Blaxter, University of Edinburgh, 2012) using default settings. HemB gene homo-
logues within the genome of A. viteae were searched for by blastn 2.2.25 [237] search
with query input sequences of Wolbachia of B. malayi, human and yeast sequences
(Accession No. AE017321, gene locus Wbm0373; X64467; J03493).
The "All Filarial Genomes 2012-08-24" assemby including Wolbachia genomes was
searched for homologous slr1790 gene sequences by tblastn 2.2.25 [237] with the
slr1790 gene product of Synechocystis sp. (strain PCC 6803, Accession No. P72793)
as query input.
2.2.30 Data and statistical analyses & Software
Microsoft Office Excel 2007 (Microsoft, Redmond, WA, USA) was used for pro-
cessing and normalization of primary data. All further transformations, statis-
tical analyses and graphical representations were done with Graph Pad Prism 5.0
(GraphPad Software, SanDiego, CA, USA). Enzymatic assay data is shown as mean
± SEM, if not stated otherwise. Worm co-culture and in vivo data are presented
as median, cell culture data as median with interquartile range. Non-parametric
two-tailed Mann-Whitney-U test was employed for significance testing (significance
level α=0.05) for statistical analyses.
The following non-linear regression algorithms and transoformation functions of
Prism 5.0 were used in this work:
"loginhibitor vs. normalized response - variable slope": IC50 determinations
in the enzymatic assay experiments. Hill-slopes were not restricted due to
possible cooperative effects using the ALAD oligomers.
"logagonist vs. response - variable slope": EC50 determinations of the stimula-
tory effects of wALADin1/derivatives on several ALAD orthologs
Allosteric sigmoidal algorithm: Standard algorithm used in type-of-inhi-
bition experiments for various proteins accounting for coopertive effects (X
as the substrate concentration, Y as enzymatic velocity, VMAX as maximum
enzymatic velocity, h as hill slope and Kprime being related to the Michaelis-
Menten constant KM (identical only for h=1)) as indicated in Equation 2.2
Y =
VMAX ×X
h
Kprime+Xh
(2.2)
Mixed Model Inhibition algorithm: Type-of-inhibition experiments for
various proteins
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Non-competitive inhibition algorithm: Type-of-inhibition experiments
for various proteins
Uncompetitive inhibition algorithm: Type-of-inhibition experiments for
various proteins
Competitive inhibition algorithm: Type-of-inhibition experiments for
various proteins
Michaelis-Menten algorithm: Determination of KM values
Eadie-Hofstee Transformation, followed by linear regression analy-
sis: Linearized representation of type-of-inhibition experiments
Hanes-Woolf Transformation, followed by linear regression analysis:
Linearized representation of type-of-inhibition experiments
Chemical structures were drawn using MarvinSketch (ChemAxon, Budapest,
Hungary). Figures were created with Prism 5.0 (GraphPad Software, San Diego,
CA, USA) or Adobe Illustrator CS6 (Adobe Systems, Munich, Germany). Image
contrast adjustments and conversion to grayscale were done with Adobe Photo-
shop CS6 (Adobe Systems, Munich, Germany) or GIMP 2 (http://www.gimp.org).
Videos were recorded with a Sony Handycam R© DCR-46E Mini DV camcorder (Sony
Deutschland, Berlin, Germany) and movies were analyzed and cut with Final Cut
Pro (Apple, Cupertino, CA, USA).
2.3 Preparative experiments
Experiments described in this section have a merely preparative character. These
experiments include the cloning and recombinant protein expression procedures
which are of no higher scientific significance to the current study but are required
for production of materials that are the basis for experiments described subsequently
in the Results (Chapter 3).
2.3.1 Cloning of P. aeruginosa hemB gene into pET-21b ex-
pression vector
For the cloning of the P. aeruginosa ALAD (pALAD) gene and subsequent over-
expression of the recombinant protein a cloning strategy was set up that included
the parallel processing of three different ALAD constructs. For PCR amplification
(Section 2.2.2) primers were used that included different restriction site sequences
that would flank the gene sequence. By choosing restriction sites in the forward
primer that have their matching part in the pET-21b sequence either downstream
(NdeI) or upstream (SacI) the T7-tag and a reverse primer restriction sites located
downstream the His6-tag sequence (NotI, XhoI) in combination with primer se-
quence with or without stop codon it was intended to obtain plasmid constructs
that would allow the expression of either untagged (UT), His6-tagged or T7-tagged
ALAD protein. The single step results of the cloning procedure in the following are
shown for the His6-tagged version, the final protein of which was purified and used
for the enzymatic assay experiments. After isolation of genomic P. aeruginosa DNA
from an overnight culture, the DNA was used as a template for PCR amplification
of the hemB gene with the different primer sets (Fig. 2.1, Section 2.2.2). Stan-
dard P.aeruginosa ALAD PCR contained ∼7.5 ng DNA. The optimal annealing
temperature was determined in a temperature gradient PCR and was found to be
72 ◦C. At this temperature a clear band of the expected size of 1kb and the lowest
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non-specific amplification of secondary bands or smears were achieved (Fig. 2.2
a). At this optimal temperature multiple 50 µL PCR reactions were run and the
products were separated on a preparative 1% Agarose gel (Fig. 2.2 b) from which
the bands were excised and the PCR product was cleaned up.
The cloning procedure, which is described in detail in Section 2.2.3, then
involved restriction digestion of the plasmid vector and the purified PCR product.
After successful digestion with NdeI and XhoI only the linearized plasmid with a
size of 5.4 kb and no supercoiled structures as for the uncut plasmid DNA were
visible in (Fig. 2.3 a). For the Not I and Sac I-digested plasmid DNA still some
faint secondary bands remained. Therefore further experiments requiring NotI/SacI
digestion were done with High-Fidelity forms of these restriction enzymes.
After 5’-dephosphorylation of the RD-plasmid in order to prevent religation of
the plasmid, the plasmid and RD-PCR product were ligated in a 1:5 molar ratio
using Quick Ligase. The ligation mixture was transformed into chemically com-
petent Top 10 E. coli and 3 different plates were streaked out with 100, 150 or
200 µL of the respective constructs and an overall number of 165 colonies for T7-
pALAD, 6 colonies of His6-pALAD and only two colonies of UT-pALAD-tranformed
bacteria had grown. The colonies were then subjected to colony PCR using T7
promoter/terminator primers in which most clones for His6-pALAD (5/6) and T7-
pALAD (8/10) revealed insertion of a DNA fragment of ∼1 kb when the result-
ing ∼1.2 kb prodcuct band was compared to the ∼250 bp amplicon of the empty
pET-21b vector (Fig. 2.4 a). In contrast, both clones of the untagged construct
were negative. PCR-positive colonies were then selected for overnight cultures and
plasmid preparation. The purified plasmids were used as a template in both T7-
primer-based PCR and in a PCR reaction using specific ALAD primers. A number
of positive clones for both T7-pALAD and His6-pALAD featured both the ∼1.2 kb
product in the T7-PCR as well as the ∼1.0 kb product in the specific PCR (Fig.
2.4 b, c). Finally, plasmid DNA was submitted to sequencing and the obtained
sequences unequivocally revealed the insertion of the hemB gene into the pET-21b
vector at the correct position and proved the cloning to be successful.
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Figure 2.1: Strategy for the cloning of the pALAD gene into the pET-21b
vector
a) Vector map of pET-21a/b vector as supplied by the manufacturer. b) Gene sequence
of the pET-21b multiple cloning site. Start and stop codons are highlighted in orange,
restriction sites in green, T7-Tag residues in blue and His6-Tag residues in red. The
sequence was taken from the manufacurer’s information sheet and is displayed in a modified
version. c) Overview of the different pALAD constructs envisionsed including tags and
size information.
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Figure 2.2: PCR amplification of the P. aeruginosa ALAD gene
1% Agarose gels stained with SafeRed are shown. a) PCR optimization in a gradient
PCR where the annealing temperature was varied from 50 ◦C to 72 ◦C, as indicated. The
specific PCR product (His6-pALAD) runs at a size of ∼1 kb. b) Preparative gel where
the products of 4 PCR reactions (at optimal annealing temperature of 72 ◦C) were applied
before excision and clean-up. M = marker; NC = negative control.
Figure 2.3: Restriction digestion of pET-21b vector
1% Agarose gel stained with SafeRed. After cutting pET-21b with NdeI and XhoI restric-
tion enzymes for 1 h clean single bands were obtained revealing successful linearization of
the 5.4 kDa vector DNA compared to uncut plasmids that run in supercoiled forms. M =
marker.
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Figure 2.4: PCR analysis of cloned gene sequences
1% Agarose gels stained with SafeRed are shown. a) Results from Colony-PCR using the
T7 primer set. For His6-pALAD 5 positive clones (1-6) and one positive clone (10) for
T7-pALAD are shown that display an increased PCR product size compared to empty
pET-21b vector indicating successful insertion of a 1 kB fragment. Clone 1 of UT-pALAD
is negative. b) The 1.2 kb PCR product was obtained by T7-primer PCR reaction using
purified plasmid DNA template. c) Correct insertion of the pALAD gene sequence was
further proven by the resulting pET-21b-His6-pALAD expression vector which yielded the
expected product of ∼1 kb after PCR amplification. Primary sequence analysis of the
encoded pALAD protein predicted a size of ∼38 kDa and a pI of 5.41. M = marker; NC
= negative control.
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2.3.2 Recombinant expression of pALAD protein
For recombinant expression of pALAD protein the plasmid DNA was transformed
into BL 21 E. coli as a T7 expression strain. Bacterial cultures were grown until
OD600nm 0.5 - 0.6 before protein expression was induced by the addition of the
non-cleavable lactose analog isopropyl β-D-1-thiogalactopyranoside (IPTG) which
binds to the lac repressor, thus inducing the lac operon encoded in the pET-21b
vector allowing transcription of the inserted hemB gene under the control of the
T7 promoter. In order to determine optimal induction conditions various concen-
trations of IPTG (25 µM, 100 µM and 400 µM) were tested for different induction
times (2 h vs. o/n) before cells were harvested and lysed. SDS-PAGE with lysate
supernatants and pellets revealed that specifically upon induction with IPTG a
protein, which runs at the expected size of ∼38 kDa, was expressed in a time- and
concentration-dependent manner (Fig. 2.5). It appeared both in the supernatant
and in the pellet and was most prominent after o/n incubation. While the concen-
tration of soluble putative pALAD protein in the supernatant drastically increased
when IPTG concentration was increased from 25 to 100 µM, another 4-fold increase
did not further increase the yield of soluble target protein but rather led to a slight
reduction. The amount of insoluble pALAD in the pellet was similar between all
IPTG concentrations tested.
Based on these results a large batch induction (500 mL culture) with 100 µM
IPTG and subsequent purification of His6-pALAD over Ni
2+-NTA-Agarose was per-
formed. Protein samples taken from the different steps of the purification procedure
were analyzed by SDS-PAGE (Fig. 2.6). Eluates 1-6 contained His6-pALAD at
high purity (> 90%) and the overall yield was ∼46 mg pALAD per 500 mL culture.
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Figure 2.5: Test expression of His6-tagged pALAD protein
The graph shows Coomassie blue stained 12.5% SDS-page gels loaded with 5 µg protein
samples from different steps of a pALAD test expression. a) Supernatants of lysates after
centrifugation. b) Resuspended pellets. A protein of the size of ∼40 kDa was induced by
IPTG and is expected to be the target protein.
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Figure 2.6: Purification of His6-tagged pALAD protein over Ni
2+-NTA-
Agarose
Samples were analysed on a 12.5% SDS-PAGE gel and visualized by Coomassie blue stai-
ning. High concentrations of the 38 kDa protein are present in the crude lysate as well
as in the pellet and supernatant. Eluates contain the target protein at high purity. M
= marker, Lys = lysate, Pel = pellet, SN = supernatant, FT = flowthrough, W = wash
fraction, E1 - E6 = eluates 1 to 6.
2.3.3 Recombinant expression of wALAD and hALAD pro-
tein
Starting from the expression plasmids, His6-tagged wALAD and hALAD proteins
were recombinantly expressed as described previously [270]. The expression pro-
tocols were adapted and optimized for the given laboratory conditions and the
optimized protocol is described in detail in Section 2.2.6. Primary sequence ana-
lysis predicted a size of 37.5 kDa (pI = 5.74) for wALAD and a size of 37.4 kDa
(pI = 6.43) for hALAD. While, following the standard protocol, hALAD was easily
expressed at high purity and with sufficient yield (∼2.5 mg hALAD per 500 mL
culture) (Fig. 2.7 c), yield for wALAD was very low under standard conditions
(< 0.5 mg per 500 mL culture). Even following the described modified protocol,
the vast majority of overexpressed protein was not soluble and found in the pellet
(Fig. 2.7 b). However, purification over Ni2+-NTA-Agarose yielded significant
amounts of pure wALAD protein. Interestingly, more (active) protein could be ex-
tracted from the pellet that formed after centrifugation of the crude lysate by simple
resuspension and further purification. Due to the activity of the protein and the
ease of preparation this protein portion does likely not represent inclusion bodies
but may result from incomplete bacterial lysis or an intrinsic affinity to cell debris
components. Taken together, the modified protocol allowed final yields of 1-2 mg
purified wALAD protein per 500 mL culture.
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Figure 2.7: Purification of recombinant wALAD and hALAD protein
6 µg or the maximal possible amount of protein samples were analysed on a 12.5% SDS-
PAGE gel and visualized by Coomassie blue staining. a) The different fractions occurring
during purification of wALAD. 37.5 kDa wALAD protein of > 90% purity is present in
considerable amounts in eluates 1-4 after primary lysis and after extraction from the pellet.
b) The majority of the expressed wALAD protein is found insoluble in the pellet. c) The
different fractions occurring during purification of hALAD. The 38 kDa protein hALAD
was successfully expressed and is present at high purity in eluates. M = marker, Lys =
lysate, SN = supernatant, E1 - E6 = eluates 1 to 6, FT = flowthrough, Pel = pellet.
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Results
3.1 wALAD HT-Screening
A standard ALAD enzymatic assay was simplified and downscaled to microplate-
format. Standard assay conditions [270] were adjusted for 1 µM wALAD to give a
robust, yet sensitive HTS-compatible protocol: A modified Ehlich’s Reagent (MER)
as a combined stopping and color reagent was developped that was based on DMAB,
acetic acid and perchloric acid but in which toxic HgCl2 and tedious transfer steps
were omitted (the assay principle of the detection of the pyrrole porphobilinogen
by Ehrlich’s Reagent is depicted in Fig. 3.1). Thus the assay was performed in
a 30 µL volume in 96-well microplates. For the substrate, 5-ALA, a concentration
of 200 µM was chosen, which was below the determined Michaelis-Menten constant
KM of ∼311 ± 52 µM (Fig. 3.2 a), but which rendered the assay sensitive for the
detection of inhibitors of all kinds. A time-curve experiment revealed that after 20
min the reaction was still in the linear phase and that this timepoint was a suitable
assay endpoint (Fig. 3.2 b).
This assay was used to screen a diversity-based chemical library of ∼18,000
small drug-like molecules for novel inhibitors of wALAD. A general overview of the
screening and validation workflow and the results is given in Fig. 3.3. The mean
Z’-factor of the assay during screening was 0.66 ± 0.20 indicating excellent assay
quality and reliable screening data [274]. The hit-threshold was set to the mean of
the DMSO control minus 3 standard deviations which was equivalent to 35% inhi-
bition and yielded 71 primary hits (0.4%). Exemplary primary screening data is
shown in (Fig. 3.2 c). All hits were rescreened in duplicate. In order to remove low
potency hits, the hit threshold during the rescreen was increased to 50% inhibition
and was exceeded by 18 confirmed hit compounds (0.1 %). For these compounds
IC50 concentrations were determined for wALAD and hALAD as a control and com-
pounds were tested for non-specific interference with the porphobilinogen detection
assay and hALAD, as shown in Table 3.1.
3.1.1 Discovery of wALADin-benzimidazole: species-selective
inhibitors of wALAD
The screening revealed a cluster of substituted benzimidazole structures (CG3 5G9,
CG3 24H7, CG3 7H5) that inhibited wALAD activity in a dose-dependent manner
while activity of the human ortholog hALAD was only marginally affected. The
most potent of these compounds inhibited wALAD with an IC50-value of ∼11 µM
and was termed wALADin1 (Wolbachia ALAD inhibitor 1) (Fig. 3.2 d). Inhibi-
tion of wALAD by wALADin1 was highly species-selective, as hALAD was inhibited
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Figure 3.1: Reaction scheme of porphobilinogen detection with Ehrlich’s
Reagent
Under acidic conditions protonated p-dimethylaminobenzaldehyde reacts in an elec-
trophlilic substitution reaction with the pyrrole at the Cα atom and produces a chro-
mophore with high extinction at 555 nm [6].
only marginally with an extrapolated IC50-value of ∼740 µM at pH 7.5 (within the
optimal buffer range of this ortholog), which is a more than 60-fold discrimination
in inhibitory potency of the two orthologs (Fig. 3.2 e). At pH 8.0 (the pH op-
timum of wALAD), hALAD was even less-sensitive to inhibition by wALADin1.
Thus, wALADin1 is a novel species-selective inhibitor of wALAD.
Table 3.1: Confirmed wALAD Screening hits
Compound %
Inhibition
Primary
Screen
%
Inhibition
Rescreen
%
Inhibition
PBG
Detection
IC50
wALAD
[µM]
IC50
hALAD
[µM]
Remark
KR1 4G3 81.0 82.0 none 8.1 19.7 Trivial name:
Cacotheline
KR1 3F10 75.2 77.6 none 9.1 15.5
CG3 5G9 39.5 79.5 none 112 > 500 Substituted
benzimidazole
CG3 24H7 57.0 63.0 none 22 > 500 wALADin1/
Substituted
benzimidazole
CG2 27D2 36.9 63.5 none ∼230 ∼781
CG2 17G2 46.5 73.1 none 158 121
CG1 23H9 34.3 61.6 none 61 127
CG6 23G7 52.6 54.2 none 95 ∼453
KR1 7D9 56.4 50.1 17 54 91
CG5 12B7 38.5 50.0 none 66 70
CG3 7H5 41.9 48.1 none 52 > 500 Substituted
benzimidazole
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Figure 3.2: wALAD enzymatic assay screening
a) 5-ALA concentration row under screening assay conditions. The dashed vertical lines
indicates the concentration of 200 µM subsequently used for HTS. The graph shows means
of three independent experiments. b) Time curve of the wALAD reaction. After 20 min
the reaction is in its steady state phase. Under the described conditions the enzymatic
assay was implemented in a HT-screen of a library comprising ∼18,000 small molecules.
The cut-off for primary hits was 35% inhibition and was increased to 50% for confirmed
hits to be brought forth for further validation. c) Primary data from one exemplary
screening plate on which the most potent species-selective inhibitor, called wALADin1
(arrow) was detected. d) Chemical structure of wALADin1. e) wALADin1 specifically
inhibited enzymatic activity of the Wolbachia ortholog (IC50 = ∼11 µM at pH 8.0) while
it had only minor effects on the human protein (IC50 > 500 µM for pH 7.5; triangles: IC50
> 1 mM for pH 8.0). The graph is representative of 3 experiments showing means ± SD
of triplicates. Pos Ctrl = positive control with 5-ALA and DMSO; Neg Ctrl = negative
control with DMSO and without 5-ALA.
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Figure 3.3: Workflow of wALAD HT-Screening and hit validation
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3.1.2 Further hit structures
A species-selective inhibitor which was based on a different chemical scaffold than
wALADin1 was CG6 23G7. Due to its low potency, this inhibitor was not pursued
further (Table 3.1).
Another apparently potent inhibitor with differential potency for wALAD and
hALAD was cacotheline, a semi-synthetic derivative plant alkaloid brucine. De-
tailed analysis of cacotheline in enzymatic inhibition experiments revealed that this
compound had a non-specific effect: An extinction spectrum of cacotheline in the
ragne of visible light revealed that it reacted with DTT, leading to a shift in the
peak extinction wavelength from 390 nm to 525 nm (Fig. 3.4 a). This shift was,
however, only temporary and its lifetime was dependent on the DTT concentration
present in the solution (Fig. 3.4 b): The higher the DTT concentration, the longer
the lifetime. When after 30 min DTT was again added exogenously, the same tran-
sition occured again indicating a previous consumption of DTT by cacotheline. As
the concentration of cacotheline in solution was only 100 µM and was thus much
lower than mM concentrations of DTT, it appears that cacotheline assumes a cata-
lytic function in the consumption (i.e. possibly oxidation) of DTT during which it
forms a red-colored intermediate (absorption at 525 nm). As the presence of DTT is
required for activity of both wALAD and hALAD, its consumption by cacotheline
may explain reduced protein activities as a non-specific artifact.
Figure 3.4: Elucidation of the DTT-consuming effect of cacotheline
a) 5 mM DTT leads to a shift in the extinction peak of cacotheline from 390 nm to 525 nm.
b) The DTT-induced shift in the absorption maximum is temporary and is correlated to
DTT concentration (Phase I). Secondary addition of DTT as depicted by the vertical line
after 30 min (Phase II) leads again to increased OD525nm indicating a previous depletion
of DTT. Cacotheline concentration was 100 µM.
57
CHAPTER 3. RESULTS
3.2 Functional characterization of wALADin1
3.2.1 Binding experiments
Before a detailed functional characterization of wALADin1 in terms of inhibition
was carried out, binding of wALADin1 to wALAD should be demonstrated. For
this purpose thermal shift assays (TSA) were employed. This technique uses the
fluorescent dye Sypro R©Orange that exhibits higher quantum yields when bound to
hydrophobic parts of a protein than in aqueous solution [275, 225]. As hydrophobic
side chains become exposed upon thermal denaturation, the melting curve of a
protein can be measured as an increase in fluorescence intensity. Upon binding
of a ligand to the protein the protein tertiary structure is stabilized and requires
higher temperatures for denaturation. Already low µM concentrations wALADin1
induced a concentration-dependent increase of the wALAD melting temperature
indicating binding of wALADin1 to the protein (Fig. 3.5 a). At 25 µMwALADin1,
the wALAD protein tolerated > 20 ◦C higher temperatures compared to the free
protein. In contrast, for hALAD≥ 250 µMwALADin1 concentrations were required
for a minimal shift of the melting temperature with a maximal ∆Tm of 1.5 ◦C at
1 mM (Fig. 3.5 b). Similarly, wALADin1 did not stabilize other control proteins
such as BSA or lysozyme (Fig. 3.5 c, d) indicating its binding specificity for
wALAD.
Figure 3.5: Thermal Shift Assay with wALADin1
Protein melting curves as a function of the fluorescence intensity of the environmentally
sensitive dye SyproR©Orange: a) wALAD protein (5 µM) is thermally stabilized by in-
creasing concentrations of wALADin1 as evident in pronounced shifts of the melting curve
at low µM concentrations. Marginal shifts of the melting curves (< 2 ◦C) observed for b)
hALAD (0.2 mg/mL or 5 µM), c) Chicken Egg White Lysozyme (3 mg/mL) or d) BSA
(0.5 mg/mL) demonstrate specificity of wALADin1 for wALAD.
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3.2.2 wALADin1 and the oligomeric equilibrium of wALAD
As a morpheein wALAD forms a complex equilibrium of multiple homomeric assem-
blies characterized by different catalytic activities. To determine whether wALA-
Din1 interferes with the oligomeric equilibrium of wALAD, we studied oligome-
rization properties of wALAD and used hALAD as a control for the localization
of hexameric and octameric bands in the native polyacrylamide gels. For hALAD,
preincubation with the substrate 5-ALA led to the expected shift towards the active
octameric conformation (Fig. 3.6 a). In the case of wALAD, a complete transition
from hexameric to the octameric state was achieved by the addition of DTT (Fig.
3.6 a). The higher molecular weight bands occasionally observed for wALAD may
represent aggregated states. (Fig. 3.6 b, upper panel). The in-gel activity assay
(Fig. 3.6 b, lower panel) revealed that, like other orthologs, wALAD is active in
the octameric and inactive in the presumably hexameric smaller molecular weight
conformation. I also showed that preincubation of wALAD with wALADin1 led to
a reduction in porphobilinogen formation detected by MER while octameric band
strength remained unaffected as evident from subsequent Coomassie blue staining
(Fig. 3.6 b). These data show that wALADin1 binds to and inhibits octameric
wALAD without disturbing the oligomeric equilibrium.
Figure 3.6: wALADin1 and the oligomeric equilibrium of wALAD
a) Non-denaturing 7.5% polyacrylamide gels stained with Coomassie blue loaded with 8
µg hALAD or wALAD. Proteins were pre-incubated for 30 min at RT in the presence or
absence of 10 µM ZnCl2, 5 mM MgCl2, 10 mM 5-ALA and/or 5 mM DTT as indicated.
Preincubation of hALAD with 5-ALA shifts the equilibrium from the hexameric towards
the octameric assembly. 5 mM DTT shifts the wALAD equilibrium completely towards
octamer formation. b) Native page of 5 µg wALAD protein preincubated with 5 mM
DTT and 0 to 670 µM wALADin1 for 30 min at RT. For monitoring of in-gel enzymatic
activity, gels were soaked in activity assay buffer containing 5-ALA and incubated for 1h at
36 ◦C before staining with MER (lower panel) and Coomassie blue (upper panel). Image
contrast was adjusted with Adobe Photoshop Elements 3.0.
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3.2.3 The molecular mode-of-action of wALADin1
Having confirmed the binding of wALADin1 to the active ALAD oligomer, the
inhibitory mechanism of this novel inhibitor was studied. wALAD being a Mg2+-
dependent enzyme (EC50 ∼11 µM, Fig. 3.7 a) the influence of Mg
2+-concentration
on the inhibitory potency of wALADin1 was analyzed. wALADin1 caused a right-
ward-shift of the Mg2+-response curve indicating a functional competition between
inhibition by wALADin1 and the activation induced by Mg2+ (Fig. 3.7 b). How-
ever, non-linear regression ("log(agonist) vs. response - variable slope") under the
constraint of a shared Hill slope for all data sets predicted decreased maximum
enzymatic velocity (Vmax) for increasing concentrations of wALADin1, indicating
that the inhibition by wALADin1 may only be partially overcome by the activation
by Mg2+.
The type of inhibition exerted by wALADin1 was studied by cross-titrating
different wALADin1 concentrations against varying concentrations of the 5-ALA
substrate in the wALAD enzymatic assay. Both non-linear regression analysis
and linearized Eadie-Hofstee representation indicate that the wALADin1 inhibitory
mechanism is best described as a mixed model inhibition (Fig. 3.7 c, d). Best
NLR curve fit was obtained employing an "Allosteric sigmoidal" model accounting
for cooperative effects. Increasing wALADin1 concentrations led to a decrease in
Vmax (non-competitive inhibition) and increase in KM values (competitive inhi-
bition) as characteristic for mixed model inhibition. Prediction of the inhibition
constant KI required a non-linear regression analysis assuming a global model such
as the "Mixed Model Inhibition" NLR. Predicted KI was 5.95 ± 0.95 µM with a
corresponding α-value of 31.44 ± 9.59 µM (R2 = 0.9794) using 1.0 mM MgCl2.
The KI predictions and the α-value varied at different MgCl2 concentrations (0.5
mM MgCl2: KI = 3.2 µM; α = 43.10, R
2= 0.9759; 5 mM MgCl2: KI = 25.1 µM;
α = 14.74, R2 = 0.9732). In general, an increase in MgCl2 led to lower predicted
affinities (higher KI) and a more pronounced substrate-competitive character of the
inhibition as indicated by increased α as in accordance with a mixed competitive/
non-competitive inhibitory mechanism.1
1 For a morpheein sampling different oligomeric states, it is accepted that two-phasic substrate-
concentration rows are observed reflecting the different catalytic activities for the reactive centers
in the different conformations [135]. It might therefore be appropriate to assume a double hy-
perbolic progression accounting for the different binding sites. However, subjecting the data to
non-linear regression assuming a double hyperbolic fit gave the following data (R2 = 0.9902 -
0.9961): 6.7 % DMSO : Vmax,1 = 0.071, µM; Vmax,2 = 0.014, KM,1 = 163 µM, KM,2 = 3.4
mM); 6.25 µM wALADin1: Vmax,1 = 0.053, µM; Vmax,2 = 0.013, KM,1 = 254 µM, KM,2 = 4.2
mM, 25 µM wALADin1: Vmax,1 = 0.046, µM; Vmax,2 = 0.023, KM,1 = 456 µM, KM,2 = 6.4
mM; 100µM wALADin1: Vmax,1 ∼0.027, µM; Vmax,2 ∼0.023, KM,1 ∼1.623 mM, KM,2 ∼1.624
mM. These data are consistent with an increase in both KM -values and the overall Vmax upon
increasing concentrations of wALADin1. Thus, while marginally improved fits were obtained for
three conditions, for 100 µM wALADin1, the fit is clearly not superior to a simple hyperbolic
fit. Furthermore, analyses of different data sets based on single experiments (Fig. 3.22, 3.24)
revealed no evidence for a double-hyperbolic progression. This finding is in accordance with na-
tive PAGE data revealing a uniform protein population under assay buffer conditions (Fig. 3.6).
Thus, suitability of double hyperbolic fits for different data sets of the wALAD protein is am-
biguous and even in the mentioned cases where a double hyperbolic fit was slightly superior,
the mechanistic conclusions are qualitatively equivalent to those drawn from a simple hyperbolic
or "Allosteric sigmoidal" fit. Therefore, throughout this work non-linear regression analysis was
performed applying the "Allosteric sigmoidal" model.
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Figure 3.7: The inhibitory mechanism of wALADin1
a) Dose-response curve for MgCl2 on wALAD activity (EC50 = 11 µM) depicted as means
± SEM of three independent experiments applying a near-saturating 5-ALA concentration
(1 mM). b) wALADin1 functionally competes with the activation induced by Mg2+ as
evident in a rightward shift of the Mg2+-response curve of wALAD (non-saturating 5-
ALA concentration of 0.2 mM). Curves were fit using the "log(agonist) vs. response -
variable slope" non-linear regression algorithm assuming (constraints: shared hill slope vor
all data sets and bottom ≥ 0). c) Substrate-concentration rows in the presence of different
concentrations of wALADin1. Continuous lines show fit with "Allosteric sigmoidal" (R2
between 0.9893 and 0.9939), dashed lines show fit with "Mixed Model Inhibition" non-
linear regression algorithm (R2 = 0.9794). d) Linearized Eadie-Hofstee representation
of wALAD activity in the presence of wALADin1. The decrease in the y-axis intercept
corresponds to a decrease in Vmax, the increased slope corresponds to an increase in the
apparent Michaelis-Menten constant. This classifies wALADin1 as a mixed competitive
and non-competitive inhibitor. b - d depict means ± SD of two independent experiments.
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3.2.4 Solubility of wALADin1
In order to determine the solubility of wALADin1, an absorption spectrum (UV-
VIS) of the compound was recorded in wALAD assay buffer with 1% DMSO. The
spectrum showed an extinction peak at 228 nm and a shoulder area between 250
nm and 280 nm (Fig. 3.8 a). Solubility of the compound was verified as an
increase in specific extinction along a two-fold concentration row of wALADin1 in
assay buffer/1%DMSO. Centrifugation would remove any precipitated compound
from the solution and the linear increase in absorption would be stopped as soon as
solubility is exceeded. As the absorption at 228 nm was very strong and exceeded
the linear detection range (with OD = 1.0 as the upper limit) already at relatively
low concentrations, OD was measured in the shoulder area at 253 nm. Throughout
the concentration range tested (up to 1 mM) solutions showed a linear increase
in OD253nm (Fig. 3.8 b) which revealed solubility of wALADin1 under these
conditions.
Figure 3.8: UV-VIS absorption spectrum of wALADin1 and solubility
measurements
a) UV-VIS absorption spectrum of wALADin1 determined in wALAD assay buffer with
1% DMSO. The vertical line indicates λ = 253 nm. b) A concentration row of wALADin1
in wALAD assay buffer/1% DMSO was prepared, incubated at RT for > 30 min and
centrifuged at maximum speed to pellet precipitated compound, if any. The concentration
row shows a linear increase increase in OD525nm throughout the concentration range tested.
wALADin1 is therefore easily soluble in wALAD assay buffer at concentrations up to 1
mM.
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3.3 Antifilarial activity of wALADin1
Having demonstrated and characterized the inhibitory effects of wALADin1 on
wALAD at the molecular level, the antifilarial activity of this species-selective in-
hibitor was addressed. wALADin1 was tested for its activity against the rodent
filarial nematode Litomosoides sigmodontis, which also harborsWolbachia endobac-
teria, and is a model for human pathogenic filarial nematodes causing LF/Oncho
[203, 258, 7]. These studies were complemented with cytotoxicity experiments ap-
plying wALADin1 on both LLC-MK2 (monkey kidney) cells and HEK (human
embryonic kidney) cells.
3.3.1 Cytotoxicity tests
Cells were exposed to different concentrations of wALADin 1 for 48 h and cellu-
lar viability was measured by MTT assay. For both cell lines 500 µM and 1 mM
wALADin1 led to reduced viability values (Fig. 3.9). In the co-culture experi-
ments described below the LLC-MK2 cell lawn was intact at 500 µM wALADin1
throughout the 14 days of the experiment and cells did not show signs of apopto-
sis. Thus, rather than exerting a genuine cytotoxic effect, wALADin1 may have
antiproliferative activity on eukaryotic cells at these high concentrations that may
account for the reduced viability rates.
Figure 3.9: Cytotoxicity of wALADin1 on eukaryotic cell lines
Cellular viability measured by MTT assay in Human Embryonic Kidney (HEK) and Mon-
key Kidney (LLC-MK2) cell lines treated for 48 h with different concentrations of wALA-
Din1. The graph shows median values (n=6) and interquartile range of data normalized
to the median OD550nm of 1% DMSO-treated cells as a 100% viability control.
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3.3.2 Efficacy of wALADin1 in L. sigmodontis co-culture as-
say
The antifilarial activity of wALADin1 was addressed in an assay system using the
model rodent filarial nematode L. sigmodontis in co-culture with LLC-MK2 monkey
kidney feeder cells. Adult female L. sigmodontis worms were exposed to wALADin1
at 125, 250 and 500 µM, concentrations that were ∼10 - 50 fold higher than the
enzymatic assay IC50 concentration. This excess was considered necessary to reach
effective concentrations in the biophase of the living worm given that the compound
must traverse the worm cuticle and several membranes to reach its enzymatic target
and that accumulating substrate would (partially) compete with the inhibitor thus
lowering its potency.
Worms were cultured as long as 1% DMSO-treated controls revealed no major im-
pairment of motility (14 - 17 days). During the course of the experiment worm
motility was rated daily while worm viability was addressed by MTT-assay at the
end of the treatment period. All concentrations tested impaired the motility of L.
sigmodontis throughout the experiment (Fig. 3.10 a, b.) While healthy worms
(worms from before treatment and control-treated worms) had rapid, fidgeting and
mostly continuous movements, affected worms had a more stretched phenotype and
their movements became slower and less continuous. wALADin1-treated worms,
however, had a very specific phenotype: Worms wound up in knot-like forms with
greatly reduced motility (motility scores 4, 3) culminating in the stretched low-
motility phenotype of dying/dead worms (Fig. 3.10 a, Supplementary Videos
1 - 3). Quantification of the filaricidal effect of wALADin1 was achieved by mea-
suring the biochemical viabiliy of the worms by MTT assay. Worms treated with
either concentration of wALADin1 produced significantly smaller amounts of MTT-
formazan compared to the DMSO-treated controls (Mann-Whitney-U test, p < 0.05,
Fig. 3.10 a). Median residual viabilities for the different treatment groups were
44%, 27% or 7.5% viability for 125 µM, 250 µM and 500 µM of wALADin1, re-
spectively. These values allowed a rough estimation of the EC50 concentration of
∼100 µM which was one order of magnitude higher than the IC50 of the in vitro
enzymatic assay.
In order to prove that the observed antifilarial effect is due to the inhibition of
the heme-biosynthesis enzyme ALAD inside the Wolbachia endosymbionts, wALA-
Din1 was also tested for activity in the Wolbachia-free filarial model nematode
Acanthocheilonema viteae [176]. As the genome of this filaria has recently been elu-
cidated, a nucleotide blast query against the A. viteae genome database (Blaxter,
M.L. The genome of the filarial nematode Acanthocheilonema viteae, Edinburgh,
UK, 2012) was conducted employing the hemB gene sequences of Wolbachia of B.
malayi, H. sapiens and yeast as input sequences. As no orthologous sequences were
found in the genome of A. viteae it was concluded that these worms lack ALAD
as the molecular target of wALADin1. Thus, A. viteae should only be sensitive
to non-specific effects exerted by wALADin1 allowing the dissection of specific and
non-specific effects of this compound. The only effect seen for A. viteae required a
wALADin1 concentration of 500 µM and became manifest as a rapid decrease in
motility, evident already ∼2 h after treatment (Fig. 3.10 d). However, after this
initial one step decline, motility did not deteriorate until day 12. Any compari-
son between L. sigmodontis and A. viteae motility should be done with caution, as
the motility phenotypes are generally dissimilar and each refers to its own scoring
system. Notwithstanding, wALADin1 did not induce the knot-like phenotype cha-
racteristic for wALADin1-treated L. sigmodontis on A. viteae. The more reliable
parameter tested was worm viability. Viability of wALADin1-treated A. viteae was
not significantly affected (Fig. 3.10 e) and lower concentrations had no effect on
either worm viability or motility (Fig. 3.10 d, e; Supplementary Videos 1,
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Figure 3.10: wALADin1 has a Wolbachia-dependent macrofilaricidal ef-
fect
a) - c) Adult females of the Wolbachia-harboring L. sigmodontis and d), e) Wolbachia-free
A. viteae model filarial nematodes were exposed to different concentrations of wALADin1
or 1% DMSO for 14 - 17 days. a) Exemplary pictures of L sigmodontis worms revealing
wALADin1-elicited phenotypes. b) All concentrations of wALADin1 showed an antifilarial
effect on L. sigmodontis evident in a continuous reduction of motility and c) significantly
impaired viability at the end of treatment (non-parametric, two-tailed Mann-Whitney-U
test, p < 0.05), d) while only 500 µMwALADin1 had a minor non-specific effect on motility
of A. viteae. e) wALADin1 did not affect viability of A. viteae. Data are representative
of 2 experiments. Motility graphs show median values (n=6). Percent viability data were
obtained by normalizing MTT assay data to the median OD490nm of 1% DMSO-treated
worms (set to 100% viability). For A. viteae data of two independent experiments are
shown in d that are marked with I and II, respectively. In e, normalized viability data of
the control groups were pooled and all groups are shown in a single graph. d = days.
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4, 5). In comparison, for L. sigmodontis there was still a ∼56% impairment at
125 µM. While the non-specific effect on A. viteae motility at 500 µM wALADin1
may correspond to the weak cytotoxicity observed at this and higher concentra-
tions (Fig. 3.9 a) the specific impairment of L. sigmodontis viability throughout
all concentrations tested demonstrates the Wolbachia-dependency of the filaricidal
effects of wALADin1.
3.3.3 Effects of 5-ALA in the L. sigmodontis co-culture
I considered that the macrofilaricidal effects induced by wALADin1 may, at least
to some extent, be due to increased levels of 5-aminolaevulinic acid (5-ALA) that
build up as a consequence of ALAD inhibition. To test this hypothesis, motility
and viability of L. sigmodontis were measured under exposure to exogenous 5-ALA.
Indeed, both motility and viability were reduced under treatment with 1 mM or 5
mM 5-ALA, respectively, while a concentration of 200 µM had little effect (Fig.
3.11). Thus, high concentrations of 5-ALA do have a filaricidal effect and this
"directed" toxicity may act in combination with a reduction in heme-levels to drive
the antifilarial effect of wALADin1.
Figure 3.11: 5-ALA has a macrofilaricidal effect on L. sigmodontis
Adult L. sigmodontis females were exposed to different concentrations of 5-ALA (the sub-
strate of the ALAD enzyme), 1% DMSO or 250 µM wALADin1 as controls. a) 1 mM and
5mM 5-ALA induced reduced worm motility and b) viability (non-parametric, two-tailed
Mann-Whitney-U test, p < 0.05, as measured by MTT-assay at the end ot the treatment
period. a depicts median values (n=6; for 1% DMSO: n=9; for 500 µM wALADin1:
n=5), bars in b indicate median values. Percent viability data were obtained by normal-
izing MTT assay data to the median OD490nm of 1% DMSO-treated worms (set to 100%
viability). d = days.
3.3.4 BLAST search for a gene with protoporphyrinogen IX
oxidase function in Wolbachia
The only heme biosynthetic genes for which no homolog has been identified are
the hemY /hemG genes encoding protoporyphyrinogen IX oxidase catalysing the
penultimate step of heme biosynthesis. A candidate gene encoding protoporphyrino-
gen IX oxidase function recently identified in Synechocystis spp. and Rhodobacter
sphaeroides is the slr1790 gene [146]. In order to test whether a homolog exists
also in the Wolbachia genome a tblastn search was undertaken querying all cur-
rently available filarial genome databases with the Synechocystis spp. slr1790 gene
(also termed hemJ ) product. Significant alignments were found in all Wolbachia
genomes (D. immitis - Score = 83, E value = 2e-15; L. sigmodontis - Score = 83,
E value = 2e-15; B. malayi - Score = 77; E value = 1e-13; O. ochengi - Score =
77; E = 1e-13), but not in nuclear or mitochondrial genome assemblies of A. viteae,
B. malayi, D. immitits, L. sigmodontis, L. loa, O. ochengi or W. bancrofti (Fig.
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Figure 3.12: Results of a tblastn search for homologs of the slr1790 gene
a) Significant alignments produced by tblastn search against the "All Filarial
Genomes 2012-08-24" assembly (Mark Blaxter, University of Edinburgh, 2012) with
the slr1790 gene product of Synechocystis spp. as input sequence (Uniprot ID:
P72793, sp|P72793|Y1790)). Homologous sequences were identified in the Wolbachia
genomes of D. immitis (wDi22.scaf1), B. malayi(ref|NC_006833.1|), L. sigmodon-
tis (wLs20.scaf01, wLs20.scaf03), O. ochengi (wOo) and the genome assembly of
O. volvulus (nOV_contig35124, nOV_contig48835). b) tblastn search against the
O. volvulus nuclear genome assembly 1.0 (Jeremy Cotton, Wellcome Trust Sanger
Institute, 2012) using the wALAD gene sequence (Uniprot ID: Q5GSR3, "anony-
mous") as input. A gene encoding the Wolbachia protein (nOv_contig47523) was
identified indicating the presence of Wolbachia genes within this assembly. All
queries were run over the "BLAST search and download server for Filaria-EU" server
(http://xyala.cap.ed.ac.uk/downloads/959nematodegenomes/blast/filareu.php) under de-
fault alignment settings.
3.12 a). The significant alignments found for the O. volvulus nuclear genome as-
sembly (Score=77, E value = 1e-13) are likely derived from contained Wolbachia
sequences, as tblastn search using the wALAD gene sequence produced a perfect
alignment (Score=680; E value = 0.0) (Fig. 3.12 b). Identification of this puta-
tive translated protein sequence encoded in the Wolbachia genome with significant
homology to the slr1970/hemJ product suggests it may fulfil the missing protopor-
phyrin IX oxidase function in the heme biosynthesis pathway of the endosymbiont.
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3.4 Tests for antifilarial activity of wALADin1 in
vivo during L. sigmodontis infection
Validation of the antifilarial activity of wALADin1 in vivo was done using the model
of BALB/c mice naturally infected with L. sigmodontis. Treatment was started at
1 day post infection and continued for up to 28 days. The gold standard of anti-
Wolbachia therapy 1 mg (50 mg/kg) doxycycline for 14 d showed the expected
potent antifilarial effect manifest in reduced female worm length and a reduction of
intracellular Wolbachia by more than 99.9% as measured by quantitative Realtime-
PCR. No such effect was evident for worms recovered from mice treated with 1
mg wALADin1 for 14 or 28 d (Fig. 3.13 a, b). As the limit of solubility was
reached for wALADin1 in the given formulation (Minimal Essential Medium, like
in the ex vivo culture system, but without supplements) a vehicle with increased
solubility of wALADin1 was selected for the delivery of higher doses. As MEM
already featured significant improvements in solubility compared to PBS or water,
Earl’s Balanced Salt Solution (EBSS), the buffer content of MEM, was selected
and supplemented with 2-Hydroxypropyl-β-cyclodextrins (CD). Cyclodextrins are
cyclic oligosaccharides derived from α-1-4-linked glucose oligomers composed of 6 - 8
subunits that present a hydrophobic core allowing formation of inclusion complexes
with biomolecular ligands, thus promoting solubility of the complexed molecules in
the aqueous vehicle [235, 98, 153]. Cyclodextrin containing vehicles are successfully
employed to deliver poorly soluble drugs in the clinic and have a mostly benign
toxicological profile [98]. However, higher doses of wALADin1 in CD-containing
vehicles (2 mg or 2 x 2 mg per day) still had no effect on filarial development and
Wolbachia numbers (Fig. 3.13 c, d).
Given the high concentrations required to achieve macrofilaricidal effects in the
ex vivo setup (≥ 125 µM) and insecurities about bioavailability of the compounds
in the mouse, wALADin1 was finally delivered locally to the site of L. sigmodontis
infection, i.e. the pleural cavity. The experimental layout was slightly changed,
as larvae appear first in the pleural cavity ∼7 days post infection [122] which was
chosen as the starting point for intrathoracic administration of 0.4 mg wALADin1
or CD-containing vehicle in a volume of 100 µL. In order to monitor any antifilarial
effect evident in the course of infection, mice were euthanized at different timepoints
(21 dpi, 28 dpi, 25 dpi) and length and viability of isolated worms were determined
(Fig. 3.14). Throughout these time points there was no significant difference
between length and viability of worms from wALADin1- and vehicle-treated mice.
Both treatment groups seemed to affect worm development in comparison to the
non-treated control groups. However, this effect requires further studies including
higher mouse numbers and a higher infection rate for a statistically sound analysis
(The worm burden of mice in the given experiment was very low with high variations
(0 - 9 females per mouse) preventing the use of a data set of "pooled worms" per
treatment group for statistical analysis). Whether the apparent antifilarial effect
of the vehicle is due to the mere presence of liquid in the pleural cavity, diluting
nutrients or growth factors, or is elicited by CD, that may non-specifically complex
these biomolecules, remains to be determined.
In summary, at the doses and formulations tested, no beneficial effects of wALA-
Din1 on the outcome of L. sigmodontis infection in mice were observed. As this
outcome may be the result of insufficient bioavailability of the compound due to
rapid metabolization and excretion or non-specific binding in vivo, the discovery of
wALAD inhibitors with similar or improved biological activity based on the benz-
imidazole and other scaffolds is of paramount importance. Such compounds may
feature improved potency, specificity and pharmokinetic profiles and may achieve
the desired in vivo efficacy. In the following section a variety of benzimidazole-
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Figure 3.13: Effects of intraperitoneally-delivered wALADin1 on murine
L. sigmodontis infection
a), b) BALB/c mice were treated i.p. for 14 - 28 days with 1 mg wALADin1 or doxycycline
or were left untreated. c), d) BALB/c mice were treated for 14 - 28 days with 2 mg wAL-
ADin1, 2 x 2 mg wALADin1, 2 mg or vehicle (25 mM 2-Hydroxypropyl-β-cyclodextrin in
EBSS) or were left untreated. a) Female worm length and b)Wolbachia ftsZ/L.sigmodontis
β-actin gene copy ratios showed no effect of wALADin1 treatment on filarial development.
Graphs depict the median female worm length or median ftsZ/Lsactin gene copy ratio,
respectively, of all worms per mouse. No statistically significant difference was observed
compared to non-treated and vehicle-treated groups, respectively (non-parametric, two-
tailed Mann-Whitney-U-Test, p > 0.05).
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based wALADin1 derivatives and chemically similar non-benzimidazole based small
molecules were tested for their wALAD-inhibitory properties in order to identify
such improved inhibitors.
Figure 3.14: Effects of intrathoracically-delivered wALADin1 on murine
L. sigmodontis infection
BALB/c mice were naturally infected with L. sigmodontis and from 7 dpi on treated for 14,
21 or 28 days with 0.4 mg wALADin1, vehicle (30 mM 2-Hydroxypropyl-β-cyclodextrin in
EBSS) or were left untreated. Worms were isolated from the thoracic cavity of euthanized
mice at a), b) 21, c), d) 28 or e), f) 35 dpi. a), c), e) There was no difference in
the female worm length or b), d), f) biochemical viability as measured by MTT-assay
throughout all time points. Graphs depict median female worm length or median OD
values (MTT-Assay), respectively, of all worms per mouse. Differences between treatment
groups were tested for significance using the non-parametric, two-tailed Mann-Whitney-
U-Test. d = days.
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3.5 wALADin1 Structure-Activity Relationship stu-
dies (SAR)
3.5.1 Inhibitory potency of wALADin1 derivatives in the en-
zymatic assay
In collaboration with the LIMES-Institute, a set of wALADin1 derivatives were
synthesized by Victoria Halls and Dr. Jeffrey Hannam that I tested for activity
in the enzymatic assay with the aim to identify more potent inhibitors and to
understand the context of chemical structure and biological activity. An overview of
the different structures and their inhibitory activities is given inTable 3.2. In a first
set of derivatives the single substitutent groups attached to the benzimidazole core
of wALADin1 at R1, R2 and R3 (Fig. 3.15), were replaced by hydrogen atoms in
order to determine the general imporance of each substituent for inhibitory activity
(Compounds 2, 3 and 4). While 3, with a hydrogen atom as the R2 substituent,
still retained the inhibitory potency of wALADin1 (IC50 -values: wALADin1: 11
µM, 3: 13 µM), loss of the R1 3-trifluoromethyl benzyl group (2) or R3-carboxylic
acid were not tolerated and led to an abrogation of inhibitory activity. The R2-
2-[(2-thienylcarbonyl)amino]ethyl substituent of wALADin1 (473.5 Da) resulted in
a smaller molecule 3 (320 Da) with nearly equivalent inhibitory potency and re-
presents an improved drug lead candidate.
Next, the influence of the R1 carboxylic acid (absent in inactive 4) on inhibitory
function was addressed in more detail. Inactivity of a methyl ester variant of wALA-
Din1 (5) further demonstrated a pivotal role of this group for inhibitory activity.
The carboxyl moiety may be important in two ways: One explanation is that it
simply enhances solubility of the compounds thus enabling concentrations sufficient
for an inhibitory effect to occur. Alternatively the carboxylic acid has a functional
role during binding/inhibition. We found that a series of consitutional isomers with
the carboxylic acid attached to the C6, C4 or C7 (instead of C5 in wALADin1) of
the benzimidazole scaffold (6, 7, 8) showed a very diverse activity spectrum. 7 was
completely inactive, while 6 showed a 29-fold and 8 a 15-fold reduced inhibitory
activity with respect to wALADin1. As solubility of these compounds should be
very similar, the differential inhibitory potency indicates a functional role of the
COOH-group. TSA experiments demonstrated that both 6 and 8 were able to
bind to and stabilize the structure of wALAD although with smaller shifts in the
melting temperature (∆Tm) than wALADin1 (Fig. 3.16). 7, which was inactive
in the enzymatic assay, did not indcuce a melt shift for wALAD, indicating that
it was unable to bind to the protein. Elicited ∆Tm are generally observed to
to be proportional to the binding affinities of protein-stabilizing ligands [198] and
reflect nicely the inhibitory potencies of these compounds in the enzymatic assay.
However, while 8 was shown to be the slighly more potent inhibitor than 6, 6
induced a higher ∆Tm. This outcome may be explained by different enthalpic and
entropic contributions to the free energy of binding of these compounds. It is also
important to note that these binding experiments were performed in the absence
of substrate. Given the partial substrate-competitive character of wALADin1, it is
conceivable that the binding potency of these derivatives is differentially influenced
by the absence of 5-ALA in thermal shift assay experiments compared to enzymatic
assay experiments resulting in a different ranking of potency. Taken together, both
enzymatic inhibition and TSA studies indicate a pivotal role for the R3-COOH in
inhibition and at the level of binding suggesting a direct interaction of this group
with the wALAD protein, e.g. by salt bridge formation.
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Figure 3.15: Benzimidazole scaffold of wALADin1 derivatives in Table
3.2
Table 3.2: Inhibitory activity of wALADin1 derivatives
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Figure 3.16: Thermal Shift Assay with wALADin1 derivatives
wALAD melting curves measured by an increase in fluorescence of the environmentally-
sensitive dye SyproR©Orange (Final concentration: 8 - 16X) upon protein denaturation: a)
wALAD (5 µM) melting curves in the presence of 25 µM of wALADin1 and isomers 6, 7,
8. b) While 6 and 8 induced melt shifts less pronounced than for wALADin1, 7 did have
no effect on the melting temperature of wALAD.
Finally, derivatives with modifications at the R1-substituent were studied. It
was noted above that compound 3 was an improved lead candidate and therefore
all R1 derivatives (except 9) were synthesized containing a hydrogen substituent at
R2 (R2-H compounds). Thus, two derivatives with the CF3 residue in R1 moved
from position 3 (wALADin1) to position 4 were available: Compound 9 with an
R2-2-[(2-thienylcarbonyl)amino]ethyl and 10 with an R2-H substituent. While 9
showed a ∼4-fold (IC50 = 38.6 µM), 10 had a ∼8-fold reduced activity (IC50 =
87.7 µM) compared to wALADin1 (and 3). The difference in inhibitory potency
of 9 and 10 revealed, that the R2 substituent may indeed contribute to inhibitory
potency. Notwithstanding, presence of the R1-4-CF3-benzyl substituent led to a
reduction in inhibitory potency for both pairs of molecules with respect to the parent
molecule. All further R1 substituents that comprised 2-trifluoromethyl benzyl (11),
benzyl (12), 3-methyl benzyl (13) or 3-methoxybenzyl (14) groups showed further
reduced inhibitory activities with IC50 concentrations between 134 and 297 µM.
Of special structural importance are the fluorine residues in the CF3-benzyl of
wALADin1 as their replacement by hydrogen atoms to CH3-benzyl led to a 10-
fold loss of inhibitory activity. The absence of the aromatic ring subsitutent in R1
in compounds 15 and 16 that featured a CH3-group or H-atom at this position,
instead, abolished any inhibitory activity against wALAD. Having tested the set
of R2-H compounds on the human ALAD ortholog an intriguing finding was made
with respect to specificity of the wALADin-inhibitors: All derivatives featuring
the R2–2-[(2-thienylcarbonyl)amino]ethyl had shown no or only marginal inhibitory
activity against the human ortholog with 9 being the most potent (IC50 = ∼618
µM). In contrast, all compounds featuring the R2-H substituent except 15 showed
substantially higher inhbitory potency for hALAD with IC50 values between 145
and 222 µM (3, 9 - 14; for 16 IC50= ∼555 µM). For 14 the specificity profile
was reversed: This compound had a lower IC50 value for hALAD (156 µM) than
for wALAD (205 µM). Thus the R2–2-[(2-thienylcarbonyl)amino]ethyl substituent
appears to be an important mediator of specificity for the Wolbachia ortholog that
prevents inhibitory activity against other orthologs such as the human protein.
Taken together, these comparative studies revealed several important structural
properties that contribute to both inhibitory potency and specificity.
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3.5.2 Antifilarial activity of wALADin1 derivatives
Two compounds from the set of wALADin1 derivatives were tested for antifila-
rial activity: 3, the R2-H fragment of wALADin1 which showed nearly equipotent
inhibitory properties compared to wALADin1 and 6, an R1 carboxylic acid con-
stitutional isomer otherwise identical to wALADin1 that showed a nearly 30-fold
reduced inhibitory potency in the enzymatic assay. Neither of these compounds
had any cytotoxic effect on LLC-MK2 cells at 500 µM (Fig 3.17 a).
Figure 3.17: Cytotoxicity of selected wALADin1 derivatives
Cellular viability of LLC-MK2 cells treated with compound 6 or 3. There is no cytotoxicity
observed below 1 mM. The graph show median values (n=4) and interquartile range of
normalized data.
3 showed generally weaker and delayed antifilarial effects on L. sigmodontis com-
pared to wALADin1. However, towards the end of treatment, lower concentrations
(125 and 250 µM) induced a reduction in motility similar to those achieved by equal
concentrations of wALADin1 (motility scores 3 - 4). Yet, only at 500 µM, there
was also a significant reduction in viability quantified by MTT-assay (38% median
residual viability), while the trend to lower viabilities continued in a concentration-
dependent manner also for the lower concentrations (Fig. 3.18 b). Compound 6
also revealed antifilarial activity at 500 µM that was weaker than for wALADin1,
but stronger than for 3 and was evident in both motility scores and viability mea-
surements (24% median residual viability, Fig. 3.18 a, b). However, while worms
treated with 6 had a non-specific appearance, 3 induced a similar balled phenotype
as reported above for wALADin1 (Supplementary Videos 1 - 3).
It was shown in Fig. 3.10 d that, at 500 µM, wALADin1 also had a non-
ALAD-dependent antifilarial property evident in the rapid effect on the motility
of Wolbachia-devoid A. viteae. Thus, the antifilarial effects of compounds of the
wALADin family may be classified as specific ALAD-dependent with an off-target
(or secondary target) effect. The differential antifilarial activity of wALADin1 and
3 in the living worm may be a result of different non-specific contributions of these
compounds in addition to the specific effects achieved by inhibition of heme biosyn-
thesis in the endosymbiont. These non-specific effects appear to be less pronounced
for 3 as indicated by the delayed antifilarial activity. In contrast, due to the great
chemical similarity of 6 to wALADin1 a retention of the non-ALAD-dependent ef-
fects is likely, which may be the major cause of the filaricidal effect of this compound.
A more detailed elucidation of the biological profile of these and other derivatives
will be required to unequivocally determine the differential effects induced by these
compounds. Notably, the remarkable antifilarial activity of wALADin1 was qua-
litatively confirmed also for the 2nd most potent inhibitor and provides a sound
basis for the design of more potent antifilarials targeting ALAD of the Wolbachia
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endosymbionts in the future. It is therefore of great importance to identify che-
mical structures that share the novel and unique Mg2+-dependent mode of action
of the inhibitors of the wALADin family but have a chemotype different to the
wALADin1-benzimidazoles. First steps into this direction were undertaken and are
presented in the following paragraphs.
Figure 3.18: Antifilarial activity of selected wALADin1 derivatives
Adult L. sigmodontis females were exposed to different concentrations of wALADin1
derivatives 3 and 6 or 1% DMSO for 17 days. The data presented in this graph (incl.
the 1% DMSO control) were collected in the same experiment shown in Fig. 3.10 to
allow a better comparison of compound activities. a) Both compounds lead to an im-
pairment of L. sigmodontis motility and b) viability as quantified by MTT-assay at the
end of the treatment period. a shows median values (n=6), bars in b) represent me-
dian values. For worm viability data, significance was tested by non-parametric two-tailed
Mann-Whitney-U test; significant p-values (p < 0.05) are depicted in the graph. d = days.
3.6 wALAD inhibitors with a different chemical
scaffold
The chemotype of the inhibitors of the wALADin1 family is a tri-substituted benz-
imidazole. However, molecules based on a single scaffold generally may be restricted
with respect to several characteristic drug-activity related properties like potency,
specificity, toxicity or bioavailability. This study therefore aimed at the discovery of
other similar inhibitors with different molecular scaffolds. One non-benzimidazole
inhibitor of wALAD already identified as a wALAD inhibitor during HTS was
the non-aromatic benzothiazole derivative CG6 23G7. A number of compounds
that showed molecular similarity to wALADin1 was selected and obtained through
different sources and subsequently tested for inhibitory activity. A selection of these
compounds with notable biological activity is presented in the following sections.
3.6.1 Inhibitory properties of virtual screening hits
A virtual screening of ∼3.7 million commercially available small molecules was
carried out by Dr. D. Stumpfe at the Life Science Informatics (Bonn - Aachen
International Center for Bioinformation Technology, LIMES-Institute Bonn, Ger-
many). wALADin1 was used as a single template or in combination with CG3
24C7 (see Appendix A) for compounds with different scaffolds that were rated
similar in a fingerprint-based similarity screening approach involving atom environ-
ment, fragment-based and pharmacophore information (Dr. D. Stumpfe, personal
communication). From the top 100 scoring chemical scaffolds molecules were ma-
nually selected that featured a carboxyl or other group involving a negative (partial)
75
CHAPTER 3. RESULTS
Figure 3.19: wALAD inhibitors VS8 and VS9
a) Percent enzymatic activity values of wALAD and hALAD, respectively, in the presence
of virtual screening hits 1 - 9. Compounds were tested at 67 µM in triplicate measurements.
Graph shows means ± SD. b) Chemical structure of VS8 and c) VS9. d) Dose-response
curves for VS8 and VS9 in the wALAD and hALAD enzymatic assay under standard
conditions. Graphs shows means ± SD of two independent experiments. Lines were fit
using the "log(inhibitor) vs. normalized response - Variable slope" non-linear regression
algorithm of GraphPad Prism 5.0. The asterisk marks absence of inhibitory activity
charge because of the dependence on a carboxyl moiety in the wALADin1 struc-
ture for inhibitory activity. 9 of these virtual screening hits were purchased and
tested for inhibitory activity against wALAD and hALAD at 67 µM (Fig. 3.19
a). The chemical structures are shown in Appendix A. Only the non-aromatic
1,3-dihydro-2H-benzimidazol-2-one derivatives VS8 and VS9 showed significant in-
hibition (> 25%) of either ortholog. In contrast to the wALADin1-scaffold these
molecules (VS8 and VS9) carry substituents at the N3 instead of the C2 atom of
the benzimidazole ring (Fig. 3.19 b, c). VS8 inhibited hALAD with an IC50 con-
centration of 119 ± 8.9 µM. However, upon exchange of the (2-pyrimidinyl)methyl
(VS8) to a 2-(1-pyrrolidinyl)propyl (VS9) activity against hALAD was lost, while
inhibitory potency for wALAD increased dramatically to an IC50 of 340 ± 61 µM
(Fig. 3.19 d). The identity of the substituent at the N3 atom therefore decides
specificity of inhibition.
3.6.2 Inhibitory properties of the Peakdale compound set
750 compounds with molecular similarity to wALADin1 had been identified in the
in-house library of Peakdale Molecular Limited (Chapel-en-le-Frith, UK) and were
purchased for testing of biological activity. Compounds were screened in unicate
measurements at a concentration of 67 µM analogous to the initial wALAD scree-
ning.
Two highly similar compounds with inhibitory properties were the phenylthio-
76
CHAPTER 3. RESULTS
phene carboxylic acid structures PD 481 and PD 593 (Fig. 3.20 a, b). These
structures only differed in the substitution at postition 4 of the phenyl ring, which
was either a bromo- (PD 481) or a chloro-substituent (PD 593). These compounds
showed very weak IC50 values in the wALAD assay of ∼299 ± 57 µM (PD 481)
and 521 ± 120 µM (PD 593), respectively (Fig. 3.20 c). When tested against
hALAD, however, the compounds showed a remarkable 3 - 5 fold increase in in-
hibitory potency with IC50 values of 100 ± 11 µM and 85 ± 5.6 µM, respectively.
Figure 3.20: wALAD inhibitors PD 481 and PD 593
a) Chemical structures of PD 481 and PD 593 b) Dose-response curves for PD 481 and PD
593 in the wALAD and hALAD enzymatic assay under standard conditions. Graphs show
means ± SD of two independent experiments. Lines were fit using the "log(inhibitor) vs.
normalized response - Variable slope" non-linear regression algorithm of GraphPad Prism
5.0.
A much more potent inhibitor was compound PD 640, which inhibited wALAD
activity with an IC50 concentration of 8.1 ± 0.1 µM while there was no effect on
hALAD throughout the concentrations tested (up to 667 µM) (Table 3.3). It was
thus not only a more specific inhibitor of wALAD than wALADin1, but it also dis-
played slightly increased inhibitory potency. This compound was therefore termed
wALADin2 and represents the 2nd generation of specific wALAD inhibitors. Che-
mically, the wALADin2 scaffold is a tricyclic quinoline derivative with a carboxyl
group attached at the 4-position and a [3-(trifluoromethyl)phenyl]carbonyl attached
to the nitrogen atom of the non-aromatic piperdinyl-like third ring (R2 position,
Fig. 3.21). Several wALADin2 derivatives were contained in the 750 compound
set that are listed in Table 3.3, none of which showed inhibitory activity against
wALAD. One requirement for inhibitory potency clearly was the trifluorometh-
lyphenyl group as its replacement by an isobutyl moiety (PD 639) abrogated in-
hibitory activity completely. Changing the [3-(trifluoromethyl)phenyl]carbonyl sub-
stituent to a benzyl moiety (PD 638) equally abrogated activity, as well as smaller
substituents like -CH3 (PD 637) or -H (PD 636). Further, none of the compounds
with sulfonyl-, 2-OH-ethyl or propyloxy-linked aromatic rings at the R2 position
were inhibitory. Taken together, identity and length of the R2 substituent are
crucial determinants of inhibitory potency and produce a steep structure-activity
profile at this site. Another derivative PD 2O features two alterations in the chemi-
cal structure compared to wALADin2: The carboxyl group at R1 was replaced by a
hydrogen atom and carbon atom at position 8 of the quinoline ring was changed to
a nitrogen atom, giving rise to a 1,8-naphthyridine core. This compound was also
found inactive. Although a role for the change in the heteroaromatic ring structure
may not be ruled out, it is likely that the absence of the carboxyl moiety has a
stronger influence on the biological properties of this compound. It is therefore as-
sumed that, analogous to wALADin1, the carboxyl group of wALADin2 is another
requirement for inhibitory activity.
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Figure 3.21: Scaffold of the tricyclic quinoline derivatives in Table 3.3
and chemical structure of wALADin2
Table 3.3: Inhibitory activity of wALADin2 (PD 640) and derivatives
78
CHAPTER 3. RESULTS
wALADin2 was identified based on its molecular similarity to wALADin1. To
see whether it also acts by the same mechanism of action substrate-concentration
curves were measured for wALAD incubated with different concentrations of wAL-
ADin2. In the presence of wALADin2 Vmax was reduced as evident in the decreased
plateaus in the normalized data (Fig. 3.22 a) and decreased y-axis intercepts in
the linear Eadie-Hofstee representation (Fig. 3.22 b). Furthermore, lines in the
Eadie-Hofstee diagram ran nearly parallel, with slightly decreased slope for the
highest concentration of wALADin2 (100 µM). This indicated a non-competitive
mode of action. Although non-linear regression analysis assuming non-competitive
inhibition gave superior fits (global R2 = 0.9215) over competitive or uncompetitive
inhibiton and was equivalent to mixed model inhibition (α=0.6214, which is very
close to 1 indicating mostly non-competitive inhibition; R2 = 0.9215), fit curves
did not represent the experimental data very well. Perfectly fit curves could be ob-
tained only by individual fits for each condition assuming an "Allosteric sigmoidal"
model (R2 between 0.9818 and 0.9971), which however did not allow unambigu-
ous conclusions with respect to the underlying inhibiton. The given data strongly
suggested a non-competitive inhibition, although classical models may underesti-
mate cooperative phenomena that result in non-canonical progression of substrate-
concentration curves. This finding was in stark contrast to wALADin1, where, be-
sides non-competitive inhibition, the type-of-inhibition also had a strong substrate-
competitive character.
Moreover, the effect of wALADin2 on the Mg2+-response curve was determined.
In analogy to wALADin1, wALADin2 induced a rightward shift of the Mg2+-
response curve and thus functionally competes with (allosteric) activation by Mg2+
(Fig. 3.22 c). In contrast, for wALADin2 concentrations ≤ 6.25 µM the maximum
enzymatic velocity could clearly be reached. For higher concentrations lower max-
imum velocities were predicted, however, these predictions may be inadequate as
only the lower parts of the curves were covered by data points and plateau activity
was not achieved. Setting a constraint to the top value ("shared by all data sets")
only led to a marginal deterioration of the R2 value from 0.9915 to 0.9909, while
the same constraint applied to non-linear regression of Mg2+-response curves in the
presence of wALADin1 led to a significant impairment of R2 value from 0.9925 to
0.9452. In addition to being a non-competitive inhibitor, wALADin2 apparently
acts entirely competitive to activation by Mg2+, while wALADin1 is only a partial
competitor. It is intriguing to speculate that the non-substrate competitive compo-
nent of inhibition exerted by wALADin inhibitors is due to functional competition
with Mg2+. While this is apparently the exclusive mechanism for wALADin2, wAL-
ADin1 additionally involves competition with 5-ALA resulting in a mixed model
inhibition and only a partial Mg2+-competitive character. Binding of wALADin2
to wALAD was also demonstrated by TSA, although the induced melt shifts were
significantly smaller than for wALADin1 (Fig. 3.23).
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Figure 3.22: Molecular mode of action of wALADin2
a) Substrate-concentration row in the presence of different concentrations of wALADin2.
Graph shows means ± SD of triplicates and is representative of three experiments. Con-
tinuous lines represent non-linear regression using the "Allosteric sigmoidal" inhibition
algorithm, dashed lines show curves obtained by non-linear regression using the "Non-
competitive inhibition" algorithm. b) Linear Eadie-Hofstee representation of the experi-
ment shown in a. Lines run nearly parallel indicating a non-competitive mechanism of
inhibition. c) Mg2+-response curve of wALAD was shifted to the right upon increasing
concentrations of wALADin2. Graph was fit using "log(agonist) vs. response - variable
slope" NLR algorithm (constraints: shared slope by all data sets, bottom ≥ 0).
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Figure 3.23: Thermal shift assay with wALADin2
a) wALADin2 induced a stabilization of wALAD tertiary structure in a concentration-
dependent manner. The binding event is documented as the rightward shift of the wALAD
melting curve measured by increased fluorescence of the environmentally-sensitive fluores-
cent dye SyproR©Orange. In contrast, wALADin2 did not bind to either b) hALAD or c)
Chicken Egg White Lysozyme.
Given these exciting differences in the inhibitory mechanism of wALADin1 and
wALADin2, the mode of inhibition of derivative 3 was also studied. This com-
pound behaved qualitatively like wALADin1 and had a mixed competitive/non-
competitive mechanism of action and acted as a partial competitor with the acti-
vation induced by Mg2+ (Fig. 3.24).
In conclusion, several wALAD inhibitors with distinct non-benzimidazole chemo-
types were discovered, some of which, however, had a preference for the human
ortholog. With wALADin2, a wALAD inhibitor was discovered that was even
slightly better than wALADin1 in terms of potency and specificity. Intriguingly,
wALADin2 also featured differences in the inhibitory mechanism being an entirely
non-competitive inhibitor (with respect to substrate 5-ALA) that functionally com-
petes with the activation by Mg2+.
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Figure 3.24: Molecular mode of action of wALADin1 derivative 3
a) Substrate-concentration row in the presence of different concentrations of compound
3. Graph shows means ± SD of triplicates and is representative of two experiments.
Continuous lines represent non-linear regression using the "Allosteric sigmoidal" inhibition
algorithm, dashed lines show curves obtained by non-linear regression using the "Mixed
model inhibition" algorithm. b) The linear Eadie-Hofstee representation confirmed a mixed
competitive/non-competitive mechanism of inhibition. c) Mg2+-response curve of wALAD
is shifted towards the right upon increasing concentrations of compound 3. Maximum
enzymatic velocity is reduced in the presence of 3. Graph was fit using the "log(agonist)
vs. response - variable slope" algorithm (constraints: shared slope by all data sets, bottom
≥ 0, R2 = 0.9919).
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3.7 ALAD Cross-species SAR
3.7.1 Inhibitory activity of wALADins on different orthologs
Species-selectivity of ALAD inhibition is an exciting characteristic of wALADin1.
The molecular mechanism of action involving functional competition with activa-
tion by Mg2+ implied that it might, in principle, be applicable to other ALAD
orthologs activated by Mg2+ while Zn2+-dependent proteins might be resistant to
inhibition. Therefore wALADin1, its derivatives and wALADin2 were tested for in-
hibitory activity of a variety of other Mg2+-stimulated ALAD orthologs from plants
(the gardener’s pea Pisum sativum) and bacteria (Pseudomonas aeruginosa, Vibrio
cholerae, Yersinia enterocolitica and Escherichia coli). The latter ortholog is Zn2+-
dependent, but further allosterically activated by Mg2+; all other orthologs are
allosterically activated by Mg2+, but are independent of Zn2+. A multiple sequence
alignment including protein sequences of all used ALAD orthologs is shown in Fig.
3.25 where key structural features are highlighted. A more detailed description of
metal cofactor requirements of these ALAD orthologs is given in the Discussion
(Section 4.4.2, 4.4.3). The recombinant pea protein used was a truncated version
lacking the N-terminal chloroplast transit peptide [148].
All orthologs were tested using respective optimal assay conditions as described
in the Methods chapter (Section 2.2.17). Based on the biological activities of
wALADin1 three different classes of ALAD orthologs were defined: One group
(referred to as group Y) comprised wALAD and the chloroplast PsALAD for which
wALADin inhibitors showed a generally similar inhibitory profile (Table 3.4 a).
wALADin1 was the most potent compound within the wALADin1-derivatives with
similar IC50 values of ∼11 µM and 12 µM followed by 3 with 13 µM and 19 µM for
wALAD and PsALAD, respectively. Notable differences were evident in the potency
of wALADin2, which was ∼10-fold less active against PsALAD (IC50 = 88 µM)
compared to wALAD (IC50 = 8 µM). While 2, featuring an R1-H substituent, did
not inhibit wALAD, it inhibited PsALAD with an IC50 of 114 µM. 15 only inhibited
PsALAD (IC50 = 260 µM) and for 11 a 5-fold increase in inhibtory potency of
PsALAD was observed (IC50 = 63 µM vs. 293 µM). Conversely, 8 inhibited wALAD
(IC50 = 164 µM) but not PsALAD. Other orthologs showed similar inhibitory
potencies within ∼2-fold variations in IC50 values for both species.
The second group (referred to as group X) represents hALAD and putatively
other Mg2+-independent orthologs that depend solely on catalytic Zn2+. As out-
lined above (Table 3.2 b) hALAD was insensitive to inhibition by wALADin1
(IC50 ≥ 500 µM) but was inhibited with moderate potency by other (preferentially
smaller) derivatives. These results are shown in Table 3.4 b again to allow a better
comparison with other orthologs.
The third group (referred to as group Z) comprised orthologs of different metal
cofactor-dependence (pALAD, VcALAD, YeALAD, EcALAD, Table 3.4 c), but all
are allosterically stimulated by Mg2+. Surprisingly, wALADin1 did not inhibit, but
rather stimulated enzymatic activity of these proteins to an extent of 20 - 60%. EC50
values were in between 60 µM and 70 µM for pALAD, YeALAD and EcALAD but
∼182 µM for VcALAD. For pALAD at the highest concentration activity decreased
again. Generally EC50 determinations were relatively inexact with R
2 values be-
tween 0.5 and 0.92 which may be due to the small increases of activity (maximum +
60% stimulation) and the absence of a defined top activity. Similar to wALADin1,
compounds 7 and 9 exerted similar stimulation of enzymatic activity. 7, a consti-
tutional isomer of wALADin1 differing in the position of the carboxyl group that
was inactive on wALAD, was the most potent agonist with EC50 values between
15 and 38 µM. Derivative 6 induced weak stimulation of VcALAD and YeALAD
(EC50 between 200 µM and 300 µM), but not of pALAD and EcALAD. All of these
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Figure 3.25: Multiple sequence alignment of ALAD orthologs
Multiples sequence alignment of H. sapiens (Hs), E. coli (Ec), V. cholerae (Vc), P. aeru-
ginosa (Pa),Y. enterocolitica (Ye), Wolbachia of B. malayi (W) and P. sativum(Ps) ALAD
orthologs was done using Clustal W. For Hs, Pa and W sequences of the recombinantly
expressed proteins are shown including C-terminal tags (italicized, underlined). Other
sequences are displayed according to UniProtKB entries (Ec: P0ACB2; Vc: C3LPU7;
Ye: F4MUJ9 ; Ps: P30124). The recombinant Ps protein did not contain the N-terminal
chloroplast targeting sequence (italicized, gray). X, Y, Z specifies functional assignment
according to modulation by wALADin1. Highlighted structural features: P-side 5-ALA
(blue), A-side 5-ALA binding (green), active side lid (green font), ZnA-site (dark purple),
ZnB-binding sited correlated to A-site (red), alternative aspartate-rich motif of Zn
2+-
independent orthologs (magenta), allosteric MgC-site (yellow) and the alternative arginine
of non Mg2+-stimulated orthologs(cyan).
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Table 3.4: Biological activity of wALADin1 and derivatives on different
ALAD orthologs
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compounds with stimulatory activity featured the 2-[(2-thienylcarbonyl)amino]ethyl
moiety at the R2 position. None of the other derivatives, including 3 and wAL-
ADin2, showed biological activity, except 14 and 15 which very weakly inhibited
VcALAD (IC50 ≥ 800 µM).
These different groups X,Y and Z are highlighted in the multiple sequence align-
ment shown in Fig. 3.25, however, no evident structural features directing the out-
come of wALADin1 modulation were identified. It was concluded that the outcome
of modulation by wALADin1 is variable among different ALAD orthologs and may
be both inhibitory and stimulatory. However, the inhibitory effects on the Wol-
bachia and pea ortholog occurred with a more than 6-fold higher potency compared
to stimulatory effects on several bacterial orthologs.
3.7.2 The inhibitory mechanism of wALADin1 on P. sativum
ALAD
The inhibitory effect that wALADin1 has on PsALAD and the influence of 5-ALA
and Mg2+ concentration was studied in analogy to the experiments described above
for wALAD. A dose-response curve for Mg2+ revealed a monophasic curve with an
EC50 concentration of ∼257 µM (Fig. 3.26 a). wALADin1 induced a marginal
rightward shift of the Mg2+-response curve (∼2-fold drop in the Mg2+ EC50 from
231 to 506 µM from 0 to 100 µMwALADin1) while for wALAD (at now equal 5-ALA
concentration of 10 mM) 100 µMwALADin1 reduced affinity for Mg2+ by nearly 19-
fold (24 µM to 453 µM) (Fig. 3.26 b, c). Although Vmax was also clearly reduced
for wALAD, this effect seemed more pronounced for the pea protein, especially
in relation to the Mg2+-competitive component. A 5-ALA concentration series
revealed a mixed competitive/non-competitive inhibition of PsALAD by wALADin1
with reduced Vmax and increased KM . This is similar to wALAD, although the
Eadie-Hofstee representation for the plant protein was non-linear and could not
be clearly interpreted (Fig. 3.26 d, e). In conclusion, the mechanism by which
wALADin1 exerts its inhibitory function on the pea protein may be described as
qualitatively similar to its effect on theWolbachia enzyme, but differs in the potency
of the Mg2+-antagonizing activity.
3.7.3 Stimulatory vs. inhibitory activity on the P. aerugi-
nosa ALAD
The stimulatory effect of wALADin1 which was evident for several bacterial ALAD
orthologs was addressed in more detail using P. aeruginosa ALAD (pALAD) as a
model. As stimulation was a surprising outcome, buffer conditions were systemati-
cally varied to verify whether such an effect was evident under all conditions tested:
A transverse scan of the effect of 50 - 200 µM wALADin1 was performed against
buffer pH, KCl concentration and 5-ALA concentration. Under the standard pH of
8.0 (as well as at pH 8.5) wALADin1 was found to stimulate pALAD activity (Fig.
3.27) as observed (Table 3.4). This effect was more pronounced at 100 mM KCl
than in the absence of KCl. Conditions were determined under which wALADin1
induced inhibition and not stimulation. Inhibition was most pronounced at pH
7.5 in the absence of KCl and at non-saturating 5-ALA conditions (0.2 mM). At
near-saturating 5-ALA concentration (1 mM) the inhibitory effect was nearly abo-
lished and under saturating conditions (5 mM) wALADin1 caused a stimulation of
enzymatic activity. At lower pH (7.0) an inhibitory effect was clearly evident even
at 1 mM 5-ALA, 100 mM KCl (Fig. 3.27 b). Taken together, it was found that
the outcome of modulation of pALAD activity by wALADin1 varied substantially
with the buffer conditions. High pH (≥ 8.5), KCl and 5-ALA induced the predomi-
86
CHAPTER 3. RESULTS
Figure 3.26: Inhibitory mechanism of wALADin1 on P. sativum ALAD
a) Mg2+-response curve measured at 5-ALA saturation (EC50 ∼257 µM) The gray data
points at high inhibitory concentrations were excluded for non-linear regression. b) wALA-
Din1 induced a weak rightward-shift of the dose-response curve but decreases Vmax. c) At
identical 5-ALA concentration (10 mM) wALADin1 induced a 10-fold more pronounced
rightward shift of the wALAD (!) Mg2+-response curve. e) Substrate concentration series
of PsALAD at different concentrations of wALADin1 assuming an "Allosteric sigmoidal"
fit indicating mixed competitive/non-competitive inhibition (increased Kprime, reduced
Vmax). f) The Eadie-Hofstee diagram had a non-linear progression preventing a clear
interpretation. (For presentation of the Eadie-Hofstee diagram data for the highest and
lowest values per data set were excluded). Graphs are representative of 2 experiments and
show means ± SD of triplicates.
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nant stimulatory phenotype, whereas lower pH (≤ 7.5) and low 5-ALA favoured an
inhibitory outcome.
Both stimulatory and inhibitory effects and the relevance of certain buffer com-
ponents on the outcome of modulation by wALADin1 were characterized in more
detail. Experiments measuring stimulation were performed at pH 8.0, 100 mM KCl,
1 mM MgCl2 and a saturating 5-ALA concentration (5 mM) as standard conditions.
The resulting KCl-response curve progressed more steeply with increasing concen-
trations of wALADin1 (Fig. 3.28 a) and higher percent stimulation values were
obtained at high KCl concentrations (% stimulation at 200 µM wALADin1: No
KCl - 92%; 1.2 mM KCl - 119%; 11 mM KCl - 129%; 100 mM KCl - 140%). The
MgCl2-response curve revealed an elevated plateau of the enzymatic velocity with
increasing wALADin1 concentrations (Fig. 3.28 b). Mg2+-EC50 and Hill slope
values were not consistently changed in a concentration-dependent manner (assu-
ming "log(agonist) vs. response - variable slope" non-linear regression). Finally, a
substrate concentration-curve revealed that modulation by wALADin1 increased
Vmax, but had no consistent effect on KM (Fig. 3.28 c, d).
The inhibitory effect of wALADin1 on pALAD was analyzed at pH 7.5 in the ab-
sence of KCl, at 1 mM MgCl2 and a non-saturationg 5-ALA concentration (200 µM)
as standard conditions. Under these conditions K+ did not stimulate enzymatic ac-
tivity of pALAD, however, it antagonized the inhibitory effect of wALADin1 (Fig.
3.29 a). The Mg2+-response curve was shifted to the right by wALADin1 in a
concentration-dependent manner indicating functional competition with allosteric
activation by Mg2+. It is important to note that allosteric Mg2+ is the only Mg2+-
ion reported for this ortholog. It may therefore be stated that the corresponding
Mg2+-induced allosteric activation of pALAD allows to overcome the inhibitory ef-
fects of wALADin1 at high Mg2+-concentrations (Fig. 3.29 b). The substrate
concentration row was measured at 0.5 mM MgCl2 to increase the inhibitory de-
tection window. However, description of the resulting effects is complex. At all
wALADin1-concentrations tested (50 - 200 µM), a wALADin1-concentration de-
pendent increase in the KPrime (approximation for KM assuming an "Allosteric
sigmoidal" fit) was consistently observed (KPrime values: At 6.7% DMSO - 0.10
mM; 50 µM wALADin1 - 0.19 mM; 100 µM wALADin1 - 0.22 mM; 200 µM wAL-
ADin1 - 0.74 mM) (Fig. 3.29 c, d). Thus, wALADin1 decreased the affinity of
pALAD for 5-ALA. However, Vmax of pALAD is reduced at 50 µM (Vmax = 0.039;
At 6.7% DMSO - Vmax = 0.047), but started to increase again at higher concen-
trations of wALADin1 (100 µM wALADin1 - Vmax = 0.041; 200 µM wALADin1
- Vmax = 0.057). This pattern was reproducibly found and concurred with the
results from the initial buffer scan experiments where at 5 mM 5-ALA wALADin1
stimulated pALAD activity while it inhibited pALAD at 0.2 mM 5-ALA (Fig. 3.27
a, c). This non-linear relationship between wALADin1 and 5-ALA might be ex-
plained by functionally different binding sites for 5-ALA and/or wALADin1 present
in the oligomeric protein as discussed later in this thesis. Summarizing, wALADin1
may act agonistically or antagonistically on pALAD and the outcome of the small
molecule - induced modulation is the result a subtle balance of different environmen-
tal factors like pH, monovalent cations, and substrate concentrations that govern
the overall conformation of the protein.
In order to verify binding of wALADin1 to pALAD under stimulatory conditions,
both in the presence and absence of 100 mM KCl (pH 8.0), thermal shift assays
were performed. Despite its activating effect in the enzymatic assay, KCl had no
influence on the progression of the melting curve and the melting temperature of
pALAD (Fig. 3.30 a, b). ∆Tm-values induced by wALADin1 were equivalent
for both conditions. This finding indicates that the thermodynamics of binding of
wALADin1 to pALAD are similar under both conditions.
Besides P. aruginosa ALAD, a stimulatory effect was also observed for the
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Figure 3.27: Effects of buffer components on the stimulatory effect of
wALADin1 on pALAD
The effect of wALADin1 (0, 50 µM, 100 µM, 200 µM) on pALAD was scanned against pH
(8.5, 8.0, 7.5, 7.0 - 100 mM Tris) and the presence/absence of 100 mM KCl at different
concentration of 5-ALA: a) 5 mM 5-ALA, b) 1 mM 5-ALA and c) 0.2 mM 5-ALA. Light
gray boxes indicate standard stimulatory conditions (pH 8.0, 100 mM KCl), dark gray
boxes indicate conditions (pH 7.5, 0 mM KCl) under which inhibition occurred at low
5-ALA concentrations and stimulation occurred at high 5-ALA conditions. "S" marks
stimulatory, "I" marks inhibitory influence of wALADin1 at the respective conditions.
Graphs show means ± SD of triplicates.
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Figure 3.28: The stimulatory effect of wALADin1 on pALAD
Enzymatic assays conducted under standard conditions for stimulation: 100 mM Tris pH
8.0, 100 mMKCl, 1 mMMgCl2, 5 mM 5-ALA (saturating), if not stated otherwise. a) KCl-
response curve: Steeper progression in the presence of wALADin1. Graph shows means
± SD of two independent experiments. b) MgCl2-response curve fit with "log(agonist) vs.
response - variable slope" NLR algorithm (R2: 0.9154 - 0.9807). Stimulatory activity of
wALADin1 is evident in increased enzymatic velocity. c) 5-ALA concentration curve fit by
"Allosteric sigmoidal" NLR (R2: 0.9206 - 0.9936). wALADin1 reduces Vmax but does not
consistently alter KPrime. d) Linearized Eadie-Hofstee representation of the data shown
in c. b - d are representative of two experiments and show means ± SD of triplicates.
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Figure 3.29: The inhibitory effect of wALADin1 on pALAD
Enzymatic assays were conducted under standard conditions for inhibition: 100 mM Tris
pH 7.5, no KCl, 1 mM MgCl2, 0.2 mM 5-ALA (non-saturating), if not stated otherwise.
a) KCl-response curve fit with "log(agonist) vs. response - variable slope" NLR algorithm
(R2: 0.9628 - 0.9982). The inhibitory effect of wALADin1 was antagonized by K+. b)
MgCl2-response curve fit with "log(agonist) vs. response - variable slope" NLR algorithm
(R2: 0.9628 - 0.9982)": Rightward-shift of the responce curve was induced by incrasing
wALADin1. c) 5-ALA - concentration series fit by "Allosteric sigmoidal" NLR (R2: 0.9676
- 0.9935) and d) linearized Eadie Hofstee representation. wALADin1 reduced the affinity
(KPrime) of pALAD to 5-ALA. At 50 µM wALADin1 Vmax was decreased but it increased
again at higher concentrations (despite increased KPrime). Graphs are representative of
two experiments and show means ± SD of triplicates.
Figure 3.30: Thermal shift assay with pALAD and wALADin1
a) Incubation of 5 µM pALAD with 1% DMSO, 100 µM or 500 µM wALADin1 in the
presence or absence of 100 mM KCl. Buffer conditions were 100 mM Tris (pH 8.0), 10
mM MgCl2, 8X Sypro
R©Orange. b) pALAD melting temperatures TM under the different
conditions. The addition of 100 mM KCl does not alter the melting temperature. ∆Tm
for 100 µM or 500 µM wALADin1 is equivalent for both conditions.
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orthologs from V. cholerae, Y. enterocolitica and E. coli. In order to determine
whether a similar stimulatory/inhibitory dichotomy was also present for these or-
thologs, a buffer scan experiment was performed testing the stimulatory properties
of different concentrations of wALADin1 (0, 50, 100, 200 µM) against different pH
values of the Bis-tris propane buffer (7.0, 7.5, 8.0, 8.5) and KCl (0 vs. 100 mM)
at non-saturating 5-ALA (200 µM) (Fig. 3.31). Thus, the conditions for which
inhibition was most pronounced for pALAD were covered. In contrast to the P.
aeruginosa enzyme, throughout all conditions wALADin1 acted in a stimulatory
fashion on these orthologs. Although it may not be ruled out that wALADin1 (or
some of its derivatives) may inhibit these proteins under conditions not-tested, ap-
parently the stimulatory effect of wALADin1 on these orthologs is more robust and
predominant than for pALAD.
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Figure 3.31: Buffer scan experiment of different ALAD orthologs against
wALADin1
Effects of wALADin1 (0, 50 µM, 100 µM, 200 µM) scanned against pH (8.5, 8.0, 7.5,
7.0 - 100 mM BTP) and the presence/absence of 100 mM KCl at non-saturating 5-ALA
concentrations (200 µM) for the following ALAD orthologs: a) V. cholerae ALAD; b) Y.
enterocolitica ALAD; c) E. coli ALAD.
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3.8 Antiprotozoal effects of wALADin1
On the background of the potent inhibitory activity of wALADin1 on both Wol-
bachia and pea chloroplast ALAD and its stimulatory/inhibitory dichotomy on
pALAD and other bacterial ALAD enzymes, wALADins may have a broad ef-
fector spectrum on a variety of human pathogens. Plasmodium falciparum and
Toxoplasma gondii are two apicomplexan parasites with apicoplast-targeted ALAD
stimulated by Mg2+. While the T. gondii ortholog shows minor Mg2+-independent
activity [227] the P. falciparum enzyme is essentially active without Mg2+, but
Mg2+ may stimulate an additional ∼20 - 30% of PfALAD activity [66]. In the ab-
sence of recombinantly expressed P. falciparum and T. gondii ALAD proteins for
enzymatic inhibition studies, wALADin1 was tested in P. falciparum and T. gondii
cell culture for any antiprotozoal effects.
3.8.1 wALADins in P. falciparum culture
The effect of wALADin1 and its derivatives was tested on P. falciparum 3D7 culture
cultivated in RBC for 4 days. Parasitemia was determined on a daily basis with
3 days as the standard readout time. wALADin derivatives were initially tested
at 62.5 µM. An antiplasmodial effect was visible for wALADin1, 6 and 9. All
other derivatives including the potent wALAD inhibitor 3 and wALADin2 did not
inhibit replication of the malarial parasite in vitro (Fig. 3.32 a). The mentioned
compounds were able to clear parasitemia completely, with 6 as the most potent
antiplasmodial compound (IC50 7.7 ± 1.7 µM), followed by 9 (IC50 12.8 ± 0.02
µM) and wALADin1, which had ∼5-fold reduced activity (IC50 39.3 ± 11.7 µM)
compared to 6 (Fig. 3.32 b, c). While the dose-response curves for 9 had a
comparatively shallow progression (Hill slope values: -1.3 to -1.5), the progression
for wALADin1 (Hill slope values: -1.8 to -9.6) and 6 (Hill slope values: -3.1 to
-6.7) was steeper with considerable interexperimental variation. Time-curves of
parasitemia further revealed that this effect was consistent throughout the course
of the experiment (Fig. 3.32 d - f).
Although it remains to be determined whether the antiplasmodial effect is due
to the inhibition of endogenous heme biosynthesis in the apicoplast, the potent in-
hibitory activity with an IC50 as low as ∼ 8 µM for 6 demands further investigations
on the antiplasomdial effect of wALADin benzimidazoles and their potential use as
antimalarial drug candidates.
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Figure 3.32: Activity of wALADin1, 6 and 9 in P. falciparum culture
a) Percent P. falciparum 3D7 parasitemia in RBC culture after 3 days of exposure to dif-
ferent wALADin derivatives assayed at 62.5 µM compound. Dashed vertical lines seperate
different experiments. b) Mean IC50 values determined for wALADin1, 6 and 9 on the
basis of 2 - 4 independent experiments (3 days of culture). c) Dose-response curves for
wALADin1, 6 and 9 after 3 days of culture. Curves were fit using the the "log(inhibitor)
vs. normalized response - Variable slope" non-linear regression algorithm of Prism 5.0
(bottom = 0; top = Shared by all data sets). d) - f) Time curve of the development of
parasitemia for treatment with d) wALADin1 , e) 6 and f) 9, respectively. Graphs c -
f are representative of ≥ two experiments and show means ± SD of four replicates. d =
days.
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3.8.2 wALADins in T. gondii culture
In order to measure drug effects on the replication of T. gondii parasites a cell
culture assay was established that uses infection of LLC-MK2 cells with T. gondii
tachyzoites. After a cultivation period of ∼2 days cells were lysed and parasite
and host cell numbers were quantified by Realtime PCR. While the standard anti-
toxoplasma drug pyrimethamine showed potent inhibition of replication (IC50 ∼1
µM) wALADin1 and 6 were not active until the 3-digit µM range (IC50 = 340 µM
and 825 µM, respectively; Fig. 3.33). These values were more than one order of
magnitude higher than those observed in the P. falciparum culture assay. In this
range also slight non-specific effects on the proliferation of LLC-MK2 cells became
visible (compare Fig. 3.9 and Fig. 3.17) and due to their rapid proliferationT.
gondii tachyzoites may be slightly more susceptible to these non-specific effects than
LLC-MK2 cells are. Thus, inactivity of wALADin1 and 6 in the T. gondii culture
revealed that the antiprotozoal effect of thes compounds was Plasmodium-specific.
Figure 3.33: wALADin1 in T. gondii culture
Replication of T. gondii in LLC-MK2 exposed to different concentrations of
pyrimethamine, wALADin1 and 6 for ∼44 h was measured as the levels of T. gondii
DNA normalized to LLC-MK2 β-actin. While pyrimethamine and wALADin1 curves
show means ± SEM pooled from 2-3 experiments, for compound 6 data from a single ex-
periment is shown. Curves were fit using the the "log(inhibitor) vs. normalized response -
Variable slope)" non-linear regression algorithm of GraphPad Prism 5.0. IC50 values were
1 ± 0.2 M µM for pyrimethamine, 340 ± 50 µM for wALADin1 and 825 ± 206 µM for 6.
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3.9 PPDK HT-Screening
3.9.1 Establishment of PPDK enzymatic screening assay
In order to establish a HTS-compatible enzymatic assay for PPDK (of Wolbachia
of B. malayi), a DNPH-based assay system [181] was used to detect the reaction
product pyruvate (Fig. 3.34). Fig. 3.35 a shows that the Pyruvate Detection
Reagent (PDR) allows the specific detection of pyruvate at concentrations ≥ 10 µM.
The PPDK-DNPH assay was downscaled to microplate format and assay conditions
were adjusted to allow a robust, yet sensitive assay suitable for HTS for inhibitors
in a semi-automated fashion involving a robotic work station. With this aim, the
concentrations of cosubstrates were adjusted: Single substrate concentration curves
were measured for each substrate (AMP, PEP, PPi, Fig. 3.35 b - d) with the
other two substrate concentrations kept constant. Screening assay concentrations
were chosen such that the concentration of each substrate was at the upper end
of the linear phase of the substrate concentration curve before reaching saturation.
This allowed for sufficient sensitivity avoiding a bias for the detection of inhibitors
with a certain mode of action. Final assay concentrations were 200 µMPEP, 200 µM
AMP and 500 µM PPi. A time curve experiment under assay conditions revealed
that at 50 min of reaction at RT the reaction was in the linear steady state phase as
required for a sensitive screening assay. The assay quality parameter Z’-factor [274]
was determined by measurement of eight replicates each of positive and negative
control values (Fig. 3.35 e). For the given assay Z’ was 0.58 which indicated good
and robust assay performance and allowed employment of this assay in HTS.
Figure 3.34: Reaction scheme of the detection of pyruvate with DNPH
2,4-dinitrophenylhydrazine (DNPH) reacts with pyruvate to a hydrazone which elicits
increased absorption at 395 nm [180, 181] in an addition-elimination mechanism: Reaction
starts with a nucleophilic attack of the primary amino group of the hydrazine to the
carbonyl carbon atom of pyruvate followed by elimination of water.
3.9.2 PPDK screening
A library of ∼18,000 drug-like small molecules was screened for inhibitors of the
PPDK-DNPH Assay. An overview of the workflow of the screening assay, assay
conditions, hit validation and the results is given in Fig. 3.36. The hit threshold
was initially set at the mean of the DMSO control - 3 SD which was equivalent 60% of
inhibition. Although the mean Z’-factor throughout the screening was satisfactory
(0.5 ± 0.20), for some screening plates, the bulk of compounds showed some 10 -
30% background interference with the assay (compare Fig. 3.37 a, b) leading to
a high number of primary hits (383 hits, hit rate: 2.1%). When the hit-threshold
was set more restrictively to 80% inhibition, the number of hits was reduced to
35 (hit rate: 0.2%), a more feasible number for further validation. The top 20 of
these hit structures plus two manually selected compounds from lower scoring hit
clusters were rescreened in triplicate measurements under HTS-conditions. 9 out of
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Figure 3.35: Establishment of PPDK-DNPH HT-Screening assay
a) Specific detection of pyruvate ≥ 10 µM by PDR. b) Substrate concentration curve for
PEP, c) AMP and d) PPi while the concentration of other substrates was kept constant as
indicated. PPDK concentration was 100 nM. Final HTS assay conditions are indicated as
dotted lines. e) Time curve of the PPDK-catalysed reaction. The standard reaction time
chosen was 50 min, at which the reaction was still in its linear phase. f) Test Z’-factors
under these conditions with eight replicates was 0.58 indicating robust assay quality.
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22 compounds were confirmed to be inhibitory to PPDK by more than 50% at 37.5
µM (Fig. 3.37 c, Table 3.5). None of these compounds interfered non-specifically
with the direct detection of pyruvate. An overview of all confirmed screening hit
structures is shown in Appendix A.
Table 3.5: Confirmed PPDK Screening hits
Compound % Inhibition
Primary
Screen
% Inhibition
Rescreen
% Inhibition
Pyruvate
Detection
IC50
PPDK
[µM]
IC50
Pyruvate
Kinase
[µM]
CG6 32F2 100 97.2 none 2.3 1.4
CG5 27H5 100 91.1 none 5.2 1.8
CG4 19G2 98.8 90.9 none 21 27
CG2 4E2 81.8 87.7 none 35 6.9
CG3 16H9 82.5 82.7 none 20 none
CG1 3E10 88.2 79.3 none 11 39
CG2 3E5 83.4 72.5 none 30 36
CG1 1H10 74.9 57.1 none n.d. n.d.
CG2 2B3 85.2 54.1 none n.d. n.d.
CG2 2A8 84.2 44.8 none n.d. n.d.
CG4 1G3 100 36.1 none n.d. n.d.
CG4 23G5 84.2 45.9 none n.d. n.d.
CG4 16F9 89.2 36.1 none n.d. n.d.
CG5 9B8 92.8 34.8 none n.d. n.d.
n.d: not determined
3.9.3 Hit validation
Confirmed hits were successively validated for specificity of inhibition. The top
hits CG5 27H5 and CG6 32F2 shared a chemical scaffold and both inhibited PPDK
activity by > 90% at 37.5 µM with IC50-values of 5.2 and 2.3 µM, respectively (Fig.
3.38 a). When tested against rabbit Pyruvate Kinase (PK) in an analogous DNPH-
based assay system, these compounds were shown to also be a potent inhibitors of
PK with IC50-values of 1.8 and 1.2 µM. Six of the residual 7 confirmed hits showed
a similar non-specific inhibition pattern on both PPDK and PK (Table 3.5). As
these compounds hold no promise in the development of specific inhibitors of PPDK
that would specifically target Wolbachia, they were disregarded in the following va-
lidation procedure. One remaining hit structure, CG3 16H9, was a specific inhibitor
of PPDK (IC50 = 20 µM) and was therfore termed PPDK inhibitor 1 (PPDKin1)
(Fig. 3.38 b). The chemical structure of PPDKin1 is shown in Fig. 3.38 c.
The inhibitory activity of PPDKin1 was further tested in a secondary PPDK assay
setup, which was the standard PPDK assay coupled to LDH-activity monitoring
the turnover of NADH/H+ to NAD+ as a decrease in OD340nm in realtime (Fig.
3.38 d, e). Inhibitory activity of PPDKin1 was evident by decreased NADH/H+
turnover rates (slopes) and resulting decreased percent activity values.
Solubility of PPDKin1
As extinction and solubility of PPDKin1 was low and no differential absorption
spectrum compared to control samples containing 3.75% DMSO could be obtained,
solubility was determined by visually rating the presence of a pellet of precipitated
compound. Solutions were prepared in PPDK-PBS buffer or H2O by adding equal
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Figure 3.36: Workflow of PPDK HT-Screening and hit validation
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Figure 3.37: Results of PPDK screening and rescreen
a), b) Primary data from two exemplary screening plates. PPDK was very sensitive for
background interference for certain classes of chemicals as those in a. Arrows point to two
confirmed screening hits (CG1 3E10 in a and CG6 32F2 in b). c) Performance of the top
20 screening hits in the rescreen and pyruvate detection control assay.
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Figure 3.38: PPDK Screning hits
a) The chemically related potent PPDK inhibitors CG5 27H5 and CG6 32F2 are also
potent inhibitors of rabbit pyruvate kinase. b) CG3 16H9 specifically inhibits PPDK
of Wolbachia while it does not affect activity of pyruvate kinase and is therefore called
PPDKin1. Solubility limit of PPDKin1 in PPDK-PBS Buffer was between 50 and 100
µM. Graphs are representative of two experiments. c Chemical structure of PPDKin1.
d) PPDKin1 also inhibits activity of PPDK in the PPDK-LDH assay (mean normalized
OD340nm data indicative of NADH/H
+ turnover of a duplicate experiment and is repre-
sentative of two experiments). e) Percent activity values were calculated as the slopes of
PPDKin1-treated samples in the PPDK-LDH assay reaction normalized on the slopes of
3.75% DMSO-treated controls set to 100% activity. Slopes were calculated by linear re-
gression of normalized OD data between 2 and 18 min and lines were forced to go through
(X=0/Y=0). The graph depicts mean pooled percent activity data from two experiments
performed in duplicates.
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amounts of substance in a concentration series, where a two-fold increase in con-
centration involved a two-fold decrease of the volume. In PPDK-PBS buffer pellets
of precipitated inhibitor were evident at concentrations ≥ 100 µM, in H2O ≥ 50
µM. This indicates that the limit of solubility of PPDKin is between 25 µM and 50
µM in H2O and between 50 µM and 100 µM in PPDK-PBS buffer. The limit of
solubility is displayed for PPDKin1-concentration curves in Fig. 3.38 b.
3.9.4 Determination of the type-of-inhibition
The mechanism underlying the inhibition of PPDK by PPDKin1 was analyzed
by a set of substrate concentration series in the presence of different concentra-
tions of inhibitor under saturating cosubstrate concentrations. For PEP and AMP,
the inhibitory potential increases with substrate concentration (Fig. 3.39 a - d)
and requires a threshold of ∼100 µM to be exceeded. This is in accordance with
an uncompetitive mode-of-inhibition in which the inhibitor binds to the enzyme-
substrate-complex. This conclusion is supported by non-linear regression analysis,
where the assumption of an uncompetitive inhibition model algorithm gives superior
fits [R2(AMP) = 0.9419; R2(PEP) = 0.9736] than non-competitive or competitive
models and is equivalent to a "Mixed Model Inhibition" NLR where α was close to
0 (characteristic of uncompetitive inhibition). Due to the dimeric nature of PPDK,
simple hyperbolic curve fits did not sufficiently represent the progression of the data
and hence the "Allosteric sigmoidal" algorithm (Prism 5.0) accounting for possible
cooperative effects was applied. In contrast to PEP and AMP, inhibitory potency
was not influenced by the PPi concentration, indicating noncompetitive inhibition
[R2(PEP) = 0.9890] with respect to this cosubstrate (Fig. 3.39 e, f). At 500 µM
PEP/AMP and assuming noncompetitive inhibtion with respect to PPi the disso-
ciation constant KI was predicted by NLR to be 52.6 ± 4.6 µM. Taken together,
PPDKin1 is a novel specific inhibitor of PPDK which acts by a an AMP/PEP-
uncompetitive mechanism.
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Figure 3.39: Inhibition studies with PPDKin1
Inhibitory properties of PPDKin1 in the presence of different concentrations of co-substrate
was tested. The left panel (a, c, e) shows normalized OD395nm values. Curves were fit
using the "Allosteric sigmoidal" NLR algorithm of GraphPad Prism 5.0. The right panel
(b, d, f) shows the corresponding data in the linearized Hanes-Woolf representation.
Data points for ≥ 0.5 PPi and ≥ 1 mM PEP were excluded from linear regression in
the Hanes-Woolf plot due to beginning substrate inhibition. a), b) PPDKin1 acts in
an uncompetitive fashion with respect to PEP and c), d) AMP (PPDKin1 reduces both
Vmax and KM ; the y-axis intercept KM/Vmax remains nearly constant) and e), f) is a
non-competitive inhibitor with respect to PPi (reduction in Vmax, nearly constant KM ).
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Discussion
4.1 The rationale for HTS-based drug discovery
of novel antifilarial compounds acting on Wol-
bachia targets
The rational design of antifilarial drugs acting on nematode targets is hindered due
to the generally high sequence homology between worm and mammalian proteins
leaving only a very limited number of suitable drug targets e.g. in nematode-specific
processes such as molting [96] or synthesis of the disaccharide trehalose [154, 155].
In contrast, thanks to their different physiology and sequence divergence, prokary-
otic Wolbachia endosymbionts provide ideal targets for the development of potent
and specific antifilarial drugs. The annotation of the B. malayi and Wolbachia
endosymbiont of B. malayi (wBm) genomes [81, 93, 124] had a major impact on
antifilarial and anti-Wolbachia drug discovery and enabled the identification of pu-
tative drug targets within essential biochemical pathways of the bacteria that may
be exploited for target-based drug discovery [208, 232]. As the biological effects
induced by Wolbachia-targeting drugs may be manifold, the following classification
scheme shall be introduced that classifies endobacterial drug targets into two dif-
ferent categories: 1) Target proteins required for bacterial homeostasis, including
the targets of classical antibiotics like protein translation (doxycycline) [118, 47],
transcription [224] or cell-wall biosynthesis [109]. Inhibition of these processes will
lead to a depletion of endobacteria from the filarial hosts with secondary effects
on the filarial host as described (a block of embryogenesis and death). 2) Drugs
directly targeting the putative pathways of symbiosis, i.e. biosynthetic pathways of
metabolites that Wolbachia is considered to provide to its host. Such drugs, which
have not been reported for Wolbachia so far, are likely to affect the worm directly,
with the neat circumstance that the molecular target is prokaryotic.
The current study aimed at the target-based discovery of novel inhibitors of two
putative enzymatic drug targets of Wolbachia: 1) Pyruvate phosphate dikinase, an
enzyme without mammalian ortholog that fulfils an essential biochemical function
in the energy metabolism and thus homeostasis of Wolbachia 2) δ-Aminolevulinic
acid dehydratase, catalyzing the second step of biosynthesis of heme in Wolbachia
that likely sustains filarial demands for porphyrins. For both target proteins enzy-
matic assays were established and subjected to High-Throughput Screening against
a diversity-based compound library comprising ∼18,000 drug-like small molecules.
Although both assys met stability criteria required for HTS [274], performance of
the wALAD screening assay was superior to that of PPDK producing lower pri-
mary hit rates and a higher number of validated hits. While for PPDK only one
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specific inhibitor was identified, screening for wALAD inhibitors revealed a cluster
of potent species-selective inhibitors along with several other hit structures with less
pronounced or absent discriminatory power between certain ALAD orthologs. Com-
pared to industrial-scale screening libraries comprising > 50,000 compounds in des-
ignated academic HTS-facilities [38] or up to 2 million compounds in pharmaceutical
companies [87], the size ot the screened library in this study was modest. However,
both assay systems established may be set up and running to screen further com-
pound libraries. While the identification of a magic bullet within this restricted set
of compounds would have been serendipitous, the provided hit structures, especially
wALADin1 benzimidazoles, fulfil the aims of the screening campaign. They repre-
sent previously undescribed chemical entities with biological activity as inhibitors of
putative enzymatic targets in antifilarial drug discovery. In the following, structural
and mechanistic aspects of the biological effects of the hit compounds originating
from both screening campaigns and their suitability as lead structures in antifilarial
drug discovery and beyond will be discussed.
4.2 Targeting Pyruvate Phosphate Dikinase of Wol-
bachia: Interfering with endobacterial energy
metabolism
4.2.1 The biochemistry of PPDK
PPDK is a ∼96 kDa homodimeric protein that contains three independently-folded
domains [111, 54, 189, 163]. The crystal structures of Clostridium symbiosum,
Trypanosoma brucei and maize PPDK revealed a C-terminal TIM-barrel domain
involved in PEP/pyruvate-binding and an N-terminal ATP-grasp domain that con-
tains the AMP/ATP-binding site. Both remote domains contain distinct active
sites and are interconnected by a swivelling phosphohistidine carrier domain where
His-455 (of Clostridium symbiosum PPDK) mediates the phosphoryl transfer.
The reaction catalyzed by PPDK is the reversible conversion of PEP, AMP and
PPi to pyruvate, ATP and Pi (see page 19 for overall Equation 1.1). It can be
divided into the following three partial reactions [268, 257]:
PPDK −His +
β
PEP⇐⇒ PPDK −His−
β
P + pyruvate (4.1)
PPDK −His−
β
P +
γ δ
PPi⇐⇒ PPDK −His−
β
P
γ
P +
δ
Pi (4.2)
PPDK −His−
β
P
γ
P +AMP ⇐⇒ PPDK −His +
βγ
ATP (4.3)
The increased energy balance of PPDK-dependent compared to PK-dependent
glycolysis due to substrate-level phosphorylation is of major advantage for anaero-
bic organisms that do not produce energy by oxidative phosphorylation but depend
on glyolysis and fermentation [231]. Consequently PPDK is present in a variety of
anaerobic protists of clinical relevance: For Giardia intestinalis a role for PPDK in
glucose metabolism has been demonstrated by knock-down of PPDK mRNA and
PPDK of G. lamblia and E. histolytica are considered promising drug targets. Inte-
restingly these parasites also have an ortholog of PK [75]. Other anaerobic protists
like Trichomonas vaginalis do not have PPDK but a pyrophosphate dependent ver-
sion of phosphofructokinase [178]. Furthermore PPDK orthologs have been found
in trypanosomatids, a variety of plants [104, 184] and eubacterial phylae including
proteobacteria (Wolbachia, Rickettsia), Firmicutes (Streptococcus, Staphylococcus,
106
CHAPTER 4. DISCUSSION
Clostridium), Spirochaetes (Treponema) and others [231]. In Trypanosoma cruzi
PPDK is present in specialized metabolic compartments termed glycosomes, where
in the absence of pyrophosphatase the role of PPDK is suggested to consume PPi
in a highly exergonic reaction and thus thermodynamically drive other energetically
less favourable reactions that depend on PPi production and turnover [5]. In this
case the PPDK reaction is regarded as irreversible due to the high ∆G of ∼-5.2
kcal/mol.
PPDK orthologs from different species have been attributed opposing roles.
For PPDK from Entamoeba histolytica the enzyme has been suggested to function
mainly to provide pyruvate [213, 257], for Propionibacterium shermanii [74] and
plants [104] a gluconeogenetic role in the synthesis of pyruvate has been proposed.
Whether in Wolbachia PPDK has its major physiological role in glycolysis or gluco-
neogenesis remains to be verified. For Wolbachia, and Rickettsiales in general, nei-
ther pyruvate kinase nor pyruvate carboxylase/PEP carboxykinase orthologs have
been found [212]. Inorganic pyrophosphatase has been annotated in the Wolbachia
of B. malayi genome (Uniprot ID: Q5GS53), although its expression levels, loca-
lization and functional importance will have to be verified. In the absence of alter-
native metabolic and biosynthetic routes, these findings suggest a possible dual role
of PPDK in these organisms: 1) Catabolism of glucose, respectively downstream-
metabolites acquired through the filarial host, in the energy metabolism. 2) Ana-
bolism of C4-carbohydrates and glucose from non-carbohydrates. As PPDK is not
present in mammalian cells it is a prime target for antiinfective drug discovery for
those species depending on its activity, including Wolbachia of Brugia malayi [212].
4.2.2 Previously described inhibitors of PPDK and screening
assays
The first known inhibitor of PPDK was phosphonopyruvate, a substrate analog of
PEP [112] which may also bind to other PEP-binding enzymes and the physico-
chemical properties are not drug-like (two negative charges, 6 oxygen atoms). Re-
cently, a new class of flavone-based inhibitors has been identified combining in vitro
enzymatic assay screening and virtual screening against the ATP-grasp domain of
Clostridium symbiosum PPDK. These flavone structures represent the most promi-
sing class of PPDK inhibitors with KI values between 1.6 and 25 µM and act as
competitive inhibitors of AMP at the active site. Two other studies have also en-
gaged computer-based drug-design approaches by in silico screening for ligands of
the active site of the N-terminal nucleotide-binding domain of Entamoeba histolytica
[236] and more recently of the Wolbachia of B. malayi ortholog [197]. Both dock-
ings were done using homology models of the respective protein sequences against
the crystal structure of C. symbiosum PPDK. However, for either of the proposed
sets of top-scoring ligands experimental evidence for binding let alone inhibition is
still lacking. Another biochemical screening approach has been taken to identify in-
hibitors of C4 plant PPDK from organic extracts of marine macroscopic organisms
[67] and marine fungal extract libraries [188]. The screening was done on the basis of
a phosphoenolpyruvate-carboxylase and nicotinamide adenine dinucleotide–malate
dehydrogenase coupled activity assay [67]. Screenings included 6679 and 2245 ex-
tracts and primary hit-rates of 4.9% and 13.2%, respectively, were obtained. The
hits then required further validation as to which of the screening enzymes was the
actual target. The simple one-step and screening-assay presented in the current
work using detection of pyruvate by a DNPH-reagent is an easy-to-analyze alter-
native superior to coupled assays when only inhibitors of PPDK are of interest.
By reducing the concentration of screening compounds and increasing Mg2+ and
the substrate concentrations, assay robustness may be easily increased for future
screening of compound libraries, although sensitivity against competitive inhbitors
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may thus be reduced. Motti et al. presented unguinol as a specific-inhibitor of the
C4 plant PPDK with an IC50 value of 42 ± 0.8 µM that was noncompetitive with
respect to PEP and AMP, but uncompetitive to PPi [188]. However, unguinol was
also shown to inhibit growth of three tested cancer cell lines with GI50 values of 28
- 51 µM and of Gram-positive S. aureus and V. harveyi (GI50: 8.7 and 69.5 µM,
respectively), but not of Gram-negative E. coli bacteria. Although unguinol may be
considered as a lead structure for the development of novel herbicides as the authors
suggest, it is not suited as an antibiotic lead-structure due to expected non-specific
cytotoxic effects on human cells which do not possess PPDK. In conclusion, no ge-
nerally applicable PPDK inhibitor had been described so far. The novel inhbitor of
Wolbachia PPDK, PPDKin1, may be the cornerstone for the development of more
potent and specific inhibitors of PPDK that may find their way to pharmaceutical
applications.
4.2.3 PPDKin1, a novel inhibitor of Wolbachia PPDK
High-Throughput Screening for inhibitors of the Wolbachia PPDK enzymatic reac-
tion initially provided a large number of primary hits (2.1%). Given the observed
instability [212] and thermal denaturation of the protein at low temperatures (∆Tm
∼43 ◦C), PPDK might be especially sensitive to non-specific effects caused by high
concentrations of certain classes of molecules. For future screening approaches using
other libraries of small molecules it is recommended to screen at lower compound
concentrations, e.g. 10 µM, which is a standard concentration for small molecule
screens [130, 191]. However, due to the previous success of the wALAD screen (at 67
µM compound), these effects of 37.5 µM compound were unforeseen. Notwithstan-
ding, when the top 22 hit compounds were analyzed, 9 compounds were confirmed
with more than 50% of inhibition while 5 others showed 30% - 50% of inhibition,
which underlines the general validity of the primary screening results. 8 out of
9 confirmed hits, including the chemically related molecules CG5 27H5 and CG6
32F2 which inhibit PPDK potently with IC50-values in the one-digit µM range,
were also active against mammalian pyruvate kinase. In light of the absence of
sequence homology between PPDK and PK this finding is very surprising. A pos-
sible explanation is that these compounds are promiscuous inhibitors that target
general protein motifs or they specifically target single residues or 3D-structural ar-
rangements shared by both proteins, e.g. for PEP-binding, which cannot be easily
recognized by primary structure analysis.
The remaining inhibitor CG3 16H9 was found to specifically inhibit PPDK with
a KI -value of ∼53 µM and was termed PPDKin1. It acts by a mechanism that is
uncompetitive with respect to the substrates PEP and AMP and non-competitive
with respect to PPi. This mechanism is unprecedented and illustrates the specificity
of the compound. However, in PPDK-PBS buffer, solubility of the compound is
between 50 and 100 µM. Therefore PPDK activity may not be completely inhibited
under the conditions tested, but a maximum inhibition of ∼75% was reached. The
inhibitory potency of wALADin1 is comparative to that of unguinol [188], but lower
than the potency of the flavone inhibitors [271]. However, the unique PEP/AMP-
uncompetitive mechanism of PPDKin1 may be superior in terms of specificity, as
it does not target a conserved site such as the active site of a nucleotide-binding
domain which is the target site of the flavone inhibitors [271]. The low solubility
of PPDKin1 will be a major impediment for the use of this compound in in vivo
studies. But as the physiological environment of PPDK function in Wolbachia
and substrate concentrations are unknown, PPDK may be more active and more
susceptible to uncompetitive inhibition by PPDKin1 in vivo.
The uncompetitive nature of PPDKin1 with respect to PEP and AMP indi-
cates, that it binds to the enzyme-substrate complexes with bound PEP and/or
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AMP. The central His-domain is connected to the N- and C-terminal domain, re-
spectively, with linker arms LC and LH, that do not actively direct catalysis, but
are able to restrict the conformational space of the His-domain and thus indirectly
guide the swivelling motion [263]. However, independently expressed central and
N-terminal domains that are unlinked are unable to form a complex able to cata-
lyze the nucleotide-partial reaction [164]. So how can PPDK1 sense the presence
of PEP and AMP which have remote and seemingly independent binding sites?
Either there are, although unexpected [263], indeed conformational changes medi-
ated across the different domains upon binding of the two substrates that would
expose a previously hidden binding site for PPDKin1, e.g. in the linker regions or
in the central His-domain. The differential crystal structures of maize PPDK with
and without PEP showed that upon substrate binding an interaction between the
C-terminal domain and the linker domain was freed, allowing a swiveling motion
to occur [189]. Thus, at least neighboring linker regions may be conformationally
influenced by the catalytic sites, although far-ranging cross-domain interactions re-
main to be demonstrated. Alternatively, the enzyme substrate PPDK-PEP complex
(which is required to form first) may be contemplated after completion of the first
partial reaction (Equation 4.1). Although formed pyruvate may be released, the
β-phosphate of PEP is bound to the His-residue of the central domain and under-
goes the swivelling motion from the PEP-domain towards the nucleotide-domain.
When AMP is then bound to the nucleotide-domain the formed binary complex of
phosphorylated PPDK and AMP [257] may present the binding-site of PPDKin1,
e.g. in the interface of His-domain and nucleotide-domain. However, given the non-
competitive inhibition with respect to PPi, it should be extraneous to PPDKin1-
binding, whether or not PPi is bound to the nucleotide-binding domain. Future
elucidation of the binding site of PPDKin1 will help unravel the precise molecular
mode of action which is currently subject to mere speculation. As different kinetic
mechanisms have been described for PPDK orthologs from different species [257],
it will be fascinating to study the inhibitory properties of PPDKin1 on the different
organisms. Knowledge of the molecular interactions involved in inhibition will allow
the rational design of inhibitors with higher potency, improved solublity and general
drug-like physico-chemical properties. Understanding the PPDKin1-mediated inhi-
bition may further give important insight into the coordination of the swivelling
reaction and catalysis, which is still an open question in PPDK biochemistry.
4.2.4 Summary PPDK
An HTS-compatible enzymatic assay for PPDK based on the colorimetric detection
of pyruvate by DNPH was established. Small molecule library screening identified
PPDKin1 as a specific inhibitor of PPDK ofWolbachia. This inhibitor has a unique
molecular mode of action involving uncompetitive inhibition with respect to PEP
and AMP and non-competitive inhibition with respect to PPi and may be used to
probe the biochemistry of PPDK enzymes. In the absence of broadly applicable,
potent and specific inhibitors of PPDK, the identificaton of PPDKin1 is a major
innovation which allows future synthesis of derivatives with improved potency and
solubility. Given the broad range of target organisms depending on PPDK function
PPDKin1-derived inhibitors may have a future as herbicidal, antiprotozoal and
antibacterial compounds including their potential use as antifilarials by targeting
Wolbachia endosymbionts.
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4.3 Interfering with the heme biosynthesis of Wol-
bachia endobacteria
While tetrapyrrole biosynthesis belongs to biochemical pathways best conserved
throughout all domains of life, the only eukaryotes reported to lack (i.e. have lost
during evolution) the ability to synthesize heme de novo are either unicellular para-
sites like Leishmania spp. that likely salvage heme or precursors from their hosts
[199] or nematodes [211, 93]. The free-living nematode C. elegans is considered to
use heme-transporters to take up heme from its natural environment [211, 209], a
strategy that may also be pursued by parasitic filarial nematodes like Loa loa and
A. viteae. A different strategy to cover their heme demand was apparently adopted
by parasitic filarial nematodes such as Brugia malayi (and all other causative agents
of LF and Oncho) that harbor Wolbachia endosymbionts. The B. malayi genome
only has a gene encoding ferrochelatase catalyzing the last enzymatic step of heme
biosynthesis. In contrast, the endobacteria, which are considered to have lost all
non-essential genes during co-evolution with their hosts, have conserved all genes
for the entire heme biosynthetic pathway within their otherwise restricted 1.1 Mb
genome [81]. The only gene not identified in the Wolbachia genome was an ortholog
of the hemY or hemG gene. It has been observed that the oxidative function of
protoporphyrinogen IX oxidase is replaced by other enzymes. Coproporphyrinogen
III oxidase was demonstrated to exert this function in hemG independent E. coli
mutants [190], but complementation assays in E. coli using the homologous Wol-
bachia gene did not restore catalytic activity. However, this work presents evidence
that protoporphyrin IX oxidase function in Wolbachia is possibly exerted by a ho-
molog of the translation product of the slr1790 gene of Synechocystis spp. [146].
Genes with significant homology were identified by tblastn searches in the genome
of Wolbachia of filarial nematodes.
As a consequence, it is expected that the endobacteria supply their filarial hosts
with tetrapyrroles [93, 270, 232] although it may be possible that Wolbachia syn-
thesize heme only for their own needs. It is expected that the Wolbachia-devoid
filariae L. loa and A. viteae have had horizontal transfer of certain endobacterial
genes to the nuclear genome of the filariae [175] and it may be speculated that the
development of molecular transport systems allowing these worms to exploit exoge-
nous heme sources was part of the evolutionary trigger that helped these filariae
to become independent of Wolbachia. However, this scenario has not been verified
experimentally. During a defined life-stage (as young adults) L. sigmodontis ingest
host red blood cells, presumably for the take-up of nutrients due to temporarily high
energy consumption at this life-stage [11]. Although it may not be completely ruled
out that at certain life stages even Wolbachia-containing filariae may, indeed, take
up tetrapyrroles from their human host, studies have collected compelling evidence
for a vital role of endobacterial heme biosynthesis for survival of filarial nematodes:
1) Antifilarial activity of heme biosynthesis inhibitors in B. malayi females in an
ex vivo culture system could not be rescued by the addition of exogenous heme
[270]. 2) Depletion of Wolbachia from L. sigmodontis by tetracycline treatment in
a natural infection model caused upregulated expression of genes encoding several
mitochondrial heme-dependent respiratory-chain complex subunits [241]. This fin-
ding is interpreted as a regulatory response of the filariae to overcome lack of heme
biosynthesis. Thus, inhibiting the enzymatic function of δ-aminolevulinic acid dehy-
dratase of Wolbachia (ALAD) that catalyzes the second step of endobacterial heme
biosynthesis (i.e. the condensation of 5-aminolevulinic acid to porphobilinogen) is
considered a suitable strategy to block biosynthesis of tetrapyrroles in Wolbachia
and to deprive the worms of their essential cofactor heme. Lack of heme would
cause a malfunction of heme-dependent processes such as oxidative phophorylation
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and may lead to oxidative stress due to a lack of catalase/peroxidase function and
will eventually result in death of the worm.
However, targeting endobacterial porphobilinogen production could synergize
with a second effector pathway. In principle, inhbition of wALAD should elicit a
pathophysiological condition in the worms similar to the effects of lead intoxication
in man, where Pb2+ displaces Zn2+B from the cysteine-rich binding site in the active
center with a corresponding loss of human ALAD activity [132]. It has been sug-
gested that the neuropathological symptoms of lead poisoning may be caused by
increased levels of 5-ALA [262]: Due to its structural analogy, 5-ALA may act as an
agonist on γ-amino butyric acid (GABA)-autoreceptors [39] and exert prooxidating
effects [65, 59, 23]. In analogy, inhibition of ALAD in Wolbachia will inherently
lead to the accumulation of 5-ALA in the endobacteria and, possibly, in the entire
worm, where 5-ALA may induce oxidative stress. Furthermore, essential biological
functions of nematodes such as locomotion and defecation were shown to be under
the control of GABA-ergic signalling [142] and the anhelminthic piperazine is a low-
potency agonist of GABA receptors as shown for the gastro-intestinal roundworm
A. suum [168] and the filaria A. viteae [48]. Notably, the most efficient antifilarial
drug, dieethylcarbamazine (DEC), is based on a piperazine ring, although DEC, it-
self, was shown not to interact with GABA receptors of Ascaris suum [168]. In this
study, I demonstrated that exposure of adult L. sigmodontis worms to exogenously
added 5-ALA in the ex vivo culture system revealed a macrofilaricidal effect at 5-
ALA concentrations of 1 mM and 5 mM, but not 200 µM. Resulting concentrations
in the worm are expected to be lower, as the cuticle represents a barrier to polar
substances like GABA [48]. Given a KM of ∼300 µM, it is easily conceivable that
in the pathophysiological context of ALAD inhibition excess 5-ALA concentrations
in the range of 1 mM may accumulate in the worm, although the physiological
concentrations of 5-ALA in the filariae remain to be determined. As outlined in
Figure 4.1, it must be considered that the antifilarial effects elicited by inhibition
of ALAD are not merely a consequence of heme-depletion, but also involve toxicity
of excess 5-ALA. Thus, inhibitory effects on a single target (ALAD) may trigger two
independent, potentially filaricidal, biological effector pathways (heme-deprivation
and 5-ALA-induced toxicity) underlining the excellence of wALAD as an antifilarial
drug target candidate.
4.3.1 Currently known inhibitors, structure analogs
A variety of ALAD inhibitors is already known. The most prominent class com-
prises substrate analogs that mostly do not have a species-selective inhibitory pro-
file. These analogs are similar to the substrate 5-aminolevulinic acid (5-amino-4-
oxo pentanoic acid) and are usually keto acids, e.g. levulinic acid (4-oxo-pentanoic
acid), succinyl acetone (SA, 4-6, dioxoheptanoic acid) or 4-keto-5-amino hexanoic
acid, that undergo Schiff base formation with a conserved active site lysine residue
(Lys263 of yeast ALAD) involved in binding of A-side ALA [69]. SA was initially
identified as a naturally occurring metabolite in patients with hereditary tyrosin-
emia [165] and is most commonly used as a specific, though not species-selective,
ALAD inhibitor in order to probe the biological effects of a blockade of heme
biosynthesis [242, 270]. The longer diketo diacid inhibitor 4,7-dioxo-sebacic acid
(4,7-DOSA) was demonstrated to cross-link the A-site and P-site by forming Schiff
bases with lysine residues of both sites (Lys263 and Lys210, yeast ALAD) [68].
For 4,7-DOSA, a certain discrimination of ALAD orthologs was observed with a
preference for Zn2+ utilizing enzymes like human ALAD [149], while 4-oxo-sebacic
acid preferentially inhibits the Zn2+-dependent E.coli enzyme, but not the human
nor any Zn2+-independent enzyme [136].
Another 5-ALA analog is 5-acetamido-4-oxo-5-hexenoic acid which was named
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Figure 4.1: Scheme depicting the presumed biological effects of ALAD
inhibition in Wolbachia endobacteria
The genes necessary for de novo biosynthesis of heme are conserved in the genome of
Wolbachia, while the filarial host B. malayi only possesses the final enzyme ferrochelatase.
Inhibition of δ-aminolevulinic acid dehydratase of Wolbachia (wALAD) by wALADin1
leads to reduced formation of porphobilinogen and the following heme precursors. Heme-
deprivation will result in a deficiency of heme-dependent enzymes like cytochromes (energy
transport chain) and catalases and peroxidases (detoxification of hydrogen peroxide), and
is expected to lead to the death of the worm. Besides, as a consequence of ALAD inhibition
5-ALA will accumulate. This molecule may have prooxidative and thus toxic effects on the
worm. Furthermore, it might activate GABA-receptors as an agonist resulting in reduced
neuromuscular activation that may further lead to paralysis and death of the filaria.
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Alaremycin ("ALA-related antibiotic produced by Streptomyces sp.") according to
its producing bacterial strain [13, 108]. Alaremycin binds to P. aeruginosa ALAD
and leads to its inhbition by conventional Schiff base formation of its keto-group
with P-site lysine.
A recently emerging strategy for the design of species-selective ALAD inhibitors
exploits the allosteric nature of the morpheein ALAD and the intrinsically different
catalytic activities of different quaternary structure assemblies. Crystal structures
of P. sativum ALAD and other orthologs revealed a surface cavity and putative
small molecule binding site unique to the low-activity hexameric assemblies [161].
In silico docking approaches were able to identify small molecules ligands of these
sites (so-called "morphlocks") that perturb the oligomeric equilibrium of P. sativum
ALAD by stabilizing inactive assemblies (here: hexamers) and thus inhibit enzy-
matic activity. As these allosteric cavities are phylogenetically very variable, this
strategy allows the design of ortholog-selective inhibitors as was shown for morph-
locks targeting P. sativum and human ALAD [161, 160]. A similar study revealed
compounds targeting inactive dimeric assemblies of P. aeruginosa ALAD although
the true inhibitory properties of these compounds were not reported [214].
4.4 wALADins as novel species-selective ALAD in-
hibitors: Structure and Function at the mole-
cular level
4.4.1 A novel Mg-dependent type of inhibition
In the current study a novel class of ALAD inhibitors, tri-substituted benzimidazoles
of the wALADin1 family, with a species-selective inhibitory profile was discovered.
Wolbachia ALAD inhibitor 1 (wALADin1), the most potent inhibitor (wALAD:
IC50 ∼11 µM) displayed pronounced species-discrimination with a marked prefe-
rence for the endobacterial ortholog compared to the human enzyme (> 70-fold
reduced potency).
wALADin1 is based on a benzimidazole scaffold with a 3-trifluoromethyl ben-
zyl group at benzimidazole atom N1(R1), a 2-[(2-thienylcarbonyl)amino]ethyl sub-
stituent at C2 (R2) and a carboxylic acid function at C5 (R3). Thus, the chemical
structure of wALADin1 does not have any evident similarity with 5-ALA and lacks
the keto acid motif of common substrate analogs required for Schiff base forma-
tion with a conserved active site lysine residue. Instead, the inhibitory mecha-
nism was found to be a mixed competitive/non-competitive inhibition. It is further
demonstrated that the compound functionally competes with the activation by a
Mg2+ cofactor, although maximum enzymatic activity could not be restored com-
pletely by increasing Mg2+ concentration. Binding of allosteric Mg2+ is a major
inducer of pro-octamer dimers and enzymatically active octameric assemblies in P.
sativum, while removal of Mg2+ acts in favour of the inactive hexameric conforma-
tion [37, 135, 137]. However, the Mg2+ antagonizing effect of wALADin1 does not
interfere with the oligomeric equilibrium as morphlock inhibitors do [161], rather
this novel inhibitor targets the wALAD octamer as documented by the native PAGE
experiments. Thus, the inhibitory mechanism of wALADin1 is novel and its Mg2+-
competitive character is the likely basis for the observed species-selective inhibitory
profile.
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4.4.2 Metal-cofactor requirements of ALAD orthologs
A general classification of ALAD orthologs into four classes according to the pre-
sence or absence of conserved metal binding sites was suggested by Eileen K. Jaffe
[133]. One criterion is the presence or absence of the cysteine-rich Zn2+-binding site
in the active center (Znb or Metalb-site). For Zn
2+-dependent orthologs, tetrahedral
complexation of ZnB to three conserved cysteine residues and A-side 5-ALA is an
absolute requirement for catalytic activity. Binding of other less-well documented
Zn2+-binding sites (ZnA) in the active center are considered dispensible for the
catalytic process and may represent "reserve ions" [132, 134, 223]. The second
classification criterion is the presence or absence of the allosteric Mg2+-binding site
(Mgc-site) at the interface of the N-terminal arm with the α/β8-barrel of the neigh-
boring subunit that stabilizes the active site lid. This allosteric binding site forms
an octahedron with Mg2+ coordinated to a conserved glutamic acid residue and five
H2O molecules.
According to this classification four groups exist, to which all orthologs that
were used in this study can be assigned:
Group A: Zn2+-dependent, without allosteric Mg2+ site
Mammalian or yeast enzymes including hALAD [132, 70]
Group B: Zn2+-dependent, with allosteric Mg2+ site for further stimulation
Many bacterial orthologs like E. coli ALAD [71]
Group C: Zn2+-independent, without allosteric Mg2+ site
Very few members like Rhodobacter spp. ALAD [27] that was not available
for the current study
Group D: Zn2+-independent, with allosteric Mg2+ site
Plant (P. sativum) and many bacterial orthologs including ALAD from Wol-
bachia [270], P. aeruginosa [83], Y. enterocolitica and V. cholerae
In addition to these categories Zn2+-independent enzymes may further differ
in the use of active site metal cofactors. The active-site Cys-residues of Zn2+-
dependent enzymes are mostly replaced by aspartic acid residues [26]. For several
of these Zn2+-independent enzymes baseline catalytic activity has been shown to
be independent of the presence of divalent metal ions at the active site, e.g. for
the P. aeruginosa and P. falciparum enzymes [84, 66]. For other orthologs, like
that of the soy been root α-proteobacterial endosymbiont Bradyrhizobium japon-
icum, Pisum sativum or the apicomplexan parasite Toxoplasma gondii a role for
active site Mg2+ has been proposed. Biphasic Mg2+-response curves and determi-
nation of binding stoichiometries measured for B. japonicum ALAD in the presence
and absence of 5-ALA suggest binding of Mg2+ to different sites of the protein
with different affinities [205]. Tightly binding Mg2+ was 5-ALA dependent and was
considered to correspond to metal-binding sites in the active center, whereas the
looser binding Mg2+ should correspond to the allosteric metal binding site (Mec-
site). Magnetic-resonance studies using 13C-labeled porphobilinogen at character-
istic Mg2+ or Mn2+ concentratons futher supported this conclusion [204]. Site-
directed mutagenesis studies replacing the active site alanine and aspartic acid
residues by cysteines induced the loss of Mg2+-dependency and the introduction
of Zn2+-dependency to the previously Zn2+-independent B. japonicum enzyme al-
though enzymatic activity of the mutant was very low [45, 85]. Similar observations
were made in site-directed mutagenesis studies inducing Zn2+-dependency into the
P. aeruginosa enzyme [85]. For the chlorplast protein from pea and the apicoplast
protein from T. gondii evidence for the presence of catalytic Mg2+ in addition to
allosteric Mg2+ was mainly derived by biphasic Mg2+-response curves interpreted
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as binding to different sites with different Mg2+-binding affinities [148, 227]. In
addition, atomic absorption spectroscopy revealed binding of up to 3 Mg2+ per
subunit of the pea protein [148]. Regardless of the binding stoichiometries, it might
be considered that the two phases of the Mg2+ response curves represent binding to
the same (allosteric) binding site in different subpopulations of the oligomeric equi-
librium (characteristic for the morpheein) with distinct affinities rather than to two
different binding sites. Finally, the presence of catalytic Mg2+-ions at the active site
of any Zn2+-independent orthologs remain undocumented by crystal structures and
thus without final experimental proof, whereas the allosteric MgC ion is documented
by a number of crystal structures [83, 138].
Furthermore, monovalent ions like K+ have been reported to activate certain
ALAD orthologs and increase the protein’s affinity for Mg2+, as demonstrated for
B. japonicum [205], P. aeruginosa [84], V. cholerae and Y. enterocolitica (Eileen
K. Jaffe, personal communication). In the active site of the P. aeruginosa ortholog
a monovalent cation (Na+) has been identified in a crystal structure, indicating
that monovalent cations, though being differentially coordinated, might fulfil the
function of catalytic Zn2+ in Zn-2+-dependent proteins [86].
4.4.3 Mg2+-usage of wALAD
Which role does Mg2+ play in the activation of the Wolbachia protein? The answer
is not trivial and remains evidence-based and thus equivocal in the absence of a
crystal structure that might document the metal cofactor usage. The evidence we
have is the following: All orthologs for which a catalytic Mg2+ is considered also
possess the allosteric MgC site and show a biphasic Mg
2+-response curve. Wolbachia
ALAD gives a monophasic response to Mg2+. Although a second binding site may
be hidden in the progression of a monophasic response curve, if the resolution is not
sufficiently high, the uniform rightward shifts of the Mg2+-response curve elicited
by wALADin1 gave no evidence for a second binding site. However, it is unlikely
that the inhibitor has a quantitatively equivalent competitive effect with respect to
two different Mg2+ binding sites at the same time. It is therefore concluded that
the activation of wALAD is only driven by binding of Mg2+ to one site.
In all ALAD orthologs that possess the allosteric Mgc site, i.e. they possess the
conserved glutamic acid residue (Glu245 of P. aeruginosa ALAD [83]), the allosteric
stimulation may be monitored as an increase in enzymatic activity although the
extent of this allosteric stimulation varies between species [84, 131, 66]. The corres-
ponding glutamate residue is also conserved in the structure of Wolbachia ALAD.
On the basis of this experimental evidence and the still ambiguous proof for the
presence of catalytic Mg2+, it is assumed that stimulation of wALAD by Mg2+ is due
to the allosteric activation by binding to the conserved MgC site. A rather unususal
effect for allosteric stimulation by MgC is the relatively high affinity (EC50 ∼11 µM)
observed in this study. For the pea protein dissociation constants of ∼35 µM for the
putative catalytic Mg2+ and 2.6 mM for the putative allosteric MgC were predicted
[148]. Interestingly, in the present study a monophasic progression was observed
even for the pea protein, with an EC50 of ∼257 µM which is in-between dissociation
constants reported in the literature, under the assay conditions used, presumably
reflecting allosteric Mg2+. Importantly, again the curve shift induced by wALADin1
was homogenous and did not reveal a biphasic nature. For the T. gondii protein two
distinct Mg2+ ions have been proposed with a dramatically higher affinity to both
ions with KD values of ∼0.7 µM and 84 µM, respectively, for the presumed catalytic
and allosteric sites [227]. Although the oberved affinity of wALAD to Mg2+ is rather
in the range of presumed catalytic ions, in light of the large variations in affinity for
the allosteric ions in P. sativum and T. gondii, tight binding of allosteric Mg2+ in
wALAD is conceivable. On this background, it may not be completely ruled out that
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active site/catalytic Mg2+ may be involved, unless the metal cofactor usage of this
protein has unambiguously been determined. However, for the P. aeruginosa ALAD
under the conditions tested in this study (pH 7.5, no KCl, low 5-ALA) wALADin1
acts as an inhibitor and leads to reduced affinity for Mg2+. As this enzyme is
independent of catalytic divalent metal ions, but features the allosteric Mg2+ [84],
it is evident that the inhibitory mechanism involves functional competition with
the common Mg2+-induced allosteric activation mechanism. Therefore, these data
strongly suggest that the Mg2+-interfering effect on wALAD and PsALAD are
related to the allosteric Mg2+.
4.4.4 The inhibitory mechanism of wALADin1 discussed at
the structural level
With respect to the observed inhibitory mechanism of wALADin1 several possi-
bilities exist. wALADin1 may antagonize binding of Mg2+ at an allosteric MgC-site
or a catalytic MgB-site. Alternatively, it may bind to a different site in the protein
and interfere with the allosteric activation process induced by MgC acting as a
negative allosteric modulator itself. Thus, it may interrupt closure of the active site
lid, a structural requirement for catalysis that is allosterically regulated by MgC in
the P. aeruginosa enzyme [83].
wALADin1 is an inhibitor with a mixed substrate-competitive and non-competi-
tive inhbitory mechanism. This means that, although 5-ALA is not able to overcome
inhbition by wALADin1, 5-ALA binding reduces the affinity of the protein for the
inhibitor. It is therfore unlikely that wALADin1 acts as a binding competitor of
allosteric MgC as it is not evident how this effect might be influenced by binding of
5-ALA to the remote active site. Competition with a putative catalytic MgB at the
active site itself is still conceivable. The allosteric scenario may also be united with
the observed inhibitory mechanism, because the conformation of the active site lid
is governed both by the allosteric MgC and by binding of A-side 5-ALA to the active
site, which represents the final trigger for closure of the lid [134]. Thus, both MgC
and A-side 5-ALA would be in favor the catalytically active conformation, while
wALADin1 may induce an alternative catalytically inactive conformation.
4.4.5 Mechanistic aspects of the stimulatory/inhibitory di-
chotomy of wALADin1
While wALADin1 is a similarly potent inhibitor of both Wolbachia and P. sativum
ALAD and nearly inactive against the Mg2+-independent human ortholog, wAL-
ADin1 had a surprising effect on the enzymatic activity of ALAD from P. aerugi-
nosa, E. coli, V. cholereae and Y. enterocolitica. For these orthologs that all feature
the allosteric MgC-site but different requirements for catalytic metal ions, wALA-
Din1 had a stimulatory effect, while for P. aeruginosa ALAD the stimulatory effect
could be turned towards inhibition under certain conditions.
One mechanism that might account for the stimulatory properties of wALADin1
would be stabilization of the octameric assembly and thus a shift of the oligomeric
equilibrium towards the active form resulting in increased enzymatic activity. How-
ever, effects on the oligomeric equilibrium are hysteretic processes that require
longer preincubation times at elevated temperatures in order to promote dissocia-
tion of preformed assemblies [246, 135, 161]. Such conditions were not used for the
conducted enzymatic assays with only 5 min preincubation at room temperature
before the enzymatic reaction occurred for 10 min at 36 ◦C. Although a stimulatory
effect of wALADin1 via the oligomeric equilibrium may not be ruled out, another
mechanism that supports an allosteric effector model for wALADin1 is more likely.
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Under the assumption that the binding site of wALADin1 is the same in these
orthologs as for wALAD, these stimulatory effects are hard to reconcile with a
model of wALADin1 binding to the active site. Instead, an allosteric model may
well explain these results. wALADin1 may bind to structural features involved
in the allosteric activation by MgC (a common feature for all orthologs at which
wALADin1 shows considerable biological activity) such as the active site lid. As
an allosteric modulator, in some orthologs wALADin1 may act agonistically with
the allosteric activation process by MgC causing stimulation, while in others it may
antagonize this effect, depending on different molecular architectures of the wALA-
Din binding site and other structural features involved in the allosteric process.
Intriguingly, it was found that the inhibitory/stimulatory dichotomy may apply
even for a single protein, as seen for the P. aeruginosa ortholog where the buffer
conditions that influence enzymatic activity and determine the overall protein con-
formation (pH, monovalent cations, substrate concentration) drive modulation by
wALADin1 towards stimulation or inhibition. Furthermore, monovalent cations,
divalent cations and substrate concentration determine sensitivity of the protein
for modulation by wALADin1. As such, depending on the physiological pH, cy-
tosolic ion concentrations and other interaction partners of ALAD that might exist
in the cell, wALADin1 may act both agonistically or antagonistically on P. aeru-
ginosa ALAD in the bacterium in vivo. The complexity of the underlying events
is especially evident for the interplay of substrate and wALADin1 under inhibitory
conditions, where wALADin1 consistently reduced affinity (KM ) of pALAD for the
substrate, while Vmax is reduced at low concentrations of inhibitor but starts to
increase at high concentrations of inhibitor where increased Vmax-values may lead
to overall stimulation although affinity to the substrate is decreased. This scenario
may be explained by multiple and functionally different binding sites for 5-ALA
and/or wALADin1. As binding of both A-side and P-side 5-ALA is required for
catalytic activity, it is unlikely that these two sites account for this outcome. In-
stead, the observed effects may be correlated to the oligomeric nature of the protein
and the phenomenon of half-sites reactivity: This term is used to describe that in
the four asymmetric dimers that assemble into the octamer, the two monomers are
functionally different (asymmetric) and only one of these contained 5-ALA bound
to the active site and a closed active site lid in the P. aeruginosa ALAD crystal
structure [83]. Thus, half of the active sites in the octamer are assumed to be in an
"active" conformation while the complementary four subunits populate an "inactive"
state. It is thus conceivable that, in addition to the primary effects occurring at
the "active subunits" with high affinity, at high concentrations of wALADin1 and
5-ALA low-affinity binding sites present in the second type of subunit (putatively
the inactive subunit) are filled with a contrasting functional outcome that may help
explain the increase in Vmax at high wALADin1 concentrations. Understanding
the interplay of the different influence on protein structure, e.g. on the basis of a
crystal structure, may help design tailored agonists or antagonists of P. aeruginosa
ALAD and potentially other orthologs on the basis of the wALADin-modulators.
4.4.6 The inhibitory mechanism of wALADin2
Intriguingly, the tricyclic quinoline carboxylic acid derivative and potent wALAD
inhibitor wALADin2 acts by a different mechanism. It is an entirely non-substrate-
competitive inhibitor with an apparently more pronounced Mg2+-competitive cha-
racter. As this inhibitor was identified due to its structural similarity to wALADin1
and as it also involved functional competition with Mg2+, it is assumed that these
two inhibitors share a common binding site. However, the functional outcome of
wALADin2 binding to the presumed binding site is different. These results suggest
that the substrate-competitive component and the non-substrate competitive com-
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ponent, which is presumably functional antagonization of activation by Mg2+, may
be separated on a structural basis. Interestingly, wALADin2 is even more specific
for wALAD than wALADin1 is. The only other ortholog which it inhibits is the
chloroplast protein from P. sativum, although with an ∼10-fold reduced potency.
In contrast, it neither led to stimulation of the enzymatic activity of those orthologs
stimulated by wALADin1, nor did it induce any background inhibition of hALAD.
The following considerations can be made with regard to the inhibitory mechansim.
Although wALADin2 only inhibited the Wolbachia protein where Mg2+ usage is
unclear and the pea ortholog, for which a role for catalytic Mg2+ has been sug-
gested [148], it appears rather unlikely that this inhibitor targets the active site and
competes with catalytic Mg2+. If present, catalytic Mg2+ is considered to be re-
quired for the recruitment of A-side 5-ALA to the active site, replacing the function
of Cys-coordinated ZnB of Zn
2+-dependent orthologs. As any catalytic Mg2+ and
A-side 5-ALA would need to be functionally and spatially tightly linked, it appears
very unlikely that an inhibitor like wALADin2 targets the active site, undergoing
a competition with catalytic Mg2+, and is not influenced by 5-ALA at the same
time. Thus, interference with allosteric activation by MgC seems likely.
4.4.7 SAR of benzimidazole derivatives
Activity testing of a variety of benzimidazole-based wALADin1 derivatives revealed
several important features in the interplay of structure and function. An absolute
requirement for inhibitory activity was the carboxylate function at the R3 position.
This residue may be involved in salt-bridge formation at the molecular binding site,
e.g. with a lysine or arginine residue.
Changes in the chemical structure of the R1 group, which conveys optimal po-
tency as the 3-trifluoromethyl benzyl in wALADin1, leads also to pronounced re-
ductions in inhibitory potency (Fig. 3.15). The benzyl ring appears indispensible
even for weak inhibitory activity of the Wolbachia ortholog, while the R1-H deriva-
tive 2 still has considerable inhibitory potency for the pea protein. In both cases,
position and identity of further substituents at the R1 benzyl moiety are major
determinants of inhibitory potency. The introduction of fluorines from -CH3 to
-CF3 involves a major gain in potency (∼10-fold) that may result from increased
lipophilicity, increased size or altered electronic effects [102, 183] to name a few
possible effects.
The R2-2-[(2-thienylcarbonyl)amino]ethyl substitutent of wALADin1 was ap-
parently dispensible for inhibition of wALAD as its exchange to -H (in 3) had
nearly no effect on inhibitory potency. However, on the basis of a different pa-
rent molecule, the same subsitutent was responsible for the > 2-fold increased po-
tency of 9 over 10. Of note, for the P.sativum ALAD wALADin1 had greater
inhibitory potency than 3, while 9 and 10 had similar activities. This indicates
that R2 should not be simply neglected, but that substituents at this position may
contribute additional potency to the parent molecule. It is conceivable that sub-
stituents other than 2-[(2-thienylcarbonyl)amino]ethyl may confer additional po-
tency even to the wALADin1-scaffold. Another important aspect of R2 is its
role as a mediator of species-selectivity. For the human ortholog the bulky 2-
[(2-thienylcarbonyl)amino]ethyl substitutent represents a major impediment for in-
hibitory activity, e.g. by imposing a steric hindrance, while most smaller R2-H
compounds (including 3) show weak to intermediate inhibitory activity and some
molecules even display an inhibitory preference for the human enzyme over the
Wolbachia enzyme. Intriguingly, for those orthologs at which wALADin1 acts sti-
mulatory, the R2 2-[(2-thienylcarbonyl)amino]ethyl is an absolute requirement. This
structural feature is common to all stimulatory active derivatives (wALADin1, 6,
7, 9) and its absence leads to a loss of activity (3, 10). The fact that the only
118
CHAPTER 4. DISCUSSION
bioactive compounds are all constitutional isomers varying in the position of the
-COOH or -CF3 position indicates a rather strict molecular binding corset.
Summarizing the role of the R2-2-[(2-thienylcarbonyl)amino]ethyl for biologi-
cal activity can be described as follows. It prevents inhibition of hALAD and is
structurally required for activity at orthologs stimulated by wALADin1 while it is
of minor importance for Wolbachia/pea ALAD. This substituent represents a key
determinant of biological activity and specificity across different members of the
ALAD family.
4.4.8 ALAD-inhibitors based on a different molecular scaf-
fold
The benzimidazole scaffold of wALADin1 (Fig. 3.15) is not the only chemical scaf-
fold which allows the building of ALAD inhibitors with wALADin-like properties.
Such inhibitors had been detected by functional screening in the wALAD assay,
after molecules with chemical similarity to wALADin1 had been selected. Besides
providing a broader chemical foundation for the design of improved inhibitors in
the future, these molecules may also contribute to the identification of structural
features of functional importance. The other scaffolds identified included substi-
tuted 1,3-dihydro-2H-benzimidazol-2-one, phenylthiophene carboxylic acid and tri-
cyclic quinoline derivatives (Fig. 3.21). For the 1,3-dihydro-2H-benzimidazol-2-
one compounds, presence of an ionizable group was a selection criterion. However,
all inhibitory compounds of these classes feature a carboxylic acid group while
the only quinoline derivative without was inactive. This finding highlights again
the functional importance of this moiety as discussed above for the benzimidazole
derivatives.
The 1,3-dihydro-2H-benzimidazol-2-one derivatives do not incorporate an R2
substituent at the C2 atom of the benzimidazole ring that carries the carbonyl moi-
ety, but they feature another substituent at the N3 atom (in the following termed
R4) with a spatially similar orientation as the R2 of wALADin1. As R2 was demon-
strated to be a major determinant of specificity it is intriguing that varying R4
substituents determine the specificity profile of the 1,3-dihydro-2H-benzimidazol-2-
one compounds although these compounds all had at best intermediate potency.
Yet, it must be considered that the loss or aromaticity in one of the core rings of
these compounds introduces a lack of planarity, which will also have an impact on
spatial projections of the substituents.
The small R2-H compounds are the only inhibitors well tolerated by the human
ortholog. It is therfore a remarkable coincidence that the small phenylthiophene
structures are the most potent inhibitors of hALAD identified in these studies with
IC50 values between 80 and 100 µM. These compounds also inhibited wALAD but
with somewhat lower potency. Finally, the class of tricyclic quinoline derivatives
has to be mentioned again, of which the already discussed inhibitor wALADin2 was
the only active member, indicating a very steep structure-activity profile for this
exciting chemotype.
4.4.9 Summarizing the functional characterization of wALA-
Din inhibitors at the molecular level
The current study has identified a novel class of benzimidazole-based inhibitors of
ALAD of Wolbachia with a species-selective inhibitory profile. It is suggested that
wALADin1, the most potent benzimidazole inhibitor, acts as an allosteric modula-
tor that may cause inhibition or stimulation of ALAD activity in different species
depending on the molecular context. Inhibition consists of a substrate-competitive
component and a non-competitive component which is considered to be equivalent
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with a functional competition with (a putatively allosteric) Mg2+ ion. wALADin1
(as well as 3) involves both inhibitory components, while the tricyclic quinoline
derivative wALADin2 only acts exclusively by functional competition with Mg2+
and shows improved specificity. The potency of wALADin2 is independent of the
substrate concentration, whereas the potency of wALADin1 is high at low 5-ALA
concentrations, but decreases upon accumulation of 5-ALA or at high initial 5-ALA
concentrations. Thus, biological activity of these two inhibitors in the physiological
environment is expected to be different and both compounds may complement one
another. Further structural components have been identified as determinants of
inhibitory potency and specificity. Finally wALADin-like inhibitors based on other
chemotypes have been discovered.
These novel inhibitors mark a significant advancement in the search for species-
selective ALAD inhibitors of potential therapeutic utility. The profound characte-
rization of structural and functional aspects of benzimimdazoles and other chemo-
types along with their inhibitory mechanisms provides the foundation for the design
of improved inhibitors with desired nanomolar inhibitory potency and tailored bio-
logical activity.
4.5 The antifilarial effect of wALADins
Beyond being an efficient inhibitor of the Wolbachia ALAD in vitro, this study
demonstrates that wALADin1 also has pronounced antifilarial activity in an ex vivo
survival assay employing the Wolbachia-harboring rodent filarial nematode Lito-
mosoides sigmodontis. L. sigmodontis worms exposed to wALADin1 at concentra-
tions from 125 - 500 µM displayed continuously reduced motility and temporarily a
specific ball-like low-motility phenotype. Viability measurements revealed an EC50
concentration of ∼100 µM and demonstrate that wALADin1 kills L. sigmodontis,
i.e. has macrofilaricidal activity. The specificity of this effect was confirmed by
parallel tests on Wolbachia-free filaria Acanthocheilonema viteae, on which wALA-
Din1 had only slight effects. Exposure to wALADin1 had evidently no effect on
viability of A. viteae in the MTT assay which is the most reliable readout for the
documentation of antifilarial effects. However, at the highest concentration tested,
motility of A. viteae was immediately reduced by 1 motility score unit within 2 h
of exposure, but motility did not decline further for the following 10 days. These
studies revealed that the filaricidal effect of wALADin1 on L. sigmodontis is de-
pendent on Wolbachia and is presumably due to an inhibition of ALAD within the
endobacteria, followed by deprivation of heme and/or 5-ALA toxicity. Nevertheless,
a secondary non-specific effector component was dissected causing the non-specific
decline of A. viteae motility at 500 µM. This activity likely acts in addition or in
synergy to the specific Wolbachia-dependent activity on L. sigmodontis. This non-
specific activity may be correlated to the observed cytotoxic effects of wALADin1
in eukaryotic cell culture at concentrations ≥ 500 µM.
wALADin derivative 6 is a significantly less potent inhibitor of wALAD that
showed no cytotoxicity below 1 mM. This compound (at 500 µM) still showed con-
siderable though less pronounced antifilarial effects with a rapid onset comparable
to the non-specific effect wALADin1 had on A. viteae. Although viability was af-
fected, the characteristic ball-like phenotye was not observed. It is therefore likely
that the biological activity of this compound is mostly derived from activity on a se-
condary target. Compound 3, an equally potent inhibitor of wALAD as wALADin1
which had no cytotoxic activity at these concentrations, although it showed reduced
species-selectivity of ∼15-fold, revealed contrasting biological activity. Onset of the
antifilarial effect was delayed compared to wALADin1, but it became evident in
reduced motility values for all concentrations tested reaching motility scores of 3-4
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at the end of treatment that were similar those achieved by wALADin1. Impor-
tantly L. sigmodontis worms exposed to 3 also featured the ball-like appearance
characteristic for wALADin1-treated worms. Viability was significantly reduced by
64% only for the highest concentrations although the trend was sustained also for
the lower concentrations. Although the antifilarial effect of 3 was quantitatively
weaker than that of wALADin1, it displayed a very similar phenotype. In 3, the
entire R2 substituent of wALADin1, which comprises about one third of the entire
molecule, is missing. Despite this chemical modification, 3 has obviously retained
the wALAD-inhibitory potency, but it may easily have lost activity on putative se-
condary targets with unique strucure-activity profiles of their own. Hence 3 might
display a more ALAD-specific biological profile. It may be expected that it takes a
while until the inhibition of ALAD (especially when not complete) translates into
heme-deficiency, depending on the turnover rates of preformed heme in the worm,
and becomes evident in reduced fitness of the worm. Also accumulation of toxic
5-ALA levels may not occur immediately. Therefore, the antifilarial effect elicited
by 3 may be a more specific result of interference with endobacterial heme biosyn-
thesis than the stronger and more rapid effect of wALADin1, that at least at 500
µM likely represents an overlap of activity at ALAD and at a secondary target.
Taken together, the pronounced antifilarial acitivity of wALADin1 and 3, the
most potent benzimidazole inhibitors of wALAD, and the Wolbachia-dependent
activity of wALADin1 reveal that the specific heme-biosynthesis inhibitors of the
wALADin benzimidazole family are a promising novel class of antifilarial agents.
4.5.1 Potential secondary target effects
Potential secondary targets of wALADin1 in Wolbachia or the nematode may be
deduced from known targets of chemically related molecules. The most closely
related class of bioactive benzimidaziole structures has been reported to target the
human kinesin spindle protein (KSP or Hs Eg5) [157, 228]. As inhibition of this
protein leads to a misassembly of the mitotic spindle and cell cycle arrest followed by
the death of cancer cells, it is an attractive target for the development of anticancer
drugs. The recently reported class of hKSP-inhibitors were 2-aminobenzimidazoles
with further substituents at the amino group and at benzimidazole atoms N1 and
C5, equivalent to the R1 and R3 substituents of wALADin1-benzimidazoles (Fig.
4.2). Although these inhibitors have tolerated a carboxyl group at the R1 position
(as required by wALADins for inhibitory activity), they had a preference for a
primary amide at R1. The R2 residue of most KSP inhibitors is a 2-trifluoromethyl
benzyl and is thus similar to the 3-trifluoromethyl benzyl of wALADin1. The largest
structural difference is in the R2 postion, where KSP inhibitors require an amino-
linked aromatic substituent in order to be characterized as active in an in vitro assay
system (IC50 values below 20 µM). Nevertheless, at the high concentrations used
in the filarial co-culture assay wALADins may have an effect on filarial orthologs
of this mitosis-releted protein.
The benzimidazole core of wALADins represents a structural link to classical
benzimidazole anthelmintics like albendazole. These anhelmintics target the filarial
β-tubulin and cause a destabilization of microtubules [156]. While the lack of a car-
boxylic acid function will prevent inhibitory activity of benzimidazole anhelmintics
on wALAD (for albendazole this was even experimentally verified, although the
data is not shown), nematode microtubules may be a secondary target of wALA-
Din inhibitors. Most benzimidazoles like albendazole, flubendazole and mebenda-
zole feature a carbamate moiety at the R2 position and differ in their R3 moieties
although the active metabolites are often biotransformed molecules [89]. In case
of albendazole, both albendazole and its in vivo metabolite albendazole sulfoxide
target worm β-tubulin. Its other major metabolite albendazole sulfone has recently
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Figure 4.2: Chemical structures of selected benzimidazole compounds
The chemical structures of wALADin1, the KSP inhbitor with highest potency [228] and of
selected benzimidazole anthelminthics including, mebendazole, flubendazole, albendazole
and its metabolites albendazole sulfoxide and albendazole sulfone are shown.
been shown to have a bacteriostatic effect on Wolbachia proliferation in B. malayi
and to disrupt binary fission [226]. It may not be ruled out that the Wolbachia-
dependent activity of wALADin1 is based, at least in part, on this yet unidentified
endobacterial benzimidazole target, although this scenario is highly speculative.
Besides testing of wALADin1 and derivatives in enzymatic assays for secondary
target candidates, if available, comparative analysis of the filarial and Wolbachia
phenotypes under exposure to wALADin1 and other chemical probes such as al-
bendazole sulfone may help unravel secondary targets and effector pathways of
wALADin1.
4.5.2 In vivo activity of wALADin1
The proof-of-principle experiments demonstrating the macrofilaricidal effects of
wALADin1 and derivatives in the ex vivo co-culture system revealed that the in
vitro ALAD-inhibitory activity of wALADin1 can be translated into an antifilarial
effect in the living worms. However, providing the required high concentrations of
> 100 µM in an in vivo infecion model of L. sigmodontis in BALB/c mice is not a
trivial task. Despite continued administration of wALADin1 of up to 4 mg/mouse
for up to four weeks, the use of different formulations and administration routes
(intraperitoneal injections and intrathoracic injections to the site of infection) no
antifilarial effect of wALADin1 treatment was observed. Treatmtent was tolerated
well without evident signs of toxicity. Although it may not be ruled out that the
filariae have access to host-derived heme sources in their physiologic environment
[11] and thus be naturally resistant to inhibition of endobacterial heme biosynthe-
sis, it is likely that the concentration of wALADin1 in the biophase is simply too
low to reach a biological effect. Possible pharmacokinetic reasons are manifold, but
determination of the pharmakokinetic profile and ADME parameters (adsorption,
distribution, metabolization and excretion) of wALADin1 in the mouse were beyond
the scope of the current study and represent a project of its own. In the mouse,
wALADin1 may be rapidly metabolized and excreted or sequestered by promiscuous
non-specifically binding proteins of the host such as serum albumin. For the ben-
zimidazole anthelminthic albendazole the major pharmakokinetic handicap is poor
absorption from the intestinal tract after oral administration [89]. This obstacle was
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circumvented in the present study as wALADin1 was administered intraperitoneally
or intrathoracically. However, in the human intestinal mucosa and the liver, al-
bendazole is rapidly metabolized to albendazole sulfoxide, albendazole sulfone and
several further metabolites [182]. Rapid hepatic and mucosal biotransformation
has also been reported for other benzimidazole drugs, i.e. flubendazole in sheep
[169]. Similar though non-analogous biotransformation of wALADin1 may occur in
the mouse liver and yield non-inhibitory metabolites devoid of antifilarial activity.
Pharmacokinetic shortcomings that prevent biologically active concentrations of a
compound are, of course, structure bound. ADME properties are determined by
defined chemical features and structural elements of a xenobiotic that e.g. represent
contact points for biotransformation enzymes. In order to develop drug-like Wol-
bachia ALAD inhibitors with a potent antifilarial activity in vivo two considerations
are imperative. First, inhibitory potency must be increased such that lower doses
are sufficient to yield bioactive concentrations in vivo. Second, the pharmacokinetic
profile must be enhanced, which may be achieved by the identification of inhibitors
based on other chemical scaffolds that retain the biological activity. A first step
towards the identification of such improved inhibitors has been undertaken and has
led to the identification of the non-benzimidazole based inhibitor wALADin2, which
has a slightly increased inhibitory potency and an improved specificity profile in the
in vitro assay.
4.6 Applications of wALADin 1 beyond filarial ne-
matodes
4.6.1 Inhibitory spectrum of wALADin and derivatives
Although the principal aim of this study was to develop specific inhbitors Wol-
bachia ALAD as antifilarial drug or lead candidates, the inactivity on the human
Zn2+-dependent ortholog and the Mg2+-dependent inhibitory mechanism led to the
consideration that wALADins might be universally applicable inhibitors specific
for Mg2+-dependent, respectively Mg2+-stimulated orthologs. As most previously
known inhibitors have no species-selective profile or exhibit higher activities on the
mammalian enzymes [270, 227], it has not been possible to specifically target heme
biosynthesis of any human pathogen without affecting the mammalian host. How-
ever, exploitation of microbial heme biosynthesis pathways as drug targets may now
be possible by wALADin-like inhibitors. By determining the spectrum of ALAD
orthologs from different species on which wALADin1 and derivatives act inhibitory
or not, it was concluded for which species these wALADin-like inhibitors might re-
present potential therapeutics. Generally, ALAD enzymes were assigned into three
groups according to whether they were X) insensitive to wALADin1, Y) inhibited
by wALADin1, or Z) stimulated by wALADin1 (Naming the groups X,Y,Z shall
prevent confusion with the classification of A-D introduced above). Each group
had characteristic structural requirements of the benzimidazole compounds for the
respective bioactivity.
As a prerequisite for any therapeutic use of wALADins, the human enzyme,
representative of group X, is insensitive to inhibition by wALADin1. According to
phylogenetic similarity, this may also apply for other metazoa and yeast. Thus,
potential use of wALADin-like inhibitors is given in veterinary medicine, but they
are not expected to be efficient antifungal agents.
For group Y ALAD enzymes, wALADins represent potent inhibitors and are of
potential therapeutic use. This class comprised the Wolbachia and the chloroplast
P. sativum protein. Potent inhibition of plant ALAD, a phylogenetically rather
homogenous group [133], reveals that wALADins are potential herbicides in addition
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to their prospective utility in antifilarial drug discovery. TheWolbachia ortholog was
the only α-proteobacterial ortholog tested, however, in light of the close relationship
of other intracellular human pathogens like Rickettsia spp., Bartonella spp. and
Brucella spp. [36]. Plant chloroplasts originate from primary symbiosis with a
cyanobacterium [8]. Thus, susceptibility to wALADin1 of the chloroplast and α-
proteobacterial ortholog may be an evolutionary coincidence or a feature conserved
throughout evolution that dates back to a common ancestor.
ALAD orthologs that cluster in group Z are from diverse human pathogenic
or opportunistic bacteria including E. coli, P. aeruginosa, Y. enterocolitica and
V. cholerae. Although metal cofactor usage of these enzymes is highly variable
(see above, Section 4.4.2), the allosteric MgC-site is found in all structures. Fur-
thermore the parent species of these proteins are all γ-proteobacteria. Under the
described experimental conditions wALADin1 led to a distinct stimulation of enzy-
matic activity. Although dysregulation of heme biosynthesis that involve increased
porphobilinogen and porphyrin production may have a slight toxic effect, a drug-
like use of wALADin stimulators does not appear as promising as for an inhibitory
compound. However, as demonstrated for P. aeruginosa ALAD environmental fac-
tors may drive the wALADin-elicited modulation towards inhibition, maybe even
in the physiological context. Future investigations will have to dissect the adequacy
of modulating ALAD activity of these species as a potential antibiotic mechanism
of action.
Although the current data are consistent with a classification based on taxonomy
of the parent organisms (chloroplasts, cyanobacteria and α-proteobacteria vs. γ-
proteobacteria) such a model would need to be corroborated by testing of further
members of the different classes. However, as no obvious structural elements can be
identified that are phylogenetically conserved in the different groups, the taxonomic
model appears to be the best approximation for classification. Susceptibility may be
best predicted by determining the phylogenetic distance to members of either group
on a case-to-case basis and for those species with ALAD orthologs most closely
related to either the chloroplast or Wolbachia proteins, wALADin-like inhibitors
may be suitable herbicide and antibiotic candidates.
4.6.2 An introduction to malaria
Malaria tropica is a life-threatening infectious disease caused by the unicellular
apicomplexan parasite Plasmodium falciparum that is transmitted by anopheles
mosquitoes. Several other less severe forms of human malaria exist that are caused
by other plasmodial species. While roughly half of the world’s population is at
risk of contracting malaria, for 2010, 216 million malaria episodes, predominantly
in Africa and South-East Asia, and 655 000 malaria deaths (mostly in African
children under the age of 5) have been estimated [266, 267].
Plasmodium sporozoites, the infectious stage transmitted through the mosquito
salivary glands during the blood meal, infect human hepatocytes where the para-
site multiplies extensively within a parasitophorous vacuole (liver schizont stage)
and rupture of the infected hepatocytes finally leads to the release of thousands
of merozoites. These extracellular forms of the parasite then invade erythrocytes
where they are referred to as trophozoites. The following, repetitively occuring
blood stage cycle involves intraerythrocytic division rounds and rupture of blood
stage schizonts releasing more erythrocyte-infecting merozoites as well as male and
female gametocytes required for sexual reproduction in the mosquito vector [100].
Sequestration of P. falciparum infected red blood cells to the endothelium of the
brain microvasculature may trigger neural pathogenesis culminating in potentially
fatal cerebral malaria [179]. Further symptoms of severe malaria are hyperthermia,
severe anemia, respiratory-distress and multi-organ failure [100]. In the absence of
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an efficient malaria vaccine, malaria prevention programs mostly rely on exposition
and vector control [266, 267]. A variety of antimalarial drugs exists for chemo-
prophylaxis and chemotherapy, however the rapid development of resistance of the
most virulent malarial parasite P. falciparum to curent drugs requires a continuous
expansion of the antimalarial drug portfolio [64]. Drugs targeting the liver stage
parasites and gametocytes are sparse.
4.6.3 ALAD and heme biosynthesis as a potential drug target
in apicomplexan parasites
Apicoplast-derived ALAD has been suggested as a potential drug target for two
human pathogenic unicellular parasitic protists, P. falciparum [66] and T. gondii
[227] that cause malaria and toxoplasmosis, respectively. The apicoplast is a non-
photosynthetic relict plastid that has been acquired by an ancestor of the apicom-
plexan parasite via secondary endosymbiosis of a red alga [171]. Thus, the api-
coplast stands in evolutionary relationship with the primary plastids (chloroplasts)
of plants and algae, with the photosynthetic red alga Chromera velia as the living
missing link [185, 139]. The biological function of the apicoplast is uncertain. It
was shown that T. gondii parasites do not die immediately upon depletion of the
apicoplast, but upon invasion of new cells [105] highlighting the general importance
of the apicoplast for the parasite. Apicoplast-derived isopentenyl pyrophosphate, a
product of isoprenoid biosynthesis and precursor of vital biomolecules such as heme
and dolichols, is required for survival of blood stage P. falciparum [140]. However,
at this life stage and under experimental conditions, the apicoplast was shown to
be dispensible when exogenous isopentenyl pyrophosphate was provided [272]. Yet,
the apicoplast may have further biological functions in other life stages of the para-
site and drug-induced clearance or functional deficiency of the apicoplast may affect
blood stage plasmodia by preventing isoprenoid biosynthesis in the apicoplast. Due
to its essential and unique biological function and prokaryotic origin the apicoplast
is considered a promising antimalarial drug target [78, 210, 33].
In 1992, Surolia and Padmanaban discovered that P. falciparum is able to syn-
thesize heme de novo although the parasite is flooded with host-hemoglobin-derived
heme that the parasite has to detoxify by polymerization to hemozoin [242]. The
authors further revealed that inhbition of parasite heme biosynthesis by succinyl
acetone leads to reduced viability of the parasites thereby validating plasmodial
heme biosynthesis as a target pathway for antimalarial drug discovery. Although it
was then reported that blood stage P. falciparum can import host-ALAD from the
parasitized red blood cell [28], further studies revealed an active plasmodial ALAD
ortholog is encoded in the P. falciparum genome [222]. Finally, it was unravelled
that the plasmodial ALAD is targeted to the apicoplast and that apicoplast-derived
heme-biosynthesis constitutes only ∼10% of total ALAD acitivity in the parasite
[66]. Hence, it is speculated that heme-biosynthesis in the apicoplast may provide
porphyrins exclusively for the plastid. Dhanasekaran et al. recombinantly expressed
ALAD from the malarial parasite that showed low activity and was independent of
any metal ions, but allosteric activation through Mg2+ could confer additional ∼20
- 30% of catalytic activity [66]. An active ALAD ortholog has also been expressed
from T. gondii which is presumed to require both catalytic and allosteric Mg2+
for optimal activity and inhibition of T.gondii ALAD by succinyl acetone induced
death of the parasites [227, 138]. Thus, species-specific inhibition of apicomplexan
ALAD enzymes in the apicoplast could be a promising strategy in the design of
novel drugs to cure the diseases caused by these parasites.
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4.6.4 Potent Antiplasmodial activity in vitro
In the absence of the recombinant enzymes for enzymatic inhibition tests, potential
inhibitory effects of wALADins were tested in cell culture systems that measured
the proliferation of blood stage P. falciparum in erythrocytes and T. gondii in
LLC-MK2 cells. Three wALADin benzimidazoles (wALADin1, 6 and 9) showed
antiplasmodial activity in the blood stage culture system with IC50 values in the
low µM range between 7 and 40 µM. From a structural perspective, antiplasmodial
activity required the presence of the R2-2-[(2-thienylcarbonyl)amino]ethyl side chain
and tolerated minor changes in the positioning of the R3-COOH and the CF3 at
the R1-benzyl substituent. All further modifications abrogated activity against
blood stage P. falciparum, a finding that indicates a clear structure-activity profile
underlying these antiplasmodial effects. Of note, the R3-COOH consitutional isomer
6 killed the malarial parasites with the greatest potency (IC50 ∼7.7 µM) and also
had the steepest progression of the dose-response curve, which is likely due to an
additive or synergistic effect of activities on different targets in the parasites.
For wALADin1 and 6 no such inhibitory effect was observed on replication of
T. gondii tachyzoites, revealing that the antiprotozoal activity of the mentioned
wALADins was specific for the malarial parasites.
Parallel to the present study, recombinant expression of the T. gondii and P.
falciparum ALAD orthologs and characterization of the inhibitory properties of
wALADins was carried out by Silke Strassel in her diploma thesis at our institute
[240]. That study revealed that the T. gondii enzyme is weakly stimulated by
wALADin1, while the P. falciparum enzym is inhibited at concentrations equiva-
lent to those required for weak inhibition of the insensitive human enzyme. These
concentrations are 1-2 magnitudes higher than IC50 concentrations measured in the
trophozoite culture system [240]. Thus the antimalarial acitivity of wALADin1, 6
and 9 may not be explained by inhibition of heme biosynthesis in the apicoplast,
but are expected to be derived from activity at other targets instead. These targets
might be homologs of β-tubulin/microtubules and kinesin spindle protein as dis-
cussed as potential secondary targets for the filariae. Biological activity has been
demonstrated for benzimidazoles targeting β-tubulin for other protozoan parasites
like Trichomonas vaginalis and Giardia lamblia [145].
Although activity of wALADins on P. falciparum are apparently not a result
of inhibition of heme biosynthesis, the potent antimalarial activity puts these com-
pounds in line for the development of urgently needed novel drugs against malaria.
Elucidation of the molecular targets of wALADins in P. falciparum is an important
goal of future research as it may unravel new attractive options for antimalarial
chemotherapy and help optimize antimalarial activity of wALADins. Finally, it
will help to elucidate the global biological profile of the novel class of wALADin
benzimidazoles.
4.7 wALADin inhibitors in light of current trends
in drug development
The 20th century experienced a pharmaceutical and clinical success story in the ad-
vent of antiinfective drugs from antibiotics over antimalarials to anthelminthics and
many prematurely declared victory in the combat against infectious diseases. Al-
though being true also for other antiinfectives such as anthelminthics [141], two im-
portant trends are menacing the achievements of this golden age that are most evi-
dent for antibiotics: 1) There is rapid emergence of multi-drug resistant pathogens
(like meticillin- and vancomycin resistant Staphylococcus aureus and multi-drug re-
sistant gram negative bugs) causing increasing numbers of fatalities. 2) In contrast,
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numbers of novel antibiotics introduced to the market have been constantly decrea-
sing over the last 30 years involving very few true innovations, i.e. novel mechanisms
of action [79, 34]. It was recently shown that antibiotic resistance mechanisms in-
cluding those conferring resistance to β-lactamases, tetracyclines or vancomycin are
ancient and date back more than 30,000 years [58]. It is therefore considered that
the upcoming clinical use of natural product-derived antibiotics rapidly selected for
the presence and transfer of preformed resistance genes [269]. As most "new" drugs
represent enhancements of existing drugs with existing resistance mechanisms, resis-
tance development is inherent and only a matter of time. However, even for entirely
synthetic drugs like oxazolidinones (linezolid, besides the lipopeptides and mutilins
the only new classes of marketed antibiotic since 1962!) resistance has developed
[97]. Genomics-based broad-spectrum antibiotic discovery strategies pursued by
the pharmaceutical industry focussed mostly on single-target-based screenings of
synthetic combinatorial chemistry libraries and were abandoned as fruitless. Most
compounds, although being highly potent inhibitors of their target enzymes in vitro,
did not enter the bacteria, were shuttled out or targets proved to be functionally
redundant [200]. Also for malaria, drug and resistance developement represent an
arms race [220] and there is a pressing need to identify and to further characterize
known bioactive compounds [87] and feed them into the drug development pipeline.
Within the field of anthelmintic drug discovery, since the introduction of macrocyclic
lactones (ivermectin) to the market in 1981 [44] and, of less importance, cyclooc-
tadepsipeptides in the 1990’s [103], the most important innovation has been the re-
purposing of tetracycline antibiotics for depletion ofWolbachia endosymbionts from
filarial worms [118]. However, no truly novel drugs were registered as anthelmintics
in the last 20 years, although single, recently discovered candidate drugs currently
hold promise such as amino-acetonitrile derivatives (monepantel) [143].
All subdisciplines of infectious disease research share the need for major innova-
tions in order to enable discovery of mechanistically novel or chemically improved
drugs that are able to circumvent conventional resistance mechanisms, e.g. directly
targeting mediators of resistance like efflux pumps [196] or using drug combinations
and drug adjuvants [234, 250]. The use of synergistic drug combinations may affect
different functional nodes in biological systems (such as microbes) with tremen-
dous downstream biological (i.e. antimicrobial) effects although single targets are
not necessarily completely inhibited [273, 216]. While highly specific single-target
inhibitors were long believed to be the ideal drugs, a paradigm-shift is ongoing
advocating the benefits of "dirty drugs" that affect multiple targets to target com-
plex diseases and pathogenic organisms [57, 187, 126]. Besides increased efficiency
a major advantage of promiscuous drugs (or drug combinations) is that resistance
development is impeded, as single amino acid mutations in one target are no longer
sufficient to confer resistance. Therefore the understanding of drug interaction
networks and drug polypharmacology may contribute essentially to the design of
efficient future drugs [126]. Concurring with this paradigm certain promiscuity is
also evident for registered antifiarial agents. Although the above mentioned pri-
mary molecular targets had been defined for antifilarial drugs like ivermectin and
albendazole, for ivermectin several lower potency targets are known [123] and for
albendazole an important secondary effect on Wolbachia in vitro has recently been
reported [226].
The current study may bring inovation into the field of antiinfective drug disco-
very based on its target pathway and the inhibitory chemotype. Pathogen-specific
targeting of heme biosynthesis by wALADin inhibitors represents an unprecedented
approach in antiinfectective drug discovery. Since the ALAD-targeting antibiotic
Alaremycin is produced by Streptomyces spp. [13, 108], ALAD has apparently
evolved as a suitable antimicrobial drug target in nature which indicates that tar-
geting the heme biosynthesis pathway is a promising antimicrobial strategy.
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The biological effects of wALADin1, Wolbachia-dependency of the antifilarial ef-
fect of wALADin1 and its antiplasmodial activity, indicate succesful cellular uptake
of the drug by the endobacteria and P. falciparum. The effect on P. falciparum is ap-
parently not ALAD-dependent and secondary targets are discussed above for filarial
nematodes (Section 4.5.1). By the use of activity-based chemical probes derived
from the wALADin1-scaffold these targets may be pulled down using bioorthogonal
chemistry and identified by mass-spectrometric analysis [24, 106]. Alternatively,
chemical similarity approaches may be applied to predict secondary targets [147].
An understanding of the different biological effector pathways as well as identifi-
cation of secondary molecular targets and the corresponding strucure-activity rela-
tionships may enable the design of efficient multi-target drugs. Given the obvious
chemical similarity to benzimidazole anthelminthics a tempting approach would be
the design of an antifilarial "wALADinazole" drug that combines ALAD-dependent
activity of wALADin1 and the β-tubulin-dependent activity of albendazole.
Notwithstanding potential secondary target effects, improvement of the inhibi-
tory potency on wALAD is a prerequisite for any potential wALADin-like drug lead
candidate. Determination of a co-crystal structure of wALAD and wALADin1 and
identification of the binding site would greatly facilitate this enterprise. However,
crystallization of both wALAD and pea ALAD are difficult, as no crystal structure
of either ortholog has been published. Although the presence of wALADin1 during
co-crystallization of wALAD or pea ALAD may be beneficial, a shortcut may be
taken by using X-ray crystallography to determine the binding mode of wALA-
Din1 on a group Z ALAD ortholog which is stimulated by wALADin1. For several
group Z ALAD orthologs, e.g. P. aeruginosa [83] or E. coli [71], crystallization
has already been done successfully and should also be feasible in combination with
wALADin1. Subsequent homology modelling may then yield the desired approxi-
mation for the endobacterial ortholog. In conjunction with the wealth of SAR-data
presented in this study, knowledge of the molecular binding site will provide a
powerful framework for the design of tailored drug-like inhibitors with improved
potency and pharmakokinetic properties.
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Summary
Filarial nematodes are the causative agents of vector-borne diseases known as lym-
phatic filariasis and onchocerciasis. More than 150 million inhabitants of endemic
tropical and subtropical countries are infected and may develop severe and chronic
pathologies such as lymphedema, hydrocele or river blindness. While prolonged
mass drug administration programs with annual treatment rounds are underway
to block the transmission of larval stages, adult worms persist in the mammalian
host for years. Thus, resistance development against the mainstay of antifilarial
chemotherapy, i.e. ivermectin and diethylcarbamazine, poses a serious threat to
the desired containment of filarial diseases which calls for the discovery of novel,
preferentially adulticidal, drugs to cure and eradicate these diseases.
A prominent target for the development of antifilarial drugs are Wolbachia en-
dobacteria, as depletion of the endosymbiont by antibiotic treatment leads to ste-
rilisation and death of adult worms. However, the regimens of currently available an-
tibiotic therapies are not compatible with mass drug administration programs. An-
notation of the genome of B. malayi, a causative agent of lymphatic filariasis, and its
endosymbiont, have revealed a variety of essential endobacterial biochemical path-
ways that may be exploited as antifilarial drug targets. The current study pursued
a target-based drug discovery strategy aimed at the discovery of novel inhibitors of
two enzymatic targets of Wolbachia: One is the glycolytic/gluconeogenetic enzyme
pyruvate phosphate dikinase (PPDK) that catalyzes the reversible conversion of
phosphoenol pyruvate to pyruvate. The other is δ-aminolevulinic acid dehydratase
(ALAD) which converts 5-aminolevulinic acid to porphobilinogen as the first com-
mon step of heme biosynthesis. PPDK is only found in bacteria, protozoa and
plants and is thus also a potential target for more broadly-applicable antibiotics.
For ALAD, a human ortholog exists (hALAD) that is, however, phylogenetically
different from the endobacterial enzyme (wALAD) and depends on Zn2+ for cata-
lytic activity, while wALAD requires Mg2+. Exploitation of these distinct metal-
dependent catalytic and allosteric mechanisms must be adressed in order to develop
species-selective inhibitors of potential therapeutic use.
High-throughput compatible screening assays were established for both recom-
binantly expressed proteins and screened against a diversity-based compound li-
brary comprising ∼18,000 drug-like small molecules for the identification of novel
inhibitors and potential drug lead candidates. For PPDK a single specific inhibitor
(PPDKin1) of moderate potency (KI ∼53 µM) was discovered that was uncompe-
titive with respect to cosubstrates AMP and PEP.
For wALAD, a cluster of novel tri-substituted benzimidazole-5-carboxylic acid
structures was discovered and shown to specifically bind to and inhibit the Mg2+-
responsiveWolbachia and pea orthologs with little effect on the human enzyme. For
the most potent compound, termed wALADin1 (IC50 = 11 µM), a novel and specific
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inhibitory mechanism was revealed that is partially substrate-competitive and par-
tially non-competitive. It further involves competition with enzymatic activation
by a Mg2+ ion on a functional level. Based on experimental evidence and analogy
to other orthologous enzymes, activation of wALAD by Mg2+ is assumed to be al-
losterically driven and it is suggested that the corresponding conformational change
is antagonized by binding of wALADin1. It was further revealed that wALADin1 is
able to stimulate enzymatic activity of several Mg2+-stimulated γ-proteobacterial
orthologs suggesting that wALADins may, in general, be described as (putatively
allosteric) modulators of ALAD.
Antifilarial activity of wALADin1 was successfully demonstrated in a proof-of-
principle experiment using the rodent filarial nematode L. sigmodontis in an ex vivo
setup, in which wALADin1 and derived inhibitors elicited a characteristic phenotype
in treated worms and affected both motility and viability of these worms (EC50
for wALADin1 ∼100 µM). Control studies on the Wolbachia-free filaria A. viteae
revealed that the macrofilaricidal effect of wALADin1 was dependent on the pre-
sence of Wolbachia and thus likely a result of inhibition of heme biosynthesis in the
endosymbionts. However, no antifilarial effect could be detected for wALADin1 in
the course of L. sigmodontis infection in mice in vivo which is presumably explained
by pharmakokinetic shortcomings.
In a first approach to identify improved inhibitors several derivatives of the benz-
imidazole wALADin1 and chemically similar non-benzimidazole compounds were
tested for their wALAD inhibitory properties. These studies allowed the delineation
of essential chemical features required for inhibitory potency, such as the carboxylate
group, and for species-selectivity of wALADin-benzimidazoles. Further bioactive
chemotypes were identified including a tricyclic quinoline derivative (wALADin2)
with improved potency and specificity that acted by a related but not identical
inhibitory mechanism.
Finally, it was shown that wALADin1 and, even more strongly, two of its deri-
vatives have pronounced activity against blood stage Plasmodium falciparum, the
causative agent of malaria tropica, the most devastating parasitic disease of man,
in vitro with IC50 values in the low µM range. This potent and specific, though
putatively not ALAD-dependent, activity on P. falciparum indicates wALADin
benzimidazoles may be useful in antimalarial drug discovery.
Taken together, with the identification of a novel class of specific wALAD in-
hibitors with their unique inhibitory mechanism, proof-of-principle demonstration
of their related antifilarial biological activity and detailed investigations on the
structural-functional foundations, this study provides the framework for the deve-
lopment of more potent wALADin-like inhibitors targeting Wolbachia and related
pathogens as potential lead structures in the development of novel antifilarial drugs
and narrow-spectrum antibiotics.
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Appendix B
Supplementary videos
Supplementary videos 1 - 5 are contained on the multimedia CD enclosed with this
work illustrating the phenotype of L. sigmodontis (Ls) and A. viteae (Av) worms in
the ex vivo experiments, i.e. under exposure to different concentrations of wALA-
Din1 or derivatives for 14 - 17 days. In the following overview the video contents
are listed and the time point, the filarial species and the identity and concentration
of the tested compounds are indicated. Median motility scores corresponding to the
worms shown in the video samples at the selected time points (6 worms per group
on 1 plate) are indicated in brackets.
Video 1: Day 0 - L. sigmodontis and A. viteae before start of treat-
ment: Ls 1% DMSO group (5); Ls 500 µM wALADin1
group (5); Av 1% DMSO group (5); 500 µM wALADin1
group (5).
Video 2: Day 5 - L. sigmodontis: 1% DMSO (5) ; 125 µMwALADin1
(5); 250 µM wALADin1 (4); 500 µM wALADin1 (3); 125
µM compound 3 (5); 250 µM compound 3 (5); 500 µM
compound 3 (4); 500 µM compound 6 (4)
Video 3: Day 17 - L. sigmodontis: 1% DMSO (5) ; 125 µM wAL-
ADin1 (4); 250 µM wALADin1 (3); 500 µM wALADin1
(0); 125 µM compound 3 (4); 250 µM compound 3 (3.5);
500 µM compound 3 (3); 500 µM compound 6 (1).
Video 4: Day 5 - A. viteae: 1% DMSO (5); 250 µM wALADin1 (5);
500 µM wALADin1 (4)
Video 5: Day 14 - A. viteae: 1% DMSO (5); 250 µM wALADin1 (5);
500 µM wALADin1 (2)
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